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ABSTRACT 
 
INVESTIGATION INTO THE MECHANISM OF A NOVEL HIV-1 FUSION 
INHIBITOR, SC12 
 
Marina Tuyishime 
Mentor: Simon Cocklin, Ph.D. 
 
Due to the emergence of drug-resistant viruses and problems with drug 
side effects, new drugs and drug targets are constantly required in the battle 
against HIV-1/AIDS. The entry of the virus into host cells and the molecular 
machine that facilitates this process, the Env glycoproteins, are extremely 
attractive and underexploited therapeutic targets. Env glycoproteins, gp120 and 
gp41, are assembled into trimeric complexes on the virion surface. The 
attachment of virus to target cells triggers conformational changes within viral 
Env that ultimately leads to the fusion of the viral and cell membranes, 
completing the viral entry process. Due to the complex nature of the viral Env 
and the multistep process of HIV-1 entry, the exact transitions that ultimately lead 
to fusion are still not fully understood. While the receptor engagement steps of 
the virus to the target cell are well characterized, post-attachment conformational 
changes within Env that subsequently lead to viral-cell membrane fusion have 
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yet to be defined. A major hurdle in the development of novel HIV-1 entry 
inhibitors is the lack of knowledge in precise post-attachment conformational 
changes that lead to viral-cell fusion and what regions within viral Env to target to 
prevent those changes. Using a combination of high-content pharmacophore in 
silico screening, chemical syntheses, bioisosteric replacement, and antiviral 
testing, we have developed a novel entry inhibitor, SC12, which inhibits the entry 
of HIV-1 into susceptible cells in the nanomolar range. Contrary to the reported 
mechanism of action of other small molecule HIV-1 entry inhibitors, direct binding 
of SC12 to HIV-1 Env did not block Env interaction with the host cellular 
receptors, thereby allowing Env attachment to the host target cell. Additionally, 
differential scanning calorimetry indicates that interaction of SC12 with the 
soluble cleaved trimeric SOSIP.664 gp140 thermally stabilizes the protein. 
Moreover, binding of SC12 to HIV-1 Env did not alter recognition of epitopes on 
Env surface by broadly neutralizing and non-neutralizing antibodies. 
Furthermore, SC12-induced resistance mutations were located away from the 
CD4-binding site contrary to other small molecule inhibitors. In addition, Envs 
from SC12-resistant viruses have conformations closely resembling the post-
engagement “prefusogenic” state exposing the conserved MPER region, 
therefore, making these viruses more susceptible to neutralization by MPER-
specific antibodies. Taken together, this study reveals that SC12 functions as a 
novel allosteric HIV-1 fusion inhibitor, binding to Env and preventing Env 
conformational changes downstream of receptor engagement that lead to viral 
and cell membrane fusion. SC12 will serve as an important molecular probe for 
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HIV-1 Env functions, providing novel insight into the complex series of structural 
transitions through which the Env molecular machine proceeds, in addition to 
illuminating the details of an elusive site of vulnerability. Moreover, it is our hope 
that it will also serve as a lead compound for the development of a new class of 
Env-targeted HIV-1 fusion inhibitors suitable for use in both systemic and 
microbicide therapies.   
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INTRODUCTION 
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HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) 
Acquired Immunodeficiency Syndrome (AIDS)-related illnesses claim the 
lives of approximately 3 million people each year with roughly 33 million 
individuals infected worldwide and despite extensive research efforts, a cure 
remains elusive (1). The first cases of this illness, thought to be Kaposi’s 
sarcoma (KS) and Pneumocystis carinii pneumonia (PCP) (2-4), were reported 
early in 1981 among a cluster of homosexual men. In 1983, the lentivirus 
implicated as the agent causing AIDS was discovered and named Human T-cell 
Leukemia Virus III (HTLV-III) (5, 6). A few years later the primary etiological 
agent causing AIDS was further characterized as a human retrovirus and 
renamed Human Immunodeficiency Virus Type 1 (HIV-1) (7). This pathogen is 
highly specific for cells vital to the human immune system, such as CD4+ T cells, 
macrophages, and dendritic cells. An infection results in the loss of CD4+ T-
lymphocytes, which leads to immunodeficiency (8).  
HIV-1 is genetically diverse and can be divided into three major groups: 
main (M), outlier (O), and non-M/non-O (N) (9-11). Group M is responsible for the 
worldwide pandemic and, based on genetic variability, can be subdivided into 10 
subtypes or clades (A to K) (12). In addition, viruses from different clades can 
combine their genetic material creating a circulating recombinant form (CRF) 
(13). 
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HIV-1 STRUCTURE 
HIV-1 is composed of two copies of positive single-stranded RNA, which 
together with Reverse Transcriptase (RT), viral protease (PR), integrase (IN) and 
ribonuclease are encapsulated by capsid protein (CA) and surrounded by matrix 
(MA). The viral particle is protected by a double lipid membrane containing viral 
envelope spikes (Env) comprised of the surface glycoproteins gp120 and a 
transmembrane glycoprotein gp41. There are 5-17 spikes on the surface of HIV-
1 (14, 15).  
The genomic structure of HIV-1 is organized into 9 genes that code for 15 
proteins (16). These are subdivided into three structural genes (gag, env, pol), 
two regulatory genes (tat, rev) and four accessory genes (vif, nef, vpr, vpu) (17). 
Gag is synthesized as a precursor protein (p55) and is cleaved by viral protease 
into matrix (p17), capsid (p24), spacer peptide 1 (SP1), nucleocapsid protein 
(p7), spacer peptide 2 (SP2) and p6. The Env precursor is synthesized as gp160 
and is cleaved in the endoplasmic reticulum by cellular protease into the 
component surface protein gp120 and transmembrane protein gp41. The Pol 
gene encodes three viral enzymes and is autocleaved into RT, IN and PR. Rev 
(regulation of virion) is responsible for viral RNA nuclear transport and production 
of viral proteins (18). Tat (trans-activator of transcription) primarily functions as a 
transcriptional activator, although other functions important for viral life cycle 
have also been identified (19). Vif (viral infectivity factor) is responsible for 
proteasomal degradation of cytidine deaminase enzyme APOBEC, preventing 
hypermutation of viral nucleic acid (20). Nef (negative regulatory factor) is 
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primarily responsible for virulence, in addition to downregulation of CD4 (cluster 
of differentiation 4)  and major histocompatibility complex I (MHC I) (21). Vpr 
(viral protein R) has been shown to control the nuclear import of the viral pre-
integration complex (PIC) and, therefore, to promote viral infection. It is also 
known to activate HIV-1 LTR transcription and support accumulation of virions in 
infected cells and, on the other hand, to destroy function of T cells and act as 
immunosuppressant (22). Vpu (viral protein unique) regulates viral particle 
release, viral load and expression of the CD4 receptor (23). Viral enzymes play 
crucial role in viral life cycle. RT transcribes viral RNA into double stranded DNA 
and is known to be very error-prone, generating novel sequences during every 
cycle of replication (24).  IN is responsible for the incorporation of proviral DNA 
into the host genome and PR cleaves viral Gag polyprotein and aids to create 
mature protein components for the virion particle.  
HIV-1 LIFECYCLE 
The entry of HIV-1 into host cells is mediated by the viral envelope (Env) 
heterotrimer composed of three non-covalently linked gp120 and gp41 subunits. 
The first step in the entry process entails binding of gp120 subunits to cell 
surface CD4 molecules (Figure 1.1 A). The resulting conformational change 
within gp120 creates the coreceptor-binding site, which enables it to bind to 
either CCR5 or CXCR4 (25). Coreceptor binding serves as the ‘trigger’ that leads 
to the final conformational changes within Env that mediate fusion between the 
viral and cellular membranes (26). It is important to note that not all 
conformational changes induced by CD4 binding are favorable for viral infectivity. 
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In some cases, these changes can cause gp120 shedding, resulting in rapid 
dissociation of gp120 from its complex with transmembrane gp4l (27). Together, 
CD4 and coreceptor binding to gp120 induce additional conformational changes 
in gp41, including exposure of the fusion peptide at the amino (N) terminal, which 
attaches directly to the host cell membrane during the first step of fusion. The 16 
residues of the fusion peptide are mainly hydrophobic and facilitate attachment to 
the cell's membrane (28). Other regions in gp41 that are important for viral fusion 
are two helical structures, heptad repeat (HR) 1 and 2 (Fig. 1.1 B), which include 
hydrophobic regions that interact with each other during virus-cell fusion via the 
formation of a six-helix bundle (6-HB) and results in membrane fusion (29).  
Upon entry, the viral core is deposited in the cytosol and viral RNA is 
reverse transcribed into DNA by RT. Proviral DNA, in association with other 
proteins, translocates to the nucleus and forms the pre-integration complex 
(PIC). Following nuclear import, proviral DNA is integrated into the host cell 
genome with the aid of IN. Newly synthesized viral DNA is transcribed and 
translates into new viral RNA and viral proteins that translocate out of the 
nucleus to the cell surface. The Env, primarily gp120 subunit, is cotranslationally 
modified in the ER by the enzymes of host cell. The addition of mannore-rich 
oligosaccharides is necessary not only for the proper folding of the Env, but also 
serves as a protection virion from the host immune system. After transporting all 
viral components to the cell surface, viral particle then assembles at the plasma 
membrane and an immature virion buds out of the cell. Immediately after viral 
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budding, PR is activated and cleaves Gag into its components, which allows the 
virion to repeat the infection cycle in a new target cell (30).    
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Figure 1.1. Entry of HIV-1 into target cells and schematic representation of 
Env subunits. (A) The process of HIV-1 entry into the target cells. (1) The 
envelope protein complex is a heterotrimer of three gp41 molecules and three 
gp120 molecules, embedded in the viral envelope. (2) The first specific high-
affinity interaction occurs between CD4 and the gp120 subunit of the envelope 
complex. (3) This interaction promotes a subsequent interaction with another cell 
surface receptor, which is usually a G protein—coupled receptor, and most 
predominantly either CXCR4 or CCR5. (4) This interaction causes 
rearrangement in the gp41 subunit, such that the fusion peptide is inserted into 
the membrane, and the helical regions (HR1 and HR2) fold back and interact 
with each other, facilitating the bringing together of the two membranes and 
eventual fusion. (The figure was modified from Wilen et al., 2012 (31)). (B) The 
schematic representation of gp120 and gp41 subunits during the entry process. 
Two hydrophobic helices of gp41 are represented in orange (HR1) and blue 
(HR2). Two helices tightly associate with each other to form structure six-helix 
bundle. (The figure was modified from Chen et al., 1998 (32)). 
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SOLUBLE CLEAVED TRIMERIC HIV-1 ENV COMPLEX 
 A lot is known about the HIV-1 life cycle but there is still much to be 
learned about the structural transitions within the Env during the entry process. 
Because HIV-1 Env is central to the interactions between the virus and its host, 
the detailed information about the gp120 structure is important not only for 
understanding HIV infection and for the design of therapeutic and prophylactic 
strategies but also for the development of new tools to better understand entry 
steps of life cycle. Therefore, Env serves as an important target for anti-HIV drug 
and microbicide development. A lot of time and effort has been devoted to 
understanding and possibly visualizing the conformational transitions within Env 
that are required during the entry steps. Binding of gp120 to the cellular receptor 
CD4 induces a series of conformational changes within the gp120 subunit and 
subsequently in gp41. Since both proteins are not covalently linked and the Env 
complex naturally has a wide range of flexibility, it was a challenge to 
synthetically duplicate the viral spike without altering its native conformation, 
causing gp120 shedding, inhibiting reactivity with CD4 or reducing flexibility (27, 
33, 34). In addition, since the entry mechanism is a multistep process, it was 
important to know the order of conformational changes necessary to occur in 
gp120 without prematurely activating gp41.  
The crystal structure of monomeric gp120 in complex with soluble CD4 
(sCD4) and a broadly neutralizing antibody (bNAb) was solved shortly after 
identification of the structural subunits of Env (35). However, there were 
difficulties in trying to solve the structure of soluble trimers that would represent 
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the native state of the Env heterotrimer. The first attempts to produce soluble 
trimers were done in 1994 by introducing a stop codon upstream transmembrane 
domain in the env precursor gp160, producing gp140 oligomers with truncated 
transmembrane and gp41 cytoplasmic regions (36). For many years different 
groups attempted to synthesize a full length Env complex that would resemble 
the native spike. The successful stabilization of soluble trimer was achieved by 
introducing an intermolecular disulfide bond (SOS) between constant region C5 
of gp120 and linker region of gp41. Also, a single point mutation was introduced 
in HR1 of gp41 (I559P) to keep gp41 helices (HR1 and HR2) in their natural 
prefusion state. In addition, to improve trimer solubility, gp41 was truncated at 
position 664 (prior the membrane proximal external region (MPER), Figure 1.2). 
The constructed soluble, oligomeric HIV-1 Env complexes termed SOSIP.664 
(37-40) elicited bNAbs against gp120 and gp41 subunits (41). They were thought 
to represent the native Env structure by the binding to sCD4 and conformational 
antibody F105 and by the similarity of recognition by monoclonal antibodies that 
recognize Env on the surface of chronically infected cells (36).  
SOSIPs quickly became a great source for investigation of different 
aspects of HIV-1 and served as a tool to develop novel strategies to target the 
virus. SOSIPs were used to isolate new bNAbs that recognize quaternary 
conformational epitopes of Env and to characterize already known bNAbs (41-
45). High resolution X-ray and cryo-EM structures revealed details about the 
“layered” composition of Env complex (46). Gp120 is connected to gp41 by the 7-
stranded β-sandwich, which remains metastable during the unliganded, CD4-
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bound or CD4 binding site (CD4bs) Ab-bound states and prevents the premature 
activation of gp41. Other invariant structures are the outer domain of gp120 and 
V1/V2 variable loops, which can adopt multiple orientations in relation to the 
anchor of viral spike. All three structures are highly glycosylated and shield 
recognition of neutralizing epitopes by most antibodies. The inner domain of 
gp120 has three dinamic layers, which are responsible for “structural plasticity” 
and adoption of numerous conformations of gp120 without transferring the 
conformational signal to gp41 (46, 47).  
The full-length unliganded “closed state” gp120 structure observed in the 
cleaved HIV-1 envelope trimer is conformationally different from the unliganded 
core structure mainly in the position of variable loops and the formation of the 
bridging sheet (42).  In the CD4-bound state, the V1/V2 loops are pointed away 
from V3 loop toward the gp120 core, creating water pore and exposing co-
receptor binding site (42, 48). The most valuable property of soluble cleaved 
trimer is the conformational flexibility (49). Therefore, it serves as a great tool to 
investigate the binding site of small molecule inhibitors that target HIV-1 Env and 
any conformational alterations caused by the binding of the inhibitors. 
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Figure 1.2. Structure of a soluble, cleaved, recombinant HIV-1BG505 Env 
trimer. (A) Schematic of the soluble, cleaved, recombinant HIV-1 Env BG505 
SOSIP.664 construct in comparison with native Env complex structure. The 
starting position of each part of the protein is numbered. The constant and 
variable regions of gp120 are indicated as C1-C5 and V1-V5, respectively. Gp41 
is represented by a fusion peptide (FP), heptad repeat 1 and 2 (HR1 and HR2) 
helices. The SOSIP mutations are shown in red, as well as the added N332 
glycan site. (B) Side view of the one Env 140 protomer showing gp120 in cyan. 
The main gp41 helical elements are colored as following: fusion peptide (FP) is 
indicated in blue; linker between FP and HR1 is shown in grey, HR1 and HR2 are 
shown is green and red, respectively. Linker connecting HR1 and HR2 is shown 
in yellow. The color coding is as in A. (C) View of Env down the trimer axis. 
V1/V2, V3, V4 and V5 regions are highlighted in orange, blue, magenta and 
yellow, respectively. Loops of high variability in gp120 (V1-V5) all map to the 
periphery of the trimer and are labeled. The color coding is as in A. (The figure 
was generated using Pymol).  
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HIV-1 TROPISM  
Env is important for HIV tropism because it is responsible for the receptor-
binding function of the virus. HIV-1 tropism is determined by the type of the cell 
the virus infects and the type of receptors expressed on the cell service. Virus 
first binds to the glycoprotein CD4 that is expressed primarily on the surface of 
immune cells such as lymphocytes, macrophages, monocytes, and dendritic 
cells. CD4 binding is a necessary first step, but this step alone is not sufficient for 
HIV entry into a human cell. A second specific attachment of the virus to 
coreceptor is required. Therefore, following CD4 binding, HIV-1 virus binds to a 
member of the chemokine receptor subfamily within the large G protein–coupled 
family of receptors, CCR5 or CXCR4. The type of coreceptor recognized by 
gp120 determines the type of CD4 cell that the virus will be able to infect, also 
known as the tropism of the virus. Initially it was thought that HIV-1 viruses that 
infect macrophages that express high levels of CCR5 receptor were called M-
tropic or R5-tropiv viruses (50, 51). Most T cell lines express CXCR4 and not 
CCR5 and, therefore, viruses infecting lymphocytes were called T-tropic or X4-
torpic strains. However, this classification was shown to be incorrect to determine 
the cellular tropism of HIV-1, which depends not only on the type of coreceptor 
expressed on the cell surface but also the efficiency of the virus to infect the cell, 
the cell susceptibility to the infection, and the amount of the CD4 present on the 
cell surface (52). Therefore, instead of attributing HIV-1 virus to the cellular 
tropism, it is more common to refer to R5-tropic HIV-viruses as to those that use 
CCR5 as a coreceptor and X4-tropic viruses  as ones that utilize CXCR4. Viruses 
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that are able to infect cells expressing either CCR5 or CXCR4 chemokine 
receptors are called dual tropic. All founder viruses are R5-tropic and CCR5 
coreceptor is most common almost all primary HIV-1 isolates regardless of viral 
genetic subtype (53). All naturally evolving HIV-1 viruses depend on the 
presence of CD4. However, chimeric recombinant viruses have been engineered 
to bypass the need for CD4 and are able to infect the cells expressing only 
chemokine coreceptor. These laboratory-generated viruses are referred to as 
CD4-independent (54). These CD4-independent viruses have more activated 
Env and, therefore, expose neutralization epitopes and thus are easily cleared by 
the immune system in vivo.  
TIERED CHARACTERIZATION OF HIV-1 
 A major obstacle for the effective therapy against HIV-1/AIDS is 
viral diversity (55).  Studies using in vitro and in vivo models showed that 
neutralizing antibodies are capable to confer protective immunity against HIV-1 
virus (56-58). However, some viruses are easily neutralized while others are 
neutralization-resistant. Therefore, in order to categorize HIV-1 viruses by 
sensitivity or resistance to antibody-mediated neutralization, the three-tier system 
was generated (59, 60). The isolates that are known to be highly sensitive to 
antibody-mediated neutralization are commonly referred to as tier 1A viruses. 
They primarily  arose from passaging HIV-1 in T cells lines (61). Compared to 
these laboratory-adapted viruses, natural HIV-1 isolates have a wider range of 
resistance to bNAbs. While some strains have neutralization sensitivity close to 
tier 1A or above average sensitivity (tier 1B), most of natural isolates appear to 
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be moderately neutralization resistant and termed tier 2 (62-64). A small fraction 
of viruses exhibit an unusual neutralization-resistant phenotype (tier 3). In our 
study we incorporated the viruses of all tiers to assess the best results and the 
average potency across lab-adopted and primary isolates.  
INHIBITION OF HIV-1 INFECTION 
The Env glycoprotein complex enables the virus to attach to and fuse with 
target cells to initiate the infectious cycle. As the only viral products accessible to 
the host cell immune system, gp120 and gp41 have evolved several strategies to 
mask functionally important regions from the neutralizing antibody response. 
These include a high degree of glycosylation of gp120 (65), highly diverse 
variable loops (47) and defectiveness of many envelope glycoprotein spikes, and 
conformational flexibility (66). Additionally, RT is an “error-prone” enzyme and 
generates markedly diverse and constantly evolving virus populations within 
infected individuals.  
In order to battle HIV, highly active antiretroviral therapy (HAART) was 
developed in 1998(67). This combinatorial treatment included a cocktail of RT 
and PR inhibitors. The current HAART therapy includes total of 40 drugs that 
belong to different classes of inhibitors targeting viral life cycle at various stages 
(68). Although the introduction of HAART has significantly decreased AIDS-
related mortality (1), current therapy is plagued by cumulative toxicities and the 
development of antiviral resistance. Therefore, HIV-1 remains pandemic and 
there is an ongoing demand for new anti-HIV compounds with diminished 
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toxicities and the ability to overcome the challenges of natural and acquired 
resistance development.  
The entry of HIV-1 into host cells is an attractive drug target for several 
reasons. First, much of the entry process occurs in water-soluble compartments 
easily accessible to drugs, which do not have to cross over the cellular 
membranes. Second, both viral and host cell components involved in HIV-1 entry 
have been identified and can potentially be targeted. Third, because inhibition of 
virus entry prevents the host cell from becoming infected, such inhibitors are 
potentially useful as prophylactic agents, such as in the form of topical 
microbicides (69). Given the preponderance of HIV-1 infections in developing 
countries and the fact that most horizontal transmissions of HIV-1 occur through 
sexual contact, it is an extremely worthy cause to pursue the development of an 
antiviral agent with the potential to be used in both pre- and post-exposure 
prophylaxis and in woman-controlled microbicides.  
HIV-1 ENTRY INHIBITORS 
 Advances in knowledge of the molecular mechanisms of HIV-1 entry have 
enabled the discovery and development of molecules that target discrete steps of 
the entry process and have been successfully used in the clinic.  For example, 
Enfuvirtide (a synthetic 36-amino acid peptide, also known as Fuzeon or T20), 
which is a homolog of amino acids 127-162 in the HR2 region of gp41, binds to 
the HR1 region and stops the fusion of the viral and the cell membrane (70). 
However, its clinical application is limited because of its limited therapeutic 
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window, easy induction of drug resistance, and low bioavailability which 
necessitates intramuscular injection twice daily (71). Another entry inhibitor, 
Maraviroc (MVC), was first discovered by Pfizer in 2004 by high-throughput 
screening to identify small molecules that could inhibit binding of ligands to CCR5 
receptor and later was modified to increase its antiviral activity (72). MVC acts as 
an antagonist of the CCR5 receptor by binding to CCR5 and blocking the 
interaction with the viral envelope (72). Clinical trials with MVC showed great 
efficacy in patients that previously had unsuccessful treatments with other ART 
inhibitors (73). However, MVC is restricted to treatment of patients with R5-tropic 
viruses and long term treatment leads to the development of mutants that can 
use MVC-bound CCR5adapt to use CXCR4 as a coreceptor. In addition, there 
have been cases with outgrowth of X4-tropic HIV-1 in MVC treated patients (74-
76). To date, however, no gp120-targeted therapies have been approved for use 
in the clinic. In the field of HIV-1 entry therapeutic targeting, three main Env-
targeted inhibitor chemotypes predominate: the NBD-556 analogues, the 18A 
and the BMS-377806 analogues, each of which are at different stages in their 
clinical development. 
NBD Chemotype Compounds  
 NBD-556 was first discovered in 2005 by Debnath and his group 
utilizing high-throughput screening of commercially available small molecule 
chemical libraries for the ability to block intracellular fusion (77) (Figure 1.3). 
Using this method, they discovered that NBD-556 inhibits viral activity of lab-
adapted and primary isolates at low micromolar levels. Mutagenesis studies and 
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crystal structure of monomeric gp120-NBD-556 complex revealed that the NBD 
compounds interfere directly with the CD4 binding pocket on gp120 known as the 
Phe-43 cavity (78, 79) (Figure 1.3 A-B). NBD chemotype compounds did not 
interfere with gp120 binding to CCR5 and CXCR4 coreceptor nor formation of 
six-helix bundle (77). However, since these compounds behave as CD4-
mimetics, binding of NBD chemotype compounds to gp120 induced 
conformational changes similar to CD4 and formed coreceptor binding site, which 
was measured by enhanced gp120-17b interaction (79) and increased infection 
of CD4(-)CCR5(+) cells (80). In 2016, the same group improved and optimized 
this class of inhibitors and developed CD4-mimetics with viral entry-antagonist 
properties (81). The novel lead compounds 45A (NBD-14009) and 46A (NBD-
14010) (Figure 1.3 C) still bind to the Phe43 cavity on gp120 and have much 
improved cytotoxicity and antiviral potency to the mid nanomolar to low 
micromolar range. The Sodroski group used NBD-chemotype compounds as a 
template and developed a series of novel inhibitors with a novel chemotype and 
improved antiviral potencies (79, 82). The lead compound in these series, BNM-
IV-147, also binds to the Phe-43 cavity, does not enhance infection of CD4(-
)CCR5(+) cells and inhibits viral infection at high nanomolar range (Figure 1.3 
D). Both of the groups continue to optimize the compounds for in vivo use. 
18A Chemotype Compounds 
In 2014 a novel fusion inhibitor was identified by Sodroski and coworkers 
(83). A screen of compounds for the ability to block cell-cell fusion revealed one 
compound, designated 18A, that arrests the virus at the cell surface (83). 18A 
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exhibited broad-range and specific inhibition of R5 and X4 HIV-1 in the low 
micromolar range and did not interfere with CD4 or coreceptor binding. 18A 
appears to have a novel mechanism of action: it partially inhibits CD4-induced 
V1/V2 movement and blocks exposure of HR1 of gp41 and, therefore, stabilizing 
the Env in the unliganded conformation (83).  
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Figure 1.3. Structure and binding site of NBD chemotype compounds. (A) 
HIVYU-2 gp120 core (surface representation in grey) in complex with NBD-557 
(stick representation in green) and Fab 48d depicted in a ribbon diagram (light 
chain in light blue and heavy chain in blue). CD4-binding footprint represented in 
yellow (79). (B) Chemical structures of NBD-556 and NBD-557 (77). (C) 
Chemical structures of 45A and 46A (81). (D) Chemical structure of the BNM-IV-
147 (82). 
 20 
 
BMS Chemotype Compounds 
The dominant and most developed chemotype is the BMS-377806 (BMS-
806), which was discovered in 2003 by Bristol-Myers Squibb via a whole cell 
infection screen against HIV-1JR-CSF isolate followed by the optimization to 
improve potency (84, 85) (Fig. 1.4). Although this compound can inhibit HIV-1 
entry, it is poorly bioavailable due to the dissolution-limited absorption. In order to 
improve pharmacodynamics, several BMS analogs were synthesized. Newly-
designed BMS-488043 (BMS-043) demonstrates improved potency against HIV-
1 isolates of various clades, demonstrated antiviral efficacy, and shows a 
favorable safety profile in HIV-infected subjects (86, 87). However, 
pharmacokinetic properties of the compound remain poor. To compensate for 
that, a prodrug of BMS-626529 (designated BMS-663068), containing a 
phosphonooxymethyl group, was made that is designed to be cleaved in the 
intestine by host alkaline phosphatase to release the active component to be 
disseminated around the body to inhibit the virus (88).  BMS-663068, as a 
function of its prodrug nature, has somewhat improved bioavailability and 
recently performed reasonably favorably in a phase III clinical trial (89).  
Despite their apparent broad therapeutic range, and their good potencies, 
both the binding site and the mechanism of action of BMS chemotype 
compounds are still under debate. Mutational studies with the BMS-806 and 
BMS-043 conducted by the inventors, Bristol-Myers Squibb, show that 
compounds bind directly to gp120 subunit deep in the Phe-43 cavity and inhibit 
gp120-CD4 interaction (86, 90, 91).   
 21 
 
 
Figure 1.4. Structure of BMS compounds and docking model of BMS-
626529 to gp120. (A) Chemical structures of BMS-378806 (BMS-806), BMS-
488043 (BMS-043), BMS-626529 (BMS-529). Half maximal effective 
concentration (EC50) and half maximal cytotoxicity concentration (CC50) for each 
compound is indicated. (B) Model of BMS-626529 docked with native 
(unliganded) HIV-1 gp120. CD4 (in white) and gp41 (in light blue) are overlaid 
onto the structure. The 7-(3-methyltriazole) azaindole moiety occupies the space 
in the binding site adjacent to the CD4 binding loop required for CD4:F43 binding 
(92).  
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The compounds were classified as an attachment inhibitors (AIs) and 
mechanistic experiments, including the failure of BMS compounds to block 
infection by CD4-independent HIV-1 isolates, support that the mechanism of 
action is through the inhibition of gp120-receptor attachment (84, 90). The 
Sodroski group verified that BMS compounds are very potent and specific to HIV-
1 but suggested a different mechanism of action. According to Sodroski et al., 
these compounds do not directly block gp120 binding to CD4 or chemokine 
receptor, and inhibit both CD4-dependent and CD4-independent viruses with 
similar potencies (93). They propose that BMS-related compounds function as 
allosteric inhibitors, preventing post-receptor engagement conformational 
changes necessary for viral and cell membrane fusion.  The BMS group 
attempted to investigate the mechanism of BMS-chemotype compounds through 
the investigation of its binding site. Although there is no structural information 
currently available for BMS-626529 bound to gp120, different available structures 
of gp120 were used for docking and molecular dynamics (MD) studies with BMS-
626529 in order to determine plausible compound-binding site(s), and provide 
insight into the mechanism of action. Based on the docking model, BMS-626529 
binds to the native conformation of gp120 within the structurally conserved outer 
domain adjacent to the CD4 binding loop (92). This docking model proposed that 
BMS-626529 binds to the unliganded state of Env to the Phe43 cavity and 
partially inhibits CD4 binding (92). BMS-626529 still has poor metabolic stability 
and has to be administered twice a day.  And, since it’s a prodrug, it has to be 
processed to become active. Because of these reasons, it is already known that 
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it will not be included in the HAART cocktail and only will be used as salvage 
therapy.   
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AIMS OF THESIS 
The aims of the studies contained herein center on improving currently 
available therapies, and informing development of novel therapies, to treat HIV-1 
infected individuals.  
Aim 1: Create a novel, potent and HIV-1 specific entry inhibitor with 
improved drug-like properties. Rationale: BMS compounds are the most potent 
having a broad therapeutic spectrum. This indicates that the binding site for 
these compounds, although currently not well described, is well conserved and 
available for targeting on the virion. However, BMS-chemotype compounds still 
have problems of low solubility and metabolic stability.  
Hypothesis 1: Our goal is to scaffold hop from piperazine to other 
chemotypes that bind to this attractive binding site on Env, retain potency and 
specificity of BMS but have improved intrinsic drug-like properties and metabolic 
stability.  
Aim 2: Investigate the mechanism of HIV-1 entry inhibition by a novel 
inhibitor, SC12. Rationale: We have created a novel class of HIV-1 entry 
inhibitors. And since we used bioisosteric replacement, the novel compound 
SC12 should inhibit HIV-1 through the similar binding site of BMS-chemotype 
compounds. However, the geometry of SC12 is a little different, so it could have 
a contact with different residues and, therefore, function through a different 
mechanism of inhibition. Important to mention, that the mechanism of action of 
BMS compounds  is unclear, with some studies claiming it to be an attachment 
inhibitor, blocking gp120 binding to cellular receptors,  while others state it is an 
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allosteric inhibitor preventing conformational signals from gp120 to gp41. We 
evaluated the literature and looked into details of all the experiment performed 
with BMS compounds. 
Hypothesis 2: The novel compound SC12 functions as HIV-1 allosteric 
inhibitor by binding to Env independent of cellular receptor binding and 
preventing downstream Env conformational changes that lead to fusion of viral 
and cell membranes.  
The discovery of novel, potent and HIV-1 specific entry inhibitors with 
minimal toxicities and improved metabolic properties is beneficial for the 
treatment and prevention of infection. Moreover, the investigation into the 
mechanism of action of this novel entry inhibitor will provide key information on 
receptor recognition by the Env complex, the structural transitions which 
components of the Env complex undergo, and the multistage process of HIV-1 
entry itself.   
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CHAPTER 2 
DISCOVERY AND OPTIMIZATION OF NOVEL SMALL-MOLECULE HIV-1 
ENTRY INHIBITORS USING FIELD-BASED VIRTUAL SCREENING AND 
BIOISOSTERIC REPLACEMENT 
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ABSTRACT 
With the emergence of drug-resistant strains and the cumulative toxicities 
associated with current therapies, demand remains for new inhibitors of HIV-1 
replication. The inhibition of HIV-1 entry is an attractive, yet underexploited 
therapeutic approach with implications for salvage and preexposure prophylactic 
regimens, as well as topical microbicides. Using the combination of a field-
derived bioactive conformation template to perform virtual screening and iterative 
bioisosteric replacements, coupled with in silico predictions of absorption, 
distribution, metabolism, and excretion, we have identified new leads for HIV-1 
entry inhibitors. 
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R, Lombart H-G, Esikov K, Berniac J, Liang K, Ji J, Ptak RJ, Madani N, Cocklin 
S. Discovery and optimization of novel small-molecule HIV-1 entry inhibitors 
using field-based virtual screening and bioisosteric replacement. Bioorg Med 
Chem Lett. 2014 Oct 16;24(23):5439-5445. 
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INTRODUCTION 
Inhibiting the process of entry of HIV-1 into susceptible cells remains an 
elusive but extremely attractive intervention point for the development of novel 
anti-HIV therapies with implications for salvage and preexposure prophylactic 
regimens, as well as topical microbicides. The entry of HIV-1 into permissible 
cells is a complex series of events orchestrated by the viral envelope (Env) 
glycoprotein complex, the only exposed viral components on the virion surface. 
The Env complex is organized on the virion surface as trimeric spikes, composed 
of three gp120 molecules noncovalently linked to three gp41 molecules.  HIV-1 
infection begins with high-affinity interaction between Env subunits gp120 and 
cell surface receptor CD4 followed by the second binding of gp120 to a member 
of the chemokine receptor subfamily within the large G protein–coupled family of 
receptors, mainly CCR5 and/or CXCR4. This interaction causes rearrangement 
in the gp41 subunit, such that the fusion peptide is inserted into the host cell 
membrane, and the helical regions (HR1 and HR2) fold back and interact with 
each other, facilitating the bringing together of the two membranes and eventual 
fusion. 
Advances in knowledge of the molecular mechanisms of HIV-1 entry 
have allowed the discovery and development of molecules that target discrete 
steps in the entry process and have shown success in the clinic. Successful 
examples include maraviroc (Selzentry; Pfizer, New York, NY), which binds to 
CCR5 and blocks the interaction of the Env complex with the coreceptor, and 
enfuvirtide (Fuzeon; Hoffman-La Roche, Nutley, NJ), which binds to gp41 and 
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stops the fusion of the viral and cell membrane. However, as of yet, no gp120-
targeted therapies have been approved for use in the clinic.  
In the HIV-1 entry field, two main Env-targeted inhibitor chemotypes 
predominate: the NBD-556 analogues (77) and the BMS-378806 analogues 
(85) (Figure 2.1). NBD-556 and its analogues bind to the conserved CD4-
binding site in gp120 and block the interaction of the Env complex with cellular 
CD4 (79, 80, 94). The binding site for BMS-378806 and its analogues is poorly 
understood, and based on resistance mutation data it may actually be a 
composite site composed of regions of gp120 and g41(84).  
The mechanism of action of BMS-378806 and its derivatives is also under 
debate, with some studies claiming a CD4 binding inhibition mechanism and 
others describing an allosteric mechanism that prevents the propagation of the 
receptor binding signals from gp120 to gp41 (93, 95). Given the huge therapeutic 
potential of inhibiting HIV-1 entry, the development of new chemotypes that 
target viral entry with broad activities is highly desirable. In this study we describe 
the use of high-content field-based pharmacophore screening as a first step in 
identifying new chemotypes for this inhibitor class.  
To date, the piperazine-based entry inhibitors as first described by Bristol–
Myers Squibb (85) are the most broadly acting and potent HIV-1 entry inhibitors. 
This indicates that the binding site for these compounds, although currently not 
well described, is well conserved and available for targeting on the virion and that 
compounds such as BMS-663068 may have great therapeutic value. In fact, the 
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entry inhibitor BMS-663068 recently performed favorably in a phase IIb clinical 
trial (89).  
Although the compounds are potent and have a broad therapeutic 
spectrum, the piperazine class of entry inhibitors developed by Bristol–Myers 
Squibb has been plagued by the problems of low solubility and poor intrinsic 
dissolution properties. To circumvent these issues, a prodrug approach was 
adopted. BMS-663068 is a phosphonooxymethyl prodrug of BMS-626529 (84, 
93-95) designed to have increased solubility in the gut. The prodrug is thought to 
be cleaved by alkaline phosphatase, located on the luminal surface of the small 
intestine brush border membranes, releasing BMS-626529, which is then rapidly 
absorbed (88). Despite the success of this approach, an entry inhibitor candidate 
with more intrinsic druglike properties would be preferable.  
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Figure 2.1. Structures of entry inhibitors developed by Bristol–Myers 
Squibb and the New York Blood Bank. The chemical structures were rawn 
with ChemAxon software (Budapest, Hungary). 
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RESULTS 
Field-based virtual screening of in silico libraries of commercially available 
compounds; identification of compound 11 (SC03) 
As a first step towards discovering entry inhibitor candidates with intrinsic 
druglike properties, we conducted a series of fieldbased three-dimensional 
similarity virtual screening experiments using Blaze (Cresset, Litlington, UK) with 
a high-content fieldbased pharmacophore template derived from BMS-626529 
(88, 95-97) (Forge/FieldTemplater, Cresset) in order to identify novel scaffolds 
that could function as entry inhibitors. To perform a Blaze virtual screen, an 
active ligand in its three-dimensional bioactive conformation should be used as a 
search query. In the absence of structural information, a binding mode 
hypothesis may be calculated.  
As no structural information is currently available for BMS-626529 in its 
target-bound state, we used FieldTemplater (Forge) to determine a hypothesis 
for the three-dimensional conformation adopted in binding to the target using field 
and shape information to create a template using compounds BMS-626529, 
BMS-488043, and BMS-378806 (84, 98). The FieldTemplater-derived hypothesis 
for the bioactive conformation was then annotated with its calculated field points, 
resulting in a three-dimensional field point pattern. The field point pattern 
provides a condensed representation of the compound’s shape, electrostatics, 
and hydrophobicity. It is well established that when two diverse structures have 
conformations with similar field point patterns, they are experienced by the 
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receptor in a similar fashion (99-109). The field-based alignment for the three 
selected templating molecules is shown in Figure 2.2. (Appendix 1 contains the 
detailed explanation of the FieldTemplater analysis).  
The field point pattern for the hypothesized three-dimensional bioactive 
conformation of BMS-626529 was subsequently used to query a database of 
approximately 6 million commercially available compounds using Blaze. The 
steps involved in the Blaze virtual screening procedure are shown schematically 
in Figure 2.3. (Appendix 1 contains the detailed explanation of the Blaze Virtual 
Screening).  
The Blaze procedure resulted in the rank ordering of the top 1000 Blaze 
library compounds whose three-dimensional arrangements of field points had 
similarities to that of the BMS-626529 template structure. Fifty compounds were 
chosen and purchased for biological testing using the single-round infection 
assay (110). Five compounds with specific anti-HIV-1 activity were discovered 
using this approach and are listed in Table 2.1.  
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Figure 2.2. The generation of the field-based template. (a) Field-based 
template A containing a single conformation of compounds BMS-378806 (pink), 
BMS-488043 (lime green), and BMS-626529 (teal green) aligned based on their 
three-dimensional field point patterns. Negatively charged field points are shown 
in blue; positively charged field points are red; van der Waals/shape field points 
are displayed in yellow; centers of hydrophobicity are shown in orange. (b) 
Conformation 69 of BMS-626529 with its associated field points. This 
conformation was common to the top three templates identified and was used as 
the query structure for the Blaze (Cresset, Litlington, UK) field-based virtual 
screen. (Generated by Dr. Cocklin, Appendix 2).  
(
a) 
(
b) 
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Figure 2.3. Steps involved in a Blaze (Cresset, Litlington, UK) field-based 
virtual screen experiment. (1) An active molecule is selected and converted to 
a relevant bioactive conformation. (2) Field points are added to this search ligand 
in the specified conformation to produce the Blaze pharmacophore seed. (3) The 
Blaze search query consists of the field point pattern of the pharmacophore seed, 
which is used to search the Blaze database by alignment of every structure 
based on field point patterns (of its up to 100 conformations). (4) Top scoring 
compounds are retrieved as three-dimensional alignments to the search query, 
along with their score (molecular similarity based on 50% shape, 50% fields). 
(Generated by Dr. Cocklin, Appendix 1).   
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Table 2.1. Structure and potency of compounds identified within this study 
with specific activity against HIV-1 YU-2.  
Compound IC50 YU-2 (µM) IC50 AMLV (µM) 
11 
 
 
 
13.1 ± 1.7 
 
 
N.A. 
12 
 
 
 
            53.5 ± 3.0 
 
 
N.A. 
28 
 
 
 
33.7 ± 4.5 
 
 
N.A. 
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79.4 ± 11 
 
 
 
 
 
N.A. 
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153 ± 44 
 
 
 
 
 
 
 
N.A. 
Chemical structures were drawn with ChemAxon software (Budapest, 
Hungary). N.A. = not active over concentration range tested. 
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In search of novelty: scaffold-hopping by bioisosteric replacement and 
identification of SC04 
All five compounds share a piperazine core comparable to the Bristol–
Myers Squibb compounds. Therefore, we decided to replace piperazine core with 
another moiety that would function in the same capacity but be chemically 
distinct. Pfizer reported a study in which replacement of an N-methylpiperazine in 
a lead compound, JNJ-7777120, with 2-methyloctahydropyrrolo[3,4-c]pyrrole led 
to a compound that retained binding affinity and selectivity but also had improved 
resistance to metabolism (111). We therefore performed in silico bioisostere 
replacement (scaffold-hopping) of the piperazine in compound 11 for dipyrrolidine 
group. We used Spark (Cresset, UK) to assess the potential of such substitution 
and calculated bioisostere factor (BIF%), a rescaled score, which indicates how 
much better or worse the replacement is compared with simply capping the 
attachment point(s) with hydrogen(s). Positive BIF% values indicate good 
bioisosteres; negative values correspond to replacements where the geometry of 
the original molecule is reproduced; however, the fragment is not a good mimic 
of the replaced part. 
A BIF% of 57 was obtained for the dipyrrolidine group, and therefore this 
replacement for piperazine was investigated. Substitution of the piperazine core 
in compound 11 with 2-methyloctahydropyrrolo[3,4-c]pyrrole yielded compound 
SC04 ([5-(1,2-dihydro acenaphthylene-5-carbonyl)-1,3,3a,4,6,6a-
hexahydropyrrolo [3,4-c]pyrrol-2-yl]-phenyl-methanone]), a novel compound that 
retains the properties of 11, albeit with lower potency (IC50 HIV-1YU-2 = 70 ± 6 µM; 
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IC50 HIV-1JR-CSF = 100 ± 30 µM; Table 2.2, synthesis scheme in Appendix 1). 
Owing to the relative decreased sensitivity of HIV-1JR-CSF to SC04, as compared 
with HIV-1YU-2, this isolate was selected for use in potency optimization. 
Increasing the potency of the dipyrrolidine scaffold: Design, synthesis and 
testing of SC07, SC08, and SC11 
We next focused on redesigning the head region of SC04 to improve its 
potency and to remove any potential toxophores. The head region of SC04 is an 
acenaphthene group, which may be carcinogenic owing to its potential to 
intercalate into DNA sequences (112, 113). Moreover, several studies by Bristol–
Myers Squib have demonstrated that this head region greatly influences the 
potency of compounds in the piperazine class. Subsequently, in order to improve 
the potency of SC04, we downloaded 453 compounds from PubChem and 
screened for similarity to BMS-488043. These compounds were exhaustively 
fragmented (Spark DBGen, Cresset, UK), and we used the resulting fragments in 
iterative Spark experiments, seeking fragments that could function as bioisosteric 
substitutions for the acenaphthene moiety but with greater potential for hydrogen 
bonding interactions. This resulted in the identification of two head groups, 7-
chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine and 4,7-dimethoxy-1H-pyrrolo[2,3-
c]pyridine, with BIF% values (compared with acenaphthene) of 57 and 64, 
respectively. Two compounds bearing these head groups were synthesized 
(SC07 and SC08, Appendix 1) and assessed in the single-round infection assay 
against HIV-1JR-CSF.  
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Both compounds were specific to HIV-1 (no inhibition of AMLV-
pseudotyped HIV-1) and inhibited HIV-1JR-CSF pseudotyped HIV-1 virus with IC50 
values of 0.98 ± 0.06 µM and 0.09 ± 0.01 µM, for SC07 and SC08, respectively 
(Table 2.2). Additionally, we tested the compounds against X4 tropic 
pseudotyped virus HIV-1Hxbc2 and determined that SC08 had higher potency of 
inhibition (IC50 value of 0.19 ± 0.08 µM) compared to SC07 (IC50 value of 16.8 ± 
6.2 µM). 
The head group of SC08 is the same as in BMS-488043 (87, 114).  
Replacement of the methoxy in the 7 position on the azaindole ring with a 
methyltriazole greatly improved the potency of the compound, resulting in the 
creation of BMS-626529 (115, 116). SC11 compound bearing this substitution 
was synthesized (Appendix 1) and tested for specificity and activity against HIV-
1JR-CSF and HIV-1Hxbc2 using the single-round infection assay. SC11 retained HIV-
1 specificity and increased potency against both HIV-1JR-CSF and HIV-1Hxbc2 with 
IC50 values of 0.0008 ± 0.0004 µM and 0.001 ± 0.0001 µM, respectively (Table 
2.2). 
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Table 2.2. Structure and potency of second-generation compounds based 
on the dipyrrolidine core scaffold. 
 
Compound IC50  (µM) 
JR-CSF HxBc2 AMLV 
SC04 
 
 
 
100 ± 30 
 
 
N.D. 
 
 
N.A. 
SC07 
 
 
 
 
 
0.98 ± 0.06 
 
 
 
 
16.8 ± 6.2 
 
 
 
 
N.A. 
SC08 
 
 
 
 
 
 
0.09 ± 0.01 
 
 
 
 
0.19 ± 0.08 
 
 
 
 
N.A. 
 
SC11 
 
 
 
 
 
0.0008 ± 0.0004 
 
 
 
 
0.001 ± 0.0001 
 
 
 
 
N.A. 
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SC26 
 
 
 
 
 
 
0.002 ± 0.0001 
 
 
 
 
 
0.0006 ± 0.00008 
 
 
 
 
 
N.A. 
 
Chemical structures were drawn with ChemAxon software (Budapest, Hungary).  
AMLV = amphotropic murine leukemia virus; IC50 = half-maximal inhibitory 
concentration; N.A. = not active over concentration range tested; N.D. = not 
determined.  
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Predicted ADME driven design of compound SC26 
Synthesis and assessment of SC11 revealed that the dipyrrolidine core 
can support compounds of nanomolar potency that prevent HIV-1 entry. The next 
step was to analyze the predicted ADME properties (absorption, distribution, 
metabolism, and excretion) of this compound and compare them with those of 
the BMS piperazine-based entry inhibitors (Figure 2.4). 
To accomplish this comparison, we used a combination of computationally 
guided bioisosteric replacement using Spark (focusing on the terminal phenyl 
group of SC11) and in silico prediction of druglike metrics of the results as 
implemented in the oral non-central nervous system (CNS) drug profile in 
StarDrop 5.5 (Optibrium, Ltd, Cambridge, UK) (117). (Appendix 1 contains the 
detailed explanation of Spark Bioisosteric Group Replacement).  
Optibrium’s oral non-CNS drug profile is composed of the following 
metrics: logS (intrinsic aqueous solubility); classification for human intestinal 
absorption; logP (octanol/water); hERG (human ether-à-go-go-related gene) 
pIC50 (mammalian cells); cytochrome P450 CYP2D6 classification; cytochrome 
P450 CYP2C9 pKi values; classification of P-glycoprotein transport; classification 
of blood–brain barrier (BBB) penetration; and predicted BBB penetration value. 
The models and their respective importance to the profile are shown in Figure 
2.4 a. 
A probabilistic scoring algorithm (118) is then used to combine the model 
predictions in the oral non-CNS drug profile into an overall score.  
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Figure 2.4. The analysis of predicted ADME properties. (a) The individual 
models that comprise the oral non-CNS (central nervous system) drug profile and 
their respective importance to the profile. HIA = human intestinal absorption; 
hERG (human ether-à-go-go-related gene); IC50 = half-maximal inhibitory 
concentration; BBB = blood–brain barrier. (b) Plot showing the StarDrop 
(Optibrium, Ltd, Cambridge, UK)—derived logS versus the score from a 
multimetric oral non-CNS profile for the BMS and SC compounds. (Generated by 
Dr. Cocklin using Optibrium, Ltd).   
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This combined Spark/StarDrop analysis suggested that a simple 
replacement of phenyl with cyclohexene may be a good transformation to 
perform in order to improve ADME properties while retaining the potency 
associated with the dipyrrolidine scaffold. StarDrop analysis of the cyclohexene 
variant of SC11 (designated SC26, synthesis in Appendix 1) versus BMS-
663068 using the oral non-CNS drug profile provided scores for SC26 and BMS-
663068 of 0.3815 ± 0.2323 and 0.0799 ± 0.1014, respectively (Figure 2.4 b). For 
reference, scores range from 0 to 1, with 0 suggesting extremely non-druglike, 
and 1 suggesting the perfect drug. Given two oral non-CNS drug profile scores 
with errors corresponding to 1 standard deviation: 
X1 ± σ1  
X2 ± σ2; 
and assuming that the error is normally distributed, the difference in the 
scores will take a normal distribution with mean X1 - X2 and standard deviation 
given by    
      
 . Therefore, the probability that X1 > X2 is the probability that 
X1 – X2 > 0 was calculated in Excel (Microsoft; Redmond, WA) using the 
NORMDIST function. This analysis predicted an 88% likelihood that SC26 has 
better druglike properties than BMS-663068. Thus, we synthesized compound 
SC26 and subjected it to specificity and potency analysis using the single-round 
infection assay. Gratifyingly, this compound exhibited IC50 values of 2.0 ± 0.1 nM 
and 0.6 ± 0.01 nM against HIV-1JR-CSF and HIV-1HxBc2, respectively, (Table 2.2). 
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Because it demonstrated good potency against two isolates in the single-
round infection assay as well as specificity to HIV-1, we next sought to quantify 
the potency of SC26 against the fully infectious virus. Moreover, this assay was 
performed using healthy, primary cells to gain further insight into potential 
toxicities of the compound towards natural target cells. Additionally, as a key 
issue in the development of novel HIV drugs is their ability to inhibit the 
replication of genetically diverse isolates (especially isolates from the most 
globally prevalent subtypes A, B, C, and D), we chose to assess the potency of 
SC26 to inhibit the replication of isolates from subtypes A, B, C, and D in primary 
human peripheral blood mononuclear cells (PBMCs) (119-121). Concomitantly, 
we assessed the toxicity of SC26 to the PBMCs using an MTS assay. The results 
of these analyses are summarized in Table 2.3. As can be observed from the 
IC50 values, the potency of SC26 against different isolates ranges quite 
dramatically, most likely reflecting differences in the binding site between 
subtypes. Moreover, SC26 had no effect on the replication of an HIV-2 isolate, 
mirroring the specificity analyses using the AMLV pseudotyped recombinant HIV-
1 virus, and further demonstrating specificity to HIV-1. 
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Table 2.3. Therapeutic spectrum of SC26 against highly prevalent HIV-1 
subtypes and HIV-2. 
Virus Isolate Subtype IC50 (µM) TC50 (µM) 
Antiviral 
index 
(TC50/IC50) 
92UG037 A 25.2 ± 6.9 
>100 
> 3.97 
91US004 B 
0.195 ± 
0.012 
> 513 
94US_3393IN B 
0.0006 ± 
0.0005 
> 166,666 
98US_MSC5016 C 3.9 ± 0.8 > 25.6 
99UG_A07412M1 D 0.49 ± 0.06 > 204 
HIV-2 
CDC310319 
NA > 100 NA 
 
IC50 = half-maximal inhibitory concentration; NA = not applicable; TC50 = 
halfmaximal toxic concentration. (Generated by Dr. Madani). 
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DISCUSSION 
Using a combination of high-content pharmacophore in silico screening, 
chemical syntheses, bioisosteric replacement, and antiviral testing, we have 
developed a novel class of entry inhibitors which inhibit the entry of HIV-1 into 
susceptible cells in the nanomolar range.  Fifty novel compounds obtained 
through the in silico screen were tested using single-round infection assay and 
results revealed their specificity to HIV-1 with half-maximal inhibitory 
concentrations (IC50) in the range of 13–150 µM. Compound 11 was found to be 
the most potent, therefore we proceeded to modify it to improve its potency. 
The substitution of the piperazine for the dipyrrolidine group led to a novel 
class of the inhibitor, however possessing a reduced potency, which was rescued 
by the substitution of the head acenaphthene group with two head groups, 7-
chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine and 4,7-dimethoxy-1H-pyrrolo[2,3-
c]pyridine, which led to the synthesis of SC07 and SC08, respectively. Both 
compounds were specific to HIV-1 (with no anti-viral activity against AMLV 
pseudotyped virus) and had an increased potency comparing to the SC04. 
Further replacement of the methoxy in the 7 position on the azaindole ring 
with a methyltriazole in SC08 greatly improved the potency of the compound 
(SC11), inhibiting HIV-1JR-CSF at low nanomolar concentration. A simple 
replacement of phenyl with cyclohexene group at the core of the compound 
SC11 led to the synthesis of SC26, which retained the low nanomolar potency 
against HIV-1 and drastically improved its predicted drug-like properties.  
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Like the BMS piperazine-based entry inhibitors, the new dipyrrolidine 
scaffold displayed varying degrees of potency against HIV-1 isolates from 
different subtypes, probably reflecting isolatespecific differences in the binding 
site on Env. Further investigation and determination of the exact binding site of 
this class of entry inhibitors will undoubtedly be invaluable in the redesign and 
optimization of such compounds, while illuminating a new site of vulnerability in 
the Env complex of HIV-1. Taken as a whole, these results extend the 
chemotypes for this class of HIV-1 inhibitor and validate the use of 
multiparameter optimization using high-content three-dimensional field-based 
models, bioisosteric replacement, and consideration of drug-like metrics in drug 
design. 
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APPENDIX 1 
Bioactive Conformation Hypotheses Prediction Using FieldTemplater 
(Forge) 
Due to the lack of structural information for BMS-626529 in its target-
bound state, FieldTemplater (Forge, Cresset, UK) was used to determine the 
most likely 3D conformation(s) adopted in binding to the target, using field and 
shape information from BMS-626529(115, 116), BMS-488043 (114, 122, 123) 
and BMS-378806 (84, 114) to calculate potential bioactive conformation 
hypotheses.  Bioactive conformations of molecules that bind to the same active 
site are expected to display a similar shape, distribution of charge and 
hydrophobic groups.  
In the FieldTemplater (124) experiment (conducted within Forge (124)), 
each of the three compounds was conformationally populated using Cresset’s 
Xedex conformational search method (embedded within Forge).  The 3D field 
point pattern for each conformation of each template molecule was calculated 
and used to cross-compare to each other in field / shape space, with no 
dependence on chemical structure.  The calculation of field points and their use 
in comparing molecules has been described in detail in previous literature (106). 
It is noteworthy that these field point patterns are generated from the whole 
molecule, and not reliant on local or isolated features such as hydrogen bonds or 
aromatic moieties, thus providing an extremely concise, high content 
representation of the molecule’s pharmacophoric features. 
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Using 3D field point patterns, the conformations of the three BMS 
molecules were exhaustively compared in a pair-wise fashion until field point 
patterns common to all three molecules were identified. The resulting templates 
(i.e., binding mode hypotheses) each consist of one conformation of each of the 
three molecules (trios). 
It is postulated and experimentally supported (106, 107, 109, 125, 126) 
that trios reported by the experiment are likely to include the correct alignment 
and bioactive conformation.  
The trios from the FieldTemplater experiment using the BMS compounds 
were visually inspected and one conformation of BMS-626529 was selected as 
the query molecule for the Blaze (Cresset, UK) field based virtual screening 
experiments.  The selected conformation of BMS-626529 appeared in several of 
the top-scoring templates. 
Blaze Virtual Screening Using BMS-626529 Template 
The 3D field point pattern for the proposed bioactive conformation of BMS-
626529 selected from the FieldTemplater experiment was used to query a 
database of approximately 6 million commercially available compounds (Blaze 
Database) using Blaze (Cresset, UK). Each of these 6 million compounds was 
previously conformationally populated using Cresset’s conformational hunter, 
XedeX (http://www.cresset-group.com/products/xedtools/#overview) which 
employs Cresset’s XED forcefield (127).  In addition to conformational hunting, 
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each conformation has its three-dimensional field point pattern calculated and 
stored with the structure. 
The Blaze search procedure has been demonstrated to be a practical, 
efficient method of ligand-based virtual screening that employs both shape and 
field based molecular comparisons that retrieve actives that are both structurally 
novel and lead-like (108, 128-130). 
The Blaze virtual screening procedure is comprised of the following steps: 
 Identification of an active ligand and its 3D bioactive conformation 
(single conformation).  This structure is known as the search 
molecule.  
 The field point pattern for this conformation of the search molecule 
is produced, and it is that arrangement of field points in 3 
dimensions that provides the Blaze Query. 
 The Blaze Query is compared to the field point pattern of every 
conformation of all of the molecules in the Blaze Database. 
 The results are returned and contain a similarity score (by default, 
based on 50% shape / 50% fields) for each molecule, a 3D 
alignment of the best scoring conformation, and a 2D 
representation.  
The Blaze experiment resulted in the rank ordering of the top 1000 
commercially available compounds whose field point patterns had similarities to 
that of BMS-626529 in the proposed bioactive conformation from the template. 
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Based on visual inspection of field point pattern comparisons and combined 
shape-field similarity scores (50:50), fifty compounds were chosen and 
purchased for biological testing using the single-round infection assay (110). 
Spark Bioisosteric Group Replacement 
The use of Cresset’s field point technology has been employed for field 
based scaffold hopping and bioisosteric replacement since 2005 (125) and has 
been well discussed in two recent reviews (131, 132).  These experiments were 
conducted using Spark (Cresset, UK). 
To summarize the method, a section a molecule in its bioactive 
conformation (not necessary, but 3D binding structure is desirable) is selected 
and designated for replacement.  When that moiety is clipped away, replacement 
candidates from Spark’s fragment databases are fit into the molecule and scored 
(more details are provided below). Spark’s native fragment databases consist of 
fragments generated from commercially available screening compounds, 
ChEMBL (133), and VeHICLE (134) databases. 
Fragments are generated by the method outlined in the Spark user 
manual (124) which entails breaking all “breakable” bonds in a molecule, then 
reconnecting sets of pieces to form bigger fragments.  Fragments, by default, 
may contain up to 15 heavy atoms and 5 rotatable bonds, with a molecular 
weight maximum of 250.  Each fragment has up to 30 conformations generated 
and stored, with field point patterns calculated for each conformation.  Along with 
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field point patterns, the relative orientations and positions of fragment attachment 
points are recorded. 
In the course of the Spark experiment, a portion of the molecule to be 
replaced is selected; the number of bonds that were broken along with the 
distances and angles between broken bonds are recorded.  The first pass 
through the Spark fragment databases involves finding fragments which have the 
same number of attachment points, and approximately the same geometry (‘bite 
size’ and ‘bite angle’).  Each one of these first-pass fragments is fit into the 
original molecule; fields and field points are calculated for the resulting whole 
molecules.  The resulting molecules are minimized using the XED forcefield, then 
the full field and shape of the molecule is scored against the full field and shape 
of starting molecule (or other designated reference molecule, or combination 
thereof).  By default, 50% shape and 50% fields are used in score calculations. 
De novo syntheses 
Synthesis of novel compounds was performed by Enamine Ltd. (Kiev, 
Ukraine), AsisChem, Inc. (Watertown, MA), HD Biosciences Co., Ltd. (Shanghai, 
China), or WuXi Apptec (Shanghai, China) according to the schemes and 
procedures outlined below. 
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Synthesis of SC04: Trifiuoroacetic acid (TFA, 1.48 g, 0.013 mol) was added to a 
cold (0ºC) solution of compound 2 12.6 g, 0.13 mol) in dichloromethane (250 mL) 
under nitrogen. A solution of compound 1 (31 g, 0.13 mol) in dichloromethane 
(200 mL) was added drop-wise over 45 min. After the addition was complete, the 
mixture was warmed slowly to ambient temperature and stirred for 16 h. The 
mixture was concentrated and the resulting residue was dissolved in 
dichloromethane (200 mL) and washed with saturated aqueous sodium 
bicarbonate (2 x 100 mL). The aqueous layer was separated and extracted with 
dichloromethane (2 x 150 mL). The combined dichloromethane extracts were 
washed with brine (150 mL), dried over anhydrous magnesium sulphate, filtered 
and concentrated to give 30 g ( 75 percent yield) of compound 3 as a light yellow 
solid. 
The crude compound 3 (30 g, 0.13 mol) was dissolved in dry 
tetrahydrofuran (THF) (500 mL) under nitrogen atmosphere, and then lithium 
aluminium hydride (14.8 g, 0.39 mol) was slowly added at 0°C over 30 min. The 
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resulting mixture was stirred at ambient temperature for 30 min and then warmed 
to reflux for 7 h. The mixture was then cooled to 0 ºC and quenched by the slow 
addition of an excess of H2O/THF solution (1/10). The mixture was warmed to 
ambient temperature and stirred for 1 h. The solids were filtered and the residue 
was washed with ethyl acetate (3 x 150 mL). The combined filtrates were 
concentrated to give 27 g of a crude material. Purification of the crude compound 
4 was successfully performed by column chromatography with EtOAc/hexene 
(3/1 + 10 % TEA) as an eluent. 19.2 g (73 percent yield) of the pure material 
were obtained.  
A solution of benzoyl chloride (6.6 g, 0.047 mol) in DCM (100 mL) was 
being added dropwise to a stirred mixture of compound 4 (9.5 g, 0.047 mol) and 
Et3N (20 g, 0.15 mol) in DCM (150 mL) at room temperature during 30 min. After 
the addition was complete, the reaction mixture was stirred at room temperature 
for 5 h and then washed with water (2 x 100 mL), 1 N aq. HCl (2 x 50 mL), water 
(2 x 50 mL), saturated aq. NaHCO3 (2 x 75 mL), and brine (2 x 50 mL). After 
drying over MgSO4, the solvent was evaporated under reduced pressure to give 
the compound 5 (13.3 g, 0.043 mol, 93 percent yield) as a yellow oil. 
Compound 5 (10.3 g, 0.033 mol) was added to the suspension of 10% 
Pd/C (1.5 g) in anhydrous methanol (250 mL). This mixture was hydrogenated at 
20 atm and RT for 10 h. The catalyst was filtered off through a pad of Celite, 
which was then washed with anhydrous methanol (200 mL). The solvent was 
evaporated under reduced pressure to afford the crude product 6 as yellow oil. 
Obtained material were dissolved in 0.5 N aq. HCl (50 mL), treated with charcoal, 
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and filtered. The filtrate was evaporated to dryness to give 7 g (0.027 mol, 83 
percent yield) of compound 6*HCl as a white solid. 
Acenaphthene-5-carboxylic acid (0.3 g, 1.5 mmol) was added to a mixture 
of compound 6*HCl (0.38 g, 1.5 mmol) and TEA (0.41 g, 4 mmol) in CH2Cl2 (25 
mL) at the room temperature. Then 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (0.3 g, 1.6 mmol) was added and the mixture 
was stirred at the room temperature for 16 h. The organic phase was then 
washed with water (2 x 200 mL), 1 N aq. HCl (2 x 150 mL), water (2 x 200 mL), 
saturated aq. NaHCO3 (2 x 200 mL), and brine (2 x 150 mL). After drying over 
MgSO4, the solvent was evaporated under reduced pressure to give the crude 
compound 7 (0.52 g) in a form of a yellow oil. The crude material was purified 
three times by column chromatography with DCM/MeOH (10/2) as an eluent. 
Final purification was performed by preparative HPLC to provide 40 mg (0.6 
mmol, 8 percent yield) of the pure compound 7 as a light yellow solid. 
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Synthesis of SC07: To a solution of compound 7 (212.3 mg; 1 mmol) in DCM 
(30 ml) was added TEA (325 mg; 3.2 mmol). The resulted solution was cooled to 
0 °C and a solution of benzoyl chloride (140 mg; 1 mmol) in DCM (5 ml) was 
added dropwise. The reaction mixture was stirred at room temperature for 2 h, 
and then water (100 ml) with NaHCO3 sat. (10 ml) were added. Organic layer 
was separated, washed with water and dried over Na2SO4. DCM was evaporated 
to afford compound 8 (160 mg; 50%) as yellow oil.  To a solution of compound 8 
(1.1 g; 3.5 mmol) in dry Et2O (5 ml) under argon was added 4N HCl in Et2O (5 
ml). The mixture was stirred for 3 h and the formed precipitate was filtered, 
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washed with Et2O and stored into a desiccator to give  compound 9 (0.67 g, 
89%) as a white powder. 
To a solution of  compound 10 (250 mg; 1.05 mmol) in dry THF (10 ml) 
under argon at -78 °C was added dropwise a 1.42 M solution of vinylmagnesium 
bromide in THF (6 ml, 8.4 mmol; prepared by dilution of 1.7 M solution of in THF 
(50 ml) with THF (12 ml)). The reaction mixture was stirred at the same 
temperature for another 1.5 h and then it was quenched by addition of NH4Cl sat. 
(30 ml). The THF-layer was separated and the aqueous layer was extracted with 
EtOAc (2×10 ml). Combined organic layers (THF with EtOAc extracts) were dried 
over Na2SO4 and concentrated to afford 270 mg of yellow oily material which was 
treated with DCM (10 ml). Light-yellow solid was filtered and dried in oven (45 
°C) to give compound 11 (70 mg, 29%).   
To a solution of compound 11 (3.8 g; 16.4 mmol), celite (6.16 g) in dry 
toluene (60 ml) was added a solution of potassium (6.39 g; 164 mmol) in MeOH 
(50 ml). The reaction mixture was heated at reflux (with Dean-Stark trap) for 12 
h, then it was cooled to ambient temperature and mixture of toluene and 
methanol (1/1, 50 ml) was added. Then the reaction mixture was heated again 
and when the temperature was 60°C, CuI (3.43 g; 18 mmol) was added. The 
mixture was held at 115°C for 1.5h while collecting a mixture of MeOH and 
toluene. The mixture was cooled to ambient temperature and water (60 ml) was 
added. A precipitate formed was filtered off and washed with EtOAc (100 ml), 
and then the aqueous layer was extracted with EtOAc (50 ml). Combined EtOAc-
layers were dried over Na2SO4 and concentrated to afford compound 12 (2.4 g, 
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82%) as light-yellow solid.  To a solution of compound 12 (0.8 g; 4.5 mmol) in N-
methylpyrrolidone (5 ml), water (0.5 ml) and hydrochloric acid (5-6 drops) were 
added. The mixture was stirred at 100°C for 6 h. The mixture was cooled to room 
temperature and water (100 ml) was added. Then NaHCO3 sat. (20 ml) was 
added, the product was extracted with EtOAc (5×20 ml). Combined extracts were 
dried over Na2SO4 and concentrated to afford compound 13 (0.6 g, 81%) as 
pink solid.  A solution of compound 13 (1.8 g; 11 mmol) in POCl3 (20 ml) was 
stirred at 100 °C for 12 h. Then POCl3 was evaporated under reduced pressure. 
To a residue ice water (100 ml) and then NaHCO3 sat. (25 ml) were added, the 
product was extracted with EtOAc (3×35 ml). Combined extracts were dried over 
Na2SO4 and concentrated to afford compound 14 (0.8 g, 40%) as light-yellow 
solid.  To a 0 °C suspension of ethyl 2-chloro-2-oxoacetate (222.7 mg; 1.63 
mmol) and AlCl3 (237 mg; 1.78 mmol) in DCM (5 ml) was added dropwise a 
suspension of compound 14 (165 mg; 0.92 mmol) and AlCl3 (122 mg; 0.92 mmol) 
in DCM (5 ml). The reaction mixture was stirred at room temperature for 2 h. 
Then the mixture was cooled again and water (50 ml) with NaHCO3 sat. (10 ml) 
were added maintaining the temperature 0 °C. Organic layer was separated, 
dried over Na2SO4 and concentrated. Crude product was purified by column 
chromatography (EtOAc/hexane 1:1) to afford compound 15 (50 mg, 20%) as 
yellow crystals.  Compound 15 (350 mg; 1.24 mmol) was dissolved in aqueous 
methanol (1/1, 14 ml) and K2CO3 (0.34 g; 2.48 mmol) was added to the solution. 
The mixture was stirred at room temperature for 8 h. The solvent was removed 
under vacuo to afford crude compound 16 (361 mg) as white powder which used 
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for the next step without further purification.  A solution of compound 16 (361 mg; 
1.23 mmol), EDCI (353 mg; 1.85 mmol) and DIPEA (635 mg; 4.92 mmol) in dry 
DMF (10 ml) was stirred for 1 h. Then compound 9 (311 mg; 1.23 mmol) was 
added and the reaction mixture was stirred at 20 °C for another 18 h. Then water 
(100 ml) with NaHCO3 sat. (10 ml) were added. Target compound was extracted 
with DCM (3×30 ml). Combined extracts were dried over Na2SO4 and 
concentrated. Crude material was purified by column chromatography 
(EtOAc/MeOH 9:1) to afford SC07 (28 mg, 4.6%) as a yellow powder. 
 
 
Synthesis of SC08: A solution of compound 12 (300 mg; 1.69 mmol) and AlCl3 
(230 mg; 1.75 mmol) in DCM (10 ml) was added dropwise to a 0 °C suspension 
of ethyl 2-chloro-2-oxoacetate (600 mg; 4.3 mmol) and AlCl3 (600 mg; 4.6 mmol) 
in DCM (10 ml). The reaction mixture was stirred at room temperature for 18 h. 
 61 
 
Then the mixture was cooled again and water (50 ml) with NaHCO3 sat. (25 ml) 
were added maintaining the temperature 0°C. Organic layer was separated, dried 
over Na2SO4 and concentrated. Crude product was purified by column 
chromatography (EtOAc/hexane 1:2) to afford compound 17 (144 mg, 30%) as a 
yellow powder. K2CO3 (0.839 g; 6.08 mmol) was added to a solution of 
compound 17 (845 mg; 3.04 mmol) in aqueous methanol (1/1; 14 ml). The 
mixture was stirred at room temperature for 8 h. A precipitate obtained was 
filtered and washed with MeOH to give compound 18 (500 mg, 57%) as a white 
powder.  A solution of compound 18 (288 mg; 1 mmol), EDCI (287 mg; 1.5 mmol) 
and DIPEA (516 mg; 4 mmol) in dry DMF (10 ml) was stirred for 1 h. Then 
compound 9 (252 mg; 1 mmol) was added and the reaction mixture was stirred at 
20 °C for another 18 h. Then water (100 ml) with NaHCO3 sat. (10 ml) were 
added. Target compound was extracted with DCM (3×30 ml). Combined extracts 
were dried over Na2SO4 and concentrated. Crude material was purified by 
column chromatography (EtOAc/MeOH 9:1) to afford SC08 (190 mg, 42%) as a 
pale green solid. 
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Synthesis of SC11: To a stirred solution of benzoic acid (116 mg, 0.94 mmol) in 
DCM (3 mL) were added compound 7 (200 mg, 0.94 mmol), TEA (0.4 mL, 2.82 
mmol) and HBTU (536 mg, 1.39 mmol).  The resulting mixture was stirred at r.t. 
overnight before quenched with sat. NaHCO3.  The layers were separated and 
the aqueous layer was extracted with DCM (10 mL x 3).  The combined organic 
layers was dried over Na2SO4, filtered and concentrated.  The residue was 
purified by flash chromatography (silica gel, 0 ~ 50% ethyl acetate in petroleum 
ether with 0.5% TEA) to provide compound 8 (164 mg, 55 %) as a yellow solid.  
Compound 9 (303 mg, 100 %) was obtained as a yellow oil by treating compound 
8 (345 mg, 1.09 mmol) with 4N HCl/Dioxane (3 mL).   
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To a solution of compound 12 (0.8 g; 4.5 mmol) in N-methylpyrrolidone (5 
ml), water (0.5 ml) and hydrochloric acid (5-6 drops) were added. The mixture 
was stirred at 100°C for 6 h. The mixture was cooled to room temperature and 
water (100 ml) was added. Then NaHCO3 sat. (20 ml) was added, the product 
was extracted with EtOAc (5×20 ml). Combined extracts were dried over Na2SO4 
and concentrated to afford compound 13 (0.6 g, 81%) as pink solid.  A solution of 
compound 13 (1.8 g; 11 mmol) in POCl3 (20 ml) was stirred at 100 °C for 12 h. 
Then POCl3 was evaporated under reduced pressure. To a residue ice water 
(100 ml) and then NaHCO3 sat. (25 ml) were added, the product was extracted 
with EtOAc (3×35 ml). Combined extracts were dried over Na2SO4 and 
concentrated to afford compound 14 (0.8 g, 40%) as light-yellow solid 
At 143°C, to a melt 3-methyl-1H-1,2,4-triazole (744 mg, 8.95 mmol) under 
N2 atmosphere was added compound 14 (392 mg, 1.79 mmol).  After stirring for 
20 hrs, the reaction mixture was cooled down to r.t. and partitioned between H2O 
(20 mL) and EA (20 mL). The layers were separated and the aqueous layer was 
extracted with EA (20 mL x 3).  The combined organic layers was dried over 
Na2SO4, filtered and concentrated.   The residue was purified by prep. HPLC 
(C18, 10% to 89% acetonitrile in water (0.1% formic acid)) to compound 19 (182 
mg, 44 %) as a white solid.   To a stirred solution of AlCl3 (1.588 g, 11.9 mmol) in 
DCM (10 mL) was added methyl 2-chloro-2-oxoacetate (389 mg, 3.18 mmol) and 
the resulting mixture was stirred at r.t. until it became a clear solution before 
introduction of  compound 19 (182 mg, 0.79 mmol, in 1 mL DCM).  The stirring 
was continued at r.t. overnight.  After completion of the reaction, the mixture was 
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quenched with saturated NaHCO3 and extracted with DCM (10 mL x 3).  The 
combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated.  The residue was purified by flash chromatography (silica gel, 0 ~ 
90% ethyl acetate in petroleum ether) to provide compound 20 (58 mg, 23 %) as 
a yellow oil. To a stirred solution of compound 20 (58 mg, 0.18 mmol) in 
MeOH/H2O (1 mL/2 mL) was added NaOH (15 mg, 0.37 mmol).  After stirring at 
r.t. for 15 min, the reaction mixture was neutralized with 1N HCl, concentrated 
and lyophilized to provide compound 21 (73 mg, 95 %, mixed with NaCl) as a 
green solid.   
Compound 21 (55 mg, 0.18 mmol) in DMF and compound 9 (59 mg, 0.27 
mmol) were added to DIPEA (0.28 mL, 1.63 mmol) and DEPBT (325 mg, 1.09 
mmol). After stirring at r.t. overnight, the reaction mixture was concentrated to 
remove DMF under the reduced pressure.  The residue was partitioned between 
with EA (10 mL) and saturated NaHCO3 (10 mL).  The layers were separated and 
the aqueous layer was extracted with EA (10 mL x 2).  The combined organic 
layers was dried over Na2SO4, filtered and concentrated.  The crude product was 
purified by preparative HPLC to give compound SC11 (22 mg, 24 %).  
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Synthesis of SC26: To a solution of cyclohexene-1-carboxylic acid (0.15 g, 1.19 
mmol) in DMF (5 mL) was added compound 7 (0.21 g, 0.99 mmol), HATU (0.45 
g, 1.19 mmol, 1.2 eq.) and DIEA (0.26 g, 1.98 mmol).  Then the mixture was 
stirred at 25oC for 16hrs. The crude product was purified by pre-HPLC to give 
tert-butyl compound 23 (0.21 g, 0.67 mmol, 67%). HCl/AcOEt (20 mL) was added 
compound 23 (0.21 g, 0.67 mmol), the mixture was stirred at 25oC for 2 hrs, TLC 
showed the S.M was consumed completely.  The mixture was concentrated to 
give compound 24 (0.15 g, 0.58 mmol) as crude product. 
To a solution of compound 21 (0.03 g, 0.99 mmol) in DMF (2 mL) was 
added compound 24 (0.026 g, 0.12 mmol), HATU (0.045 g, 0.12 mmol) and DIEA 
(0.026 g, 0.2 mmol).  Then the mixture was stirred at 25°C for 16 hrs.  The crude 
product was purified by pre-HPLC to give SC26 (15 mg, 30%). 
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CHAPTER 3 
CORE CHEMOTYPE DIVERSIFICATION IN THE HIV-1 ENTRY INHIBITOR 
CLASS USING FIELD-BASED BIOISOSTERIC REPLACEMENT. 
DISCOVERY OF A NOVEL INHIBITOR, SC12 
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ABSTRACT 
 
Demand remains for new inhibitors of HIV-1 replication and the inhibition 
of HIV-1 entry is an extremely attractive therapeutic approach. Using field-based 
bioisosteric replacements, we have further extended the chemotypes available 
for development in the HIV-1 entry inhibitors. Moreover, using field-based 
disparity analysis of the compounds, 3D structure-activity relationships were 
derived that will be useful in the further development of these inhibitors towards 
clinical utility. 
 
 
 
 
Citation: Tuyishime M, Lawrence R, Cocklin S.Core chemotype 
diversification in the HIV-1 entry inhibitor class using field-based bioisosteric 
replacement. Bioorg Med Chem Lett. 2016 Jan 1;26(1):228-34.  
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INTRODUCTION 
Inhibiting the process of entry of HIV-1 into susceptible cells remains an 
elusive but extremely attractive intervention point for the development of novel 
anti-HIV therapies. HIV-1 entry into cells is solely orchestrated by the Env 
complex on the surface of the virion. The Env complex is organized on the virion 
surface as trimeric spikes, composed of three gp120 molecules non-covalently 
linked to three gp41 molecules. Recently, two structures of a soluble, cleaved 
HIV-1 Env trimer from a clade A founder virus has been solved providing 
additional and much needed information on the quaternary organization of the 
Env complex (42, 47, 135). 
HIV-1 infection usually occurs only after two sequential and specific 
binding steps. The first interaction is between gp120 and CD4 antigen present on 
CD4+ T cells, monocyte/macrophages, and other immune and non-immune cells. 
This interaction results in a series of conformational rearrangements in gp120 
that permits the second binding event to occur. This second interaction occurs 
between gp120 and a member of the chemokine receptor subfamily, within the 
large G protein–coupled family of receptors, mainly CCR5 and/or CXCR4. This 
interaction also promotes considerable rearrangement in gp120 and transduction 
of this conformational signal to gp41. This then elicits the exposure of the fusion 
peptide within the N-terminus of gp41, which through additional conformational 
rearrangements in gp41 facilitates fusion between the viral and cellular 
membranes and release of the viral core into the cell.  
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Several groups are actively involved in the development of small 
molecules targeted to gp120 that disrupt the Env molecular machine to stop HIV-
1 entry into cells (77, 79, 83, 84, 93, 95, 136-139). Despite this only one 
chemotype, developed by Bristol Myers Squibb, has successfully made it to 
clinical trials. The newest compound in the drug class, BMS-663068, a 
phosphonooxymethyl prodrug of BMS-626529 (140), recently performed 
favourably in a Phase IIb clinical study highlighting the potential utility of these 
Env-directed entry inhibitor class of compounds (89). 
Our group recently described the computational design of new compounds 
intented to act through a common binding site to that of the Bristol Myers Squibb 
piperazine-based entry inhibitors, of which BMS-663068/BMS-626529 are 
members. Our most potent compounds, SC11 and SC26, both contain a 
dipyrrolodine core scaffold, and specifically inhibit HIV-1JR-CSF at 0.8 nM and 2 
nM, respectively (141).  
Having successfully demonstrated that scaffold-hopping of the piperazine 
moeity can be achieved, in this study we sought to extend the core chemotypes 
available for the entry inhibitor class in the hopes of improving drug-like 
properties.  
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RESULTS 
Computationally directed scaffold hopping from the dipyrrolodine 
chemotype 
Our underlying goal is to design a potent HIV-1 entry inhibitor that has 
properties that overcome the limitations of those compounds in development and 
in clinical trials. We have already demonstrated that we can replace the core 
piperazine moeity that is present in all of the BMS compounds to a dipyrrolidine – 
opening up the door to further replacements. Therefore, we performed 
computationally directed scaffold-hopping studies (focused on the core regions of 
select BMS compounds and our compounds SC11/SC26). This computational 
analysis was subsequently coupled to synthesis, antiviral potency analysis and 
computational 3D Quantitative Structure–Activity Relationship (QSAR) to derive 
new core chemotypes for HIV-1 entry inhibitor class. 
Due to the lack of structural information on the bioactive conformation of 
our inhibitors and the BMS piperazine based inhibitors, we first used 
FieldTemplater (Forge, Cresset) (99-109) to determine the most likely 3D 
conformation adopted by BMS-377806 (84), BMS-488043 (114), BMS-626529 
(116), and SC11/SC26 (141) upon binding to the HIV-1 Env target (Figure 3.1). 
This FieldTemplater-derived 3D conformation was then used as input into Spark 
(Cresset, UK). Spark searches a database of up to 600,000 fragments to find 
bioisosteres that exhibit similar shape and electronic properties as the region of 
interest when placed in the context of the final molecule. To maximize the 
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likelihood of identifying interesting potential replacements, we performed 
bioisosteric searches of the piperazine groups of BMS-377806, BMS-488043, 
and BMS-626529, in addition to the dipyrrolodine group of compounds 
SC11/SC26.   
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Figure 3.1. Overlaid field point representation of compounds BMS-377806, 
BMS488043, BMS-626529, and SC11 from the derived binding mode (Forge, 
UK). Red field points highlight energy minima for a positively charged probe, blue 
for a negative probe. Yellow spheres represent attractive van der Waals minima 
for a neutral probe and gold spheres represent hydrophobic centroids. Oxygen 
atoms are shown in red, nitrogen in blue. The size of the points is related to the 
strength of a potential interaction (i.e., absolute value of the field strength at that 
point in space). (The figure was generated by Dr. Cocklin)  
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The results of each search were analyzed and common structures were 
identified. From this analysis, four different core chemotypes were chosen for 
investigation based upon diversity and BIF% scores (a factor that indicates how 
good the replacement is in the context of the conformation of the entire 
molecule). Compounds containing core pyrrolo-pyrazole, azetidine, 
tetrahydropyridine, azabicyclo-hexane and diazaspiro-decane groups were then 
synthesized. First, a common head group to be used in all of the molecules was 
synthesized, compound 6 (Appendix 3, Scheme 1).  This was subsequently 
used in the synthesis of compounds SC12, SC15, SC27, SC28, and SC45 
(Appendix 3, Schemes 2-7).  
After successful synthesis of each of the five novel-scaffold derivatives, 
we then tested them for specificity and potency against HIV-1 using single round 
infection assay. The effect of the compounds on the infection of target cells by 
AMLV Env pseudotyped recombinant HIV-1 was used to determine the specificity 
of the compounds to HIV-1 Env-mediated cell entry. Table 3.1 shows that 
compounds SC12, SC15 and SC28, baring pyrrolo-pyrazole, azetidine and 
azabicyclo-hexane cores, respectively, have higher potencies against all HIV-1 
isolates tested, with IC50 values in low nanomolar range. Compounds SC14, 
SC27 and SC45, bearing azetidine, diazaspiro-decane and tetrahydropyridine 
core chemotypes, respectively, had half inhibitory concentration micromolar 
range. 
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Table 3.1: Specificity and potency of compounds against HIV-1JR-CSF, HIVB41, 
HIV-1HxBc2 Env, and AMLV pseudotyped HIV-1.   
 
Compound IC50JR-
CSF (µM) 
IC50 B41 
(µM) 
IC50 HxBc2 
(µM) 
IC50 
AML
V 
(µM) 
SC12 
 
 
 
 
 
0.008± 
0.002 
 
 
 
 
0.006± 
0.003 
 
 
 
 
0.08 ± 0.02 
 
 
 
 
N.A. 
SC14 
 
 
 
 
 
 
   2.5 ± 0.4 
 
 
 
 
  3.8 ± 0.4 
 
 
 
 
 3.8 ± 1.6 
 
 
 
 
N.A. 
SC15 
 
 
 
 
 
 
0.003± 
0.001 
 
 
 
 
 
0.007± 
0.001 
 
 
 
 
 
0.009± 
0.0011 
 
 
 
 
 
N.A. 
SC27  
 
 
 
 
 13.0 ± 9.0 
 
 
 
 
 
  3.9 ± 0.7 
 
 
 
 
 
   36 ± 21  
 
 
 
 
 
N.A 
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                        SC28 
 
 
 
 
 
 
 
 
0.096± 
0.019 
 
 
 
 
 
 
0.085± 0.03 
 
 
 
 
 
 
0.069± 0.014 
 
 
 
 
 
 
N.A. 
SC45 
 
 
 
 
0.224± 
0.017 
 
 
 
 
0.35 ± 0.03 
 
 
 
 0.38 ± 0.03 
 
 
 
N.A. 
 
Chemical structures were drawn with ChemAxon software (Budapest, Hungary).  
AMLV = amphotropic murine leukemia virus; IC50 = half-maximal inhibitory 
concentration; N.A. = not active over concentration range tested; N.D. = not 
determined.  
 
  
76 
 
76 
 
3D Structure-Activity relationships using Activity Miner and Activity Atlas 
To better understand the structural and property factors driving activity of 
these HIV-1 entry inhibitors, inclusive of those compounds previously reported by 
our group, and the compounds tested in this body of work, we assessed them 
computationally in Activity Miner and Activity Atlas (Cresset, UK). Activity Miner 
provides an interface for the rapid assessment of structure-activity landscapes for 
a set of aligned compounds in the context of activity cliffs. It achieves this by 
comparing pairs of molecules to find where small changes in the molecule’s 
structure or local properties results in a large change in activity. In the software, 
this notion of disparity is expressed as: 
            
         
            
  
The higher the calculated disparity corresponds to a sharper change in 
activity between a pair of very similar molecules and hence an activity cliff. 
Activity Atlas (Cresset, UK) provides a probabilistic approach to analyzing 
Structure Activity Relationships (SAR). Like all 3D SAR approaches, 
comprehensive conformation hunting and correct alignments are critical, thus, 
alignments were hand checked to reduce noise arising from inadequate 
alignments, since, being a probabilistic method, Activity Atlas assumes that the 
alignments are correct. Activity Atlas helps provide insight into what feature(s) 
the active compounds in a collection have in common – in essence, it 
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summarizes the Activity Miner analysis to illuminate what activity cliffs reveal 
about the nature of the SAR. 
Compounds SC03, SC04, SC07, SC08, SC11 and SC26 from our 
previous report (141) and compounds SC12, SC14, SC15, SC27, SC28 and 
SC45 from this analysis were input into Activity Miner. From the pairwise 
comparisons (50% field – 50% shape) a Disparity Matrix is generated (Figure 
3.2), which provides an overview of the dataset. For each pair, the comparison is 
color-coded by color and shade, with red and green meaning a decrease or in 
increase activity, respectively.  The shading corresponds to the disparity: darker 
shading indicates a higher disparity, and thus, a steeper activity cliff.  
As can be clearly seen in Figure 3.2, the highest ranked activity cliff is 
between molecules SC11 (pIC50 = 9.1) and SC27 (pIC50 = 4.890); this pair has a 
3D Similarity of 0.844 (quite high), combined with a ∆pIC50 = 4.21.  When the 
field differences are examined, as shown in Figure 3.3, it can be observed that 
the electron density spanning the dipyrollidine in SC11 is not present in the 
central diazaspiro-decane group of SC27. This suggests that electron density in 
this region may be important for activity. 
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Figure 3.2. Disparity Matrix showing the pairwise comparisons for the 
compounds reported using IC50 HIV-1JR-CSF as activity. Red and green boxes 
correspond to decreases and increases in activity between the pair, respectively. 
The darker the shading, the sharper the activity cliff  (higher calculated Disparity). 
The matrix is symmetrical—for every red box, there is a corresponding green box 
for the comparison going in the opposite direction. (Generated by Rae 
Lawrence). 
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Panel A 
 
Panel B 
 
Figure 3.3. Comparison of field differences for a selection of molecules in 
which the negative electrostatics over the central moiety appears to be 
important for activity. The field difference map displays the surfaces as relative 
values between pairs of molecules. The regions where the surface is displayed 
have stronger electrostatic fields than the corresponding regions in the compared 
molecule. (Panel A) SC27 is compared to SC11; (Panel B) SC15 is compared to 
SC14. Again, IC50 refers to IC50 HIV-1JR-CSF. (Generated by Rae Lawrence). 
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This observation is conserved in the comparisons of SC15 and SC26 to 
SC27, with the higher potency compounds having this region of electron density.  
Furthermore, this observation is even borne out in the comparison of SC15 to 
SC14. SC14 and SC15 share a core azetidine moiety but differ in its orientation. 
Again, the reduction of negativity in the core region is again seen in the lower 
potency compound SC14 but maintained in the highly active SC15 compound.  
Comparison of SC11 to its parental compound SC04 (IC50 HIV-1JR-CSF = 
100 μM), highlights key differences that could explain the corresponding 5-order 
of magnitude difference in activity (Figure 3.4). Most strikingly are the differences 
between the “head regions” of the compounds. The acenaphthene head group of 
SC04 shows an intact π-cloud, as well as positivity associated with the in-plane 
hydrogens that is not observed in the azaindole group of the more active SC11 
(Figure 3.4, Panel B). 
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Panel A 
 
Panel B 
 
Figure 3.4. Comparison of field differences and electrostatic surfaces of 
SC11 and SC04. (Panel A) Comparing the field differences between SC11 and 
SC04. The p-cloud associated with the fused rings remains intact, whereas in the 
more active SC11, that electron density has been pulled out of the region. (Panel 
B) Comparison of the calculated electrostatic surfaces for SC11 and SC04. 
Notice the intact π-cloud of the acenaphthene, as well as the positive field 
associated with the in-plane hydrogens, which leaves them available for potential 
hydrogen bonding. (Generated by Rae Lawrence). 
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Evaluating the complex structure-activity relationship for this set of 
compounds, which have only loosely related 2D structure based on Tanimoto 
similarity scores (based on Merck Atom Pairs), resulted in a number of 
comparisons to examine in Activity Miner.  The visualization of single-pair 
comparisons provide plenty of insight for molecule pairs with only minor structural 
or featural changes resulting in activity cliffs. However, when examining more 
complex datasets containing multiple chemotypes with multiple simultaneous 
scaffold modifications, it is more convenient and illuminative to summarize the 
pair-wise information using Activity Atlas (Cresset, UK). 
Activity Atlas analyzes SAR by employing a Bayesian approach to 
qualitatively attain a global overview of available 3D structure and activity 
information. Effectively, this approach automates and summarizes the pair 
comparisons that could be examined and exploited for SAR understanding in 
Activity Miner. The aim of Activity Atlas is to: determine what 
electrostatic/hydrophobic/ shape features active molecules in the data set have in 
common; to understand what the activity cliffs suggest about the SAR; and 
finally, to be able to assess how well the compounds cover available chemical (or 
feature) space. 
 Once the Activity Atlas calculated average field contributions to activity for 
the data set are plotted, one can look at new molecules in the context of these 
averages to assess suitability for progression. 
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Examining three of the compounds in the dataset with high, mid, and low 
potencies in the context of the average field contributions (Figure 3.5, Panel A), 
we see that one of the most active compounds (SC26), shows a field pattern that 
aligns well with the average electrostatics. SC14, which has mid-range activity 
(IC50 JR-CSF = 2.5 μM), has a field point pattern which aligns acceptably in some 
areas, but doesn’t meet the negative electrostatic directionality associated with 
the carbonyl group shown on the right. Finally, SC04, with IC50 of 100 μM, shows 
reasonable field matching across the core, but the acenaphthene “head region” 
lacks much of the fields present in the higher potency molecules (Figure 3.5, 
Panel B). 
When the activity cliff information is summarized using Activity Atlas 
(Figure 3.5, Panel C), it is seen that there are regions with specific electrostatic 
conditions, as well as hydrophobicity considerations. In essence, these regions 
qualitatively express our 3D SAR in a graphical fashion and provide a blueprint 
for the design of further analogues. 
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Panel A 
 
Panel B 
 
Panel C 
 
Figure 3.5. The Activity Atlas summary. (Panel A) Compound SC11 showing 
the average electrostatics and average hydrophobic regions based on the 
Activity Atlas summary of active molecules in the dataset. (Panel B) Assessing 
three compounds in the context of the average electrostatics associated with 
activity based on the dataset. The higher active molecules have better correlation 
with the average fields for actives (shown in Panel A), while the less active 
compounds miss critical features of the SAR. Red and blue maps depict the 
average positive and negative electrostatics associated with active molecules, 
based on the dataset. IC50 refers to IC50 HIV-1JR-CSF. (Panel C) Summary graphic 
of the activity cliffs found by pairwise comparisons in Activity Miner and 
summarized in Activity Atlas. The maps in this graphic show the key features that 
drive activity, as determined from the alignment of the reported compounds. Note 
that ‘more negative’ can also mean ‘less positive’, and vice versa. (Generated by 
Rae Lawrence). 
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Predicted ADME of the five new chemotypes: Identification of SC12 – a 
compound with improved druglike properties  
Following the successful diversification of the core chemotypes, we next 
analyzed the predicted ADME properties (absorption, distribution, metabolism, 
and excretion) of these novel compounds (Figure 3.6). 
To accomplish this comparison, we used in silico prediction of druglike 
metrics of the results as implemented in the oral non-central nervous system 
(CNS) drug profile in StarDrop 5.5 (Optibrium, Ltd, Cambridge, UK) (117) 
(Appendix 1 in Chapter 2 contains the detailed explanation of Spark Bioisosteric 
Group Replacement).  
Optibrium’s oral non-CNS drug profile is composed of the following 
metrics: logS (intrinsic aqueous solubility); classification for human intestinal 
absorption; logP (octanol/water); hERG (human ether-à-go-go-related gene) 
pIC50 (mammalian cells); cytochrome P450 CYP2D6 classification; cytochrome 
P450 CYP2C9 pKi values; classification of P-glycoprotein transport; classification 
of blood–brain barrier (BBB) penetration; and predicted BBB penetration value. 
The models and their respective importance to the profile are shown in Figure 
3.6 a. 
A probabilistic scoring algorithm (118) is then used to combine the model 
predictions in the oral non-CNS drug profile into an overall score range from 0 to 
1, with 0 suggesting extremely non-druglike, and 1 suggesting the perfect drug. 
StarDrop analysis of the new chemotype compounds versus BMS-663068 using 
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the oral non-CNS drug profile provided scores for SC12 and BMS-663068 of 
0.3815 ± 0.2323 and 0.0799 ± 0.1014, respectively (Figure 3.6 b).  
  
87 
 
87 
 
 
(b) 
 
Figure 3.6. The analysis of predicted ADME properties. (a) The individual 
models that comprise the oral non-CNS (central nervous system) drug profile and 
their respective importance to the profile. HIA = human intestinal absorption; 
hERG (human ether-à-go-go-related gene); IC50 = half-maximal inhibitory 
concentration; BBB = blood–brain barrier. (b) Plot showing the StarDrop 
(Optibrium, Ltd, Cambridge, UK)—derived logS versus the score from a 
multimetric oral non-CNS profile for the BMS and SC compounds. (Generated by 
Dr. Cocklin).   
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DISCUSSION 
We have extended our previous work using computational means to 
diversify the core scaffolds. To increase the variety, we included the most potent 
compound previously identified, SC12, to create the hypothesized three-
dimensional bioactive conformation of the compound bound to its target.  In the 
entry inhibitor class of compounds, 5 new core chemotypes were identified. The 
novel head group, 4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridine, was previously 
proven to increase antiviral potency without affecting HIV-1 specificity. Therefore, 
we used a combination of this head group with 5 new core chemotypes to create 
inhibitors, which demonstrated specific anti-HIV activity although their half 
maximum inhibitory concentrations (IC50) showed noticeable variation. 
In order to identify whether minor structural differences affect each 
compound’s antiviral activity, we used Activity Atlas (Cresset, UK), which 
provides a probabilistic approach to analyzing Structure Activity Relationships 
(SAR). SC11 and SC27 bear different core chemotypes (dipyrollidine and 
diazaspiro-decane, respectively) but have high similarity in overall chemical 
structure based on the Disparity Matrix comparison. These minor changes 
resulted in the difference of the electrostatic surrounding of the compounds. 
Moreover, SC15 and SC14 both bear an azetidine core chemotype but the 
orientation of the core resulted in completely different electrostatic surfaces 
around the compound and, hence, drastic differences in antiviral potencies. This 
indicates the importance of the negative electrostatics over the central moiety for 
activity of the compound. 
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In addition to the electrostatics, hydrophobicity of the compound plays a 
crucial role as well. Modeling of the bioactive conformations of SC11 and SC04 
shows huge differences in the electrostatics in the head region and correlates 
with the difference in antiviral potency. 
Most importantly in the development of the novel small molecule inhibitors, 
we have discovered a novel chemotype compound, SC12, which not only has 
specificity and high potency against HIV-1, but also has improved ADME 
properties. 
 Computational analysis of these core chemotype-diversified inhibitors has 
provided a blueprint that can be used in the design of next generation entry 
inhibitors to improve potency. Taken together, the results from this study validate 
the combined use of field-based bioisosteric replacement and field-based 
disparity analysis as a means to further the potential utility of Env-targeted HIV-1 
entry inhibitors. Future studies in our group will include assessment of the drug-
like properties of these new chemotypes, modulation and optimization of their 
potencies based upon SAR relationships derived in this study and simultaneously 
against genetically distinct isolates, and detailed mechanism of action studies, 
including structural studies. 
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APPENDIX 2 
De novo syntheses  
Synthesis of novel compounds was performed by Enamine Ltd. (Kiev, 
Ukraine), AsisChem, Inc. (Watertown, MA), HD Biosciences Co., Ltd. (Shanghai, 
China), or WuXi Apptec (Shanghai, China) according to the schemes and 
procedures outlined below.  
Scheme 1. Synthesis of common compound 6. 
 
The solution of compound 1 (30 g, 0.13 mol) in THF (1.5 L) was cooled to -78oC.  
Then a solution of vinylmagnesium in THF (508 mL, 1N, 0.51 mol) was added 
dropwise to the above solution maintained below -40oC.  The mixture was stirred 
for 3 hrs at -78oC before being quenched with saturated aqueous NH4Cl solution.  
The layers were separated, the aqueous layer was extracted with EtOAc (3×500 
mL) and the combined organic layer was washed with brine and concentrated.  
The crude product was purified by silica gel column chromatography to obtain 
compound 2 (5 g, 17%). Compound 2 (4.0 g, 17.2 mmol) was dissolved in freshly 
prepared NaOMe (20 mL).  CuI (3.2 g, 17.2 mmol) was added to the above 
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solution.  The mixture was stirred at 110oC under microwave for 3 hrs.  After the 
mixture was completed, the mixture was added EtOAc and H2O, then the 
suspension was filtered, the filtrate was separated.  The organic layer was 
concentrated to give crude product which was purified by column 
chromatography to give compound 3 (1.8 g, 45%). A mixture of compound 3 (0.7 
g, 3.8 mmol) and 3-methyl-1,2,4-triazole (6.4 g, 76.8 mmol) was added copper 
powder (0.49 g, 7.68 mmol) and KOH (0.43 g, 7.68 mmol).  The mixture was 
heated to melt at 170-175oC under N2.  After the starting material was consumed 
completely, the mixture was added EtOAc and H2O, then the suspension was 
filtered, the filtrate was separated.  The organic layer was concentrated to give 
crude product which was purified by column chromatography to give compound 
4 (0.23 g, 26%). A solution of compound 4 (0.23 g, 1 mmol) in THF (12 mL) was 
cooled to -10oC, EtMgBr (0.47 g, 3.5 mmol) was added dropwise at -10oC 
followed by the addition of pyridine (0.3 mL).  The slurry was cooled to -45oC, 
and the ethyl 2-chloro-2-oxoacetate (0.55 g, 4 mmol) was added dropwise at -
45oC.  The slurry was allowed to -10oC and stirred at this temperature for 1h.  
After the reaction was completed, the mixture was quenched with IPA (2 mL) and 
H2O (20 mL).  The mixture was extracted with EtOAc, the organic layer was 
washed with brine and concentrated to give crude product which was purified by 
column chromatography to give compound 5 (0.17 g, 52%). A solution of 
compound 5 (0.17 g, 0.52 mmol) in MeOH (5 mL) was added NaOH (0.041 g, 
1.03 mmol) and H2O (2 mL).  The mixture was stirred at 25
oC for 6 hrs and then 
added 1N HCl to adjusted pH 6, the mixture was concentrated to give 
compound 6 (0.29 g) as crude product. 
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Scheme 2: Synthesis of SC12 
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To a solution of compound 7 (34.52 g, 0.204 mol) in DCM (500 mL) was added 
3-chloroperoxybenzoic acid (75%, 108 g, 0.47 mol). The mixture was stirred at 
ambient temperature for 4 days. The suspension was concentrated. The crude 
product was purified by silica gel column chromatography to obtain compound 8 
as a yellow oil (31.17 g, 83%). To a suspension of compound 8 (2.66 g, 0.0144 
mol) and copper (I) cyanide (0.129 g, 0.00144 mol) in THF anhydrous (40 mL) at 
-78°C was added dropwise 1M solution of vinylmagnesium bromide in THF (45.3 
mL, 0.0453 mol). The resulting suspension was allowed to warm slowly to 
ambient temperature and stirred for 7 h. The reaction mixture was quenched with 
saturated NH4Cl (100 mL), extracted with EtOAc (3×50 mL), dried over MgSO4 
and concentrated. The crude product was purified by silica gel column 
chromatography to obtain compound 9 as yellow oil (2.82 g, 83%).  NaH (50% 
suspension in mineral oil, 0.245 g, 0.00511 mol) was added to a solution of 
compound 9 (1 g, 0.00464 mol) in DMF anhydrous (10 mL) at -5°C. The mixture 
was stirred at -5°C for 15 min when TsCl (0.984 g, 0.00511 mol) was added. The 
reaction mixture was stirred at ambient temperature for 18 h, quenched with H2O 
(50 mL), extracted with EtOAc (2×30 mL), washed with H2O (50 mL), dried over 
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Na2SO4 and concentrated. The crude product was purified by silica gel column 
chromatography to obtain compound 10 as a yellow oil (1.00 g, 60%). To a 
solution of compound 10 (1.8 g, 4.73 mmol.) in 30 mL of THF-H2O (2:1 vol.) 
were added OsO4 (0.122 g, 0.473 mmol) and NaIO4 (1.790 g, 8.28 mmol) and 
mixture was stirred 5 h at room temperature. Then 100 mL of 5% solution 
NaHCO3 was added to the reaction mixture and extracted with EtOAc (3×30 mL), 
combined organic layers were dried over MgSO4 and concentrated to give 
compound 11 as a yellow oil as crude product (1.5 g, 85%).  To the solution of 
compound 11 (1.4 g, 3.75 mmol) in methanol (10 ml of) at -78°C was added 
phenylhydrazine (0.934 g, 7.5 mmol) and the solution was stirred for 1h at -78°C 
and refluxed for 1 h, concentrated. The crude product was purified by silica gel 
column chromatography and recrystallized (Hexane:EtOAc / 4:1)  to obtain 
compound 12 as a white solid (0.7 g, 68%). To a 4M solution of HCl in dioxane 
was added compound 12 (254 mg, 0.88 mmol) and stirred overnight at room 
temperature. The precipitate was filtered off, treated with dry ether and dried to 
give compound 13 as a pale green solid (230 mg, 88%). A mixture of 
compound 6 (250 mg, 0.82 mmol), compound 13 (216 mg, 0.82 mmol), DIEA 
(965 mg, 7.39 mmol) and HATU (947 mg, 2.46 mmol) in DMF (5 mL) was stirred 
for 4 h at room temperature. The reaction mixture was poured into 100 mL of 
water and extracted with EtOAc (5×20 mL), washed with brine (2×50 mL) and 
water (100 mL), dried with Na2SO4 and concentrated. The crude product was 
purified by silica gel column chromatography to give 100 mg of crude product, 
which was recrystallized from 3 mL of EtOH to give SC12 as a pale green solid 
(37 mg, 10%). 
 
Reagent conditions: (a) m-CPBA CH2Cl2, rt. (b) vinylmagnesium 
bromide, CUCn, THF. (c) TsCl, NaH, DMF. (d) K2OsO4·2H2O, NalO4, 
MeOH/H2O. (e) PhNH-NH2, MeOH. (f) HCl (4N), dioxane. (g) 6, HATU, DIEA, 
DMF. 
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Scheme 3. Synthesis of SC14 
TFA
14
15 6  16
 SC14
TFA
 Scheme 3. (a) compound  7, HATU, DIEA, DMF; (b) TFA, DCM; (c) benzoyl chloride, DIEA, DCM
a b
c
 
The solution of compound 6 (0.1 g, 0.33 mmol) in DMF (3 mL) was added DIEA 
(0.086 g, 0.66 mmol), compound 14 (0.074 g, 0.4 mmol) and HATU (0.15 g, 0.4 
mmol).  The mixture was stirred at 25oC for 2 hrs and purified by pre-HPLC to 
give compound 15 (0.089 g, 57%). TFA (1 mL) in DCM (10 mL) was added to 
compound 15 (0.089 g, 0.19 mmol).  The mixture was stirred at 25oC for 3 hrs 
and the mixture was concentrated to give compound 16 (0.13 g, crude). The 
solution of compound 9 (0.13 g, 0.35 mmol) in DCM (2 mL) was added DIEA 
(0.09 g, 0.66 mmol), benzoyl chloride (0.049 g, 0.35 mmol) was added dropwise 
to the above solution at 0oC.  The mixture was stirred at 25oC for 2 hrs and 
purified by pre-HPLC to give SC14 (0.031 g, 19%). 
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Scheme 4. Synthesis of SC15 
 
Synthesis of SC15 (1-4-methoxy-7-(3-methyl-1H—1,2,4-triazol-1-yl)-1H-
pyrrolo[2,3-c]pyridine-3-yl]-2-(3-oxo-3-phenylpropyl)azetidin-1-yl]ethane-1,2-
dione) was achieved using the synthesis scheme shown in Scheme 4. A solution 
of ethyl-2-(diethoxyphosphoryl) acetate (1.45 g, 6.5 mmol) in THF (30 mL) was 
added NaH (0.26 g, 10.8 mmol) at 0oC.  The suspension was stirred at 0oC for 5 
min.  Then compound 17 (1 g, 5.4 mmol) was added to the above mixture, the 
mixture was stirred at 0oC for 10 min, TLC showed the starting material was 
consumed completely.  The mixture was quenched with saturated aqueous 
NH4Cl solution and extracted with EtOAc (3×30 mL) and the combined organic 
layer washed with brine and concentrated.  The crude product was purified by 
silica gel column chromatography to obtain compound 18 (0.6 g, 43%). A 
mixture of compound 18 (0.6 g, 2.3mmol), Pd/C (0.05 g) in EtOAc (50 mL) was 
degassed and flushed with H2 for three times, the bubbled H2 to keep the 
pressure is 20 Psi, stirred at 25oC for 5 hrs.  The reaction mixture was filtered, 
96 
 
96 
 
and the filtrate was evaporated to give compound 19 (0.56 g, 95%). A solution 
of compound 19 (0.56 g, 2.18 mmol) in MeOH (15 mL) was added LiOH (0.16 g, 
4.36 mmol) and H2O (2 mL).  The mixture was stirred at 25
oC for 6 hrs and then 
added saturated citric acid to adjusted pH=6, the mixture was extracted with 
EtOAc (3×30 mL) and the combined organic layer washed with brine and 
concentrated.  The crude product was purified by silica gel column 
chromatography to obtain compound 20 (0.48 g, 96%). The solution of 
compound 20 (0.48 g, 2.06 mmol) in DMF (5 mL) was added DIEA (0.53 g, 4.12 
mmol), N,O-dimethylhydroxylamine hydrochloride (0.24 g, 2.47 mmol) and HATU 
(0.94 g, 2.47 mmol).  The mixture was stirred at 25oC for 2 hrs and purified by 
pre-HPLC to give compound 21 (0.52 g, 93%). A solution of compound 21 
(0.52 g, 1.91 mmol) in THF (20 mL) was cooled to 0oC, phenylmagnesium 
bromide (0.69 g, 3.82 mmol) was added dropwise to the above mixture below 
0oC, after addition, the mixture was stirred at 0oC for 2 hrs.  The mixture was 
quenched with saturated aqueous NH4Cl solution and extracted with EtOAc(3×30 
mL) and the combined organic layer washed with brine and concentrated.  The 
crude product was purified by silica gel column chromatography to obtain 
compound 22 (0.52 g, 94%). TFA (2 mL) in DCM (20 mL) was added to 
compound 22 (0.52 g, 1.79 mmol).  The mixture was stirred at 25oC for 3 hrs 
and the mixture was concentrated to give compound 23 (0.7 g, crude). The 
solution of compound 23 (0.068 g, 0.36 mmol) in DMF (3 mL) was added DIEA 
(0.074 g, 0.6 mmol), compound 6 (0.09 g, 0.3 mmol) and HATU (0.14 g, 0.36 
mmol).  The mixture was stirred at 25oC for 2 hrs and purified by pre-HPLC to 
give compound SC15 (0.034 g, 24%). 
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Scheme 5. Synthesis of SC27 
 
To a solution of compound 24 (300.00 mg, 1.25 mmol, 1.00 eq.) and benzoic 
acid (183.18 mg, 1.50 mmol, 1.20 eq.) in DCM (6 mL) was added NMM (252.88 
mg, 2.50 mmol, 2.00 eq.) and T3P (1.19 g, 1.88 mmol, 1.50 eq.).  The mixture 
was stirred at 25°C for 4 hrs.  Then the mixture was purified by TLC 
(PE:EtOAc=1:1) to compound 25 (310.00 mg, 899.99 umol, 72.00% yield). To a 
solution of compound 25 (310.00 mg, 899.99 umol, 1.00 eq.) in DCM (2 mL) 
was added HCl/AcOEt (30 mL) at 0°C.   The mixture was stirred at 25°C for 2 
hrs.  Then it was concentrated to dryness to give compound 26 (300.00 mg, 
crude). To a solution of compound 6 (20.00 mg, 66.39 umol, 1.00 eq.) and 
compound 26 (19.47 mg, 79.67 umol, 1.20 eq.) in pyridine (3.00 mL) was added 
EDCI (19.09 mg, 99.59 umol, 1.50 eq.) at 25°C , the mixture was stirred for 3 
hour at 25°C.  LCMS showed the SM consumed, desired product was formed as 
major product. The reaction was concentrated, dissolved in to DMF (3 mL), 
purified by prep-HPLC (base condition) and concentrated to give SC27 (11.00 
mg, 20.37 umol, 30.68% yield, 97.7% purity) as yellow gum. 
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Scheme 6. Synthesis of SC28 
 
Synthesis of SC28 (N-[3-benzoyl-3-azabicyclo[3.1.0]hexan-6-yl]-3-[4-methoxy-7-
(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-2,3-
dioxopropanamide) is shown in Scheme 6. To a solution of compound 27 
(200.00 mg, 1.01 mmol, 1.00 eq.), T3P (320.97 mg, 1.01 mmol, 1.00 eq.) and 
NMM (204.32 mg, 2.02 mmol, 2.00 eq.) in DCM (2 mL)was added benzoic acid 
(148.01 mg, 1.21 mmol, 1.20 eq.). The mixture was stirred at 25°C for 12 hrs.  
Then it was washed with water, 5% HCl aqueous solution to give compound 28 
(450.00 mg, crude) as yellow oil. To a solution of compound 28 (450.00 mg, 
1.49 mmol, 1.00 eq.) in DCM (2 mL) was added HCl/AcOEt (40 mL) at 0°C.  The 
mixture was stirred at 25°C for 2 hrs. Then it was concentrated to dryness to 
compound 29 (113.00 mg, 558.71 umol, 37.50% yield). A mixture of compound 
6 (25.00 mg, 82.98 umol, 1.00 eq.) and compound 29 (16.78 mg, 82.98 umol, 
1.00 eq.) in pyridine (3.00 mL) was added EDCI (23.86 mg, 124.47 umol, 1.50 
eq.) at 25°C, the mixture was stirred for 3 hour at 25°C.  LCMS showed the SM 
consumed, desired product was formed as major product.  The mixture was 
concentrated, dissolved in to DMF (3 mL) and purified by prep-HPLC (TFA 
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condition).  The product was concentrated to give SC28 (33.00 mg, 65.25 umol, 
78.64% yield, 96% purity) as yellow gum. 
 
Scheme 7. Synthesis of SC45 
 
Scheme 6 depicts the synthesis of SC45 (N-[(1-[2-[4-methoxy-7-(3-methyl-1H-
1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-2-oxoacetyl]-1,2,3,6-
tetrahydropyridin-4-yl)methyl]benzamide).To a solution of compound 30 (3.0 g, 
15.15 mmol) in dry DCM (50 mL) was added K2CO3 (4.19 g, 30.3 mmol) and the 
reaction was cooled at 0 °C. Br2 (3.146 g, 19.7 mmol) in DCM (10 mL) was added 
dropwise. The mixture was stirred overnight at room temperature. The reaction 
mixture was filtered, washed with water (2×100 mL), dried and concentrated to 
give compound 31 as yellow oil (5.16 g, 95%).  Aqueous NH3 (20 mL) was 
added to the solution of compound 31 (3.87 g, 10.82 mmol) in 30 mL of EtOH 
and stirred at 75 °C in pressure tube for 15 h. The reaction mixture was 
concentrated to give crude compound 32 (1.21 g). To a 0 °C solution of 
compound 32 (0.6 g) in DCM (10 mL) was added Et3N (0.25 g, 4.23 mmol). 
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Benzoyl chloride (0.297 g, 2.115 mmol) was added dropwise, and the solution 
was stirred overnight and then poured into 20 mL of 10% solution of citric acid, 
extracted with DCM (3×30 mL), dried and concentrated. The crude product was 
purified by silica gel column chromatography to obtain compound 33 as a 
colorless oil (0.261 g, 30%, 2 steps). To a solution of compound 33 (0.85 g, 2.69 
mmol) in DCM (10 mL) was added TFA (10 mL, 15.3 g, 134 mmol) and the 
reaction mixture was stirred at 35 °C for 5 h and the concentrated to give of 
crude product 34 as yellow solid as TFA salt (1.77 g). A mixture of compound 6 
(0.210 g, 0.72 mmol), compound 34 (0.240 g, 0.72 mmol), DIEA (0.657 g, 5.03 
mmol) and HATU (0.552 g, 1.44 mmol) in DMF (5 mL) was stirred for 18 h at 
room temperature. The reaction mixture was poured into 100 mL of water and 
extracted with DCM (3×30 mL), washed with brine (2×20 mL) and water (30 mL), 
dried with MgSO4 and concentrated. The crude product was purified by silica gel 
column chromatography and recrystallized from 2.5 mL of EtOH to give SC45 as 
a pale green solid (18 mg, 5%). 
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CHAPTER 4 
INVESTIGATION INTO THE MECHANISM OF ACTION OF A NOVEL FUSION 
INHIBITOR, SC12 
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ABSTRACT 
We have developed a novel, potent, and specific entry inhibitor, SC12. 
Our results indicate that direct binding of SC12 to HIV-1 Env does not block Env 
interaction with the host cellular receptors, thereby allowing Env attachment to 
the host target cell. Moreover, SC12 inhibits infection of CD4-independent 
viruses, validating that SC12 does not block gp120-CD4 interaction. 
Furthermore, differential scanning calorimetry indicates that interaction of the 
soluble cleaved trimeric SOSIP.664 gp140 with SC12 thermally stabilizes the 
protein. SC12-induced pressure on the virus resulted in a single point mutation in 
gp120 and gp41, which led to SC12 resistance. These mutations alter the 
conformational state of HIV-1 Env and negatively affect viral fitness, making the 
virus more susceptible to neutralization by bNAbs. Altogether, SC12 functions as 
an HIV-1 fusion inhibitor through conformational restriction of the Env complex, 
independent of CD4 and coreceptor binding, preventing conformational changes 
necessary for the viral and cell membrane fusion.  
 
 
The study contained in this chapter was conducted in collaboration with 
others, specifically Drs. Zentner, Madani, Ozorovski and Mr. Ptak. 
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INTRODUCTION 
In previous chapters we explained the modification of piperazine scaffold 
inhibitors and discovery of the novel class entry inhibitor, SC12, with a pyrrolo-
(142)-pyrazole moiety. Using the single-round infection system, SC12 was tested 
for potency and specificity against various HIV-1 isolates (Figure 4.1). The 
specificity was determined by testing SC12 against HIV-1 particles pseudotyped 
with amphotropic murine leukemia virus (AMLV) Env, which uses cell surface 
receptors distinct from HIV, and vesicular stomatitis virus glycoprotein (VSV-G), 
which enters the cell through endocytosis. HIV-1, unlike most of pH-dependent 
viruses, uses receptor engagement to elicit the conformational changes in the 
viral envelope glycoproteins required for fusion. The receptor used by HIV-1 is 
CD4. Many studies have demonstrated that CD4 engagement induces significant 
conformational changes in gp120 and it is these changes in gp120 that allow 
chemokine receptor binding and also result in the formation and/or exposure of 
the HR1 coiled coil on gp41(66, 143-148). The effects of gp120 binding to CD4, 
in conjunction with binding to the chemokine receptor, initiate the conformational 
transitions required for membrane fusion. Therefore, both intra- and 
intermolecular interactions coordinate to facilitate the transduction of receptor-
binding signals between the components of the Env complex and ultimately 
result in fusion. As such, compounds that bind HIV-1 gp120 and inhibit viral entry 
could hypothetically block CD4 binding, chemokine receptor binding, 
conformational changes required for membrane fusion; or could alter the nature 
of the gp120-gp41 interaction/association. Previous investigations on the BMS-
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piperazine scaffolded entry inhibitors have implicated a mechanism of action 
based upon the disruption of the gp120-CD4 interaction (84, 86, 90). Other 
studies with BMS compounds indicate allosteric mode of action (92, 93). Since 
SC12 was designed to function through the same binding site as the BMS 
piperazine-derived compounds, we sought to determine the mechanism in which 
SC12 inhibits HIV-1 entry.  
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Figure 4.1. The effect of compound SC12 on viral infectivity. Shown are the 
effects of compound SC12 on the infection of U87CD4+CCR5+/CXCR4+ cells by 
recombinant luciferase-expressing HIV-1 bearing the envelope glycoproteins of 
the HIV-1JR-CSF, HIV-1B41, HIV-1Hxbc2 strains  and amphotropic murine leukemia 
virus (AMLV). Virus infection is expressed as the percentage of luciferase activity 
measured in the target cells in the presence vs. the absence of compound. The 
data from three replicates are shown. The chemical structure of compound SC12 
is shown inset.  
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RESULTS  
Therapeutic spectrum and cellular toxicity of SC12 
SC12 inhibits HIV-1 entry in the nanomolar range, and displays favorable 
predicted aqueous solubility (logS as predicted in StarDrop, Optibrium, UK)(141, 
149). We next evaluated the therapeutic spectrum of SC12 using the single-
round infection assay. SC12’s potency against single-round infectious HIV-1 
pseudotyped with Envs from isolates from clades A, B, C, D and circulating 
recombinant forms was determined (Table 4.1). The summary of this analysis is 
shown in Figure 4.2 A, which demonstrates that SC12 inhibits all isolates tested. 
The relative refractivity of recombinant clade AE to SC12 may be a function of 
the limited number of isolates tested.  
We next determined the toxicity effect of the compound on U87 CD4+ 
CCR5/CXCR4+ cells using MTT assay. Figure 4.2 B demonstrates the effects of 
the increased concentrations of SC12 on cell viability. The compound showed no 
significant toxicity (CC50 > 221 µM) and the established half cytotoxic 
concentration is much greater than the IC50 range across all of the isolates 
tested.  
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Table 4.1. Potency of SC12 against HIV-1 pseudotyped with Envs 
fromvarious clades determined using the single-round infection assay. IC50 
= half-maximal inhibitory concentration; N.D. = not determined. 
Clade  Isolate  IC50 (µM) Tier 
A  BG505  2.2 ± 0.6 2 
QG984.21M.ENV.A  0.507  ± 0.081 unk 
AC 246F3 15 ± 3.5 2 
CRF01_AE CNE55 32 ± 15 2 
B  Bal  0.181 ± 0.068 1B 
AC10.0.29  0.160 ± 0.135 2 
pRHPA4259  0.209 2 
1054.TC4.1499 0.385 ±  0.390 2 
1059_09.A4.1460 0.308 ± 0.600 2 
9021_14.B2.4571  0.253 ± 0.195 2 
JR-CSF 0.0087 ±  0.0015 2 
JR-FL  0.073 ± 0.018  1 
Hxbc2 (X4)  0.070 ± 0.014 1B 
YU-2  0.066 ± 0.010 2 
X2278 29 ± 12 2 
TRO11 18.3 ± 6 2 
398F1 19 ± 5 2 
THR04156   0.0125 ± 0.001   2 
9014_01.TB1.4769  0.0093 ± 0.0038 2 
B41 0.0061 ± 0.0027 2 
ADA160 0.0173 ± 0.003 2 
J1Hx(197) 0.036 ± 0.013 2 
J1Hx 0.05 2 
IIIB 0.07 1B 
CRF07_BC BJOX2000 0.248 ± 0.052 2 
CH119 0.263 ± 0.077 2 
C  DU156 2.5 2 
25710 0.506 ± 0.130 2 
CE0217 0.058 ± 0.009 2 
ZM53M.PB12 1 ± 0.28 2 
D  QA465.59M.env.A1 0.022 unk 
G X1632 0.761 ± 0.200 2 
Non-HIV  AMLV  N.D.   
VSV-G  N.D.   
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The antiviral activity of SC12 identified from the single-round infection 
assay was verified using infectious HIV-1 derived from infectious molecular 
clones and by assessing virus replication in peripheral blood mononuclear cells 
(PBMCs). Viral stocks of two primary subtype B and one subtype C isolates were 
produced by transfection of molecular clones (NIH AIDS Reagent and Reference 
Program) and used to infect PBMCs. Supernatants of these cells were assessed 
for the amount of virus by reverse transcriptase assay. Equivalent amounts of 
virus were incubated with human PBMCs in the presence of increasing 
concentrations of SC12. HIV-1 replication was then followed by periodic 
measurement of viral reverse transcriptase in culture supernatants (150). 
Concomitantly, toxicity of the SC12 to the PBMCs was assessed using the MTT 
assay, establishing the therapeutic index (Table 4.2) 
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Figure 4.2. Antiviral potency and toxicity of SC12. (A) Therapeutic spectrum 
of SC12 determined by single-round infection assay against different isolates 
pseudotyped HIV-1 pNL4-3-LucR+E for 48 hrs. Data represents the mean ± 
standard error of the mean from three independent experiments (each performed 
in triplicate). (B) Toxicity of SC12 determined by MTT assay on U87 
CD4+CCR5/CXCR4 cells for 48 hrs. Data represents the mean ± standard error 
of the mean from three independent experiments (each performed in triplicate). 
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Table 4.2. Therapeutic spectrum of SC12 against HIV-1 subtypes replicating 
in PBMCs. 
 
Virus Isolate Subtype  IC50  (µM)  TC50 (µM)  Therapeutic 
index range 
(TC50/IC50)  
JR-CSF B 0.015 ± 0.002  
 
>100 
> 7,639 
IIIB B 0.07 > 1,480 
93MW965 C 0.3 ± 0.04 > 334 - 6667 
 
IC50 = half-maximal inhibitory concentration; NA = not applicable; TC50 = 
halfmaximal toxic concentration. (Generated by Dr. Ptak). 
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SC12 directly binds to monomeric gp120 
Having demonstrated potency of SC12 across clades, in addition to 
specificity to HIV-1 Env pseudotyped viruses, we reasoned that SC12 targets 
HIV-1 Env. Therefore, we next sought to characterize the interaction of SC12 
with monomeric gp120 using a Surface Plasmon Resonance (SPR) assay to 
determine a kinetic profile of interaction between the compound and gp120. We 
immobilized monomeric HIV-1YU2 gp120 on the surface of a GLH sensor chip 
using the amine coupling. A reference surface was similarly created by 
immobilizing a non-specific protein (CH1). First we validated the activity of the 
immobilized proteins by characterizing the interaction with soluble CD4 (sCD4). 
The determined affinity of sCD4-gp120 association was in line with those 
reported for other clade B gp120 – CD4 interactions (KD = 3.1 nM, Figure 4.3 A). 
Having established activity of our gp120 surfaces, we next determined the kinetic 
profile of direct binding of SC12 with monomeric HIV-1YU2 gp120. As a positive 
small molecule inhibitor control, we chose NBD-556 (77) as it inhibits the entry of 
HIV-1 into CD4 positive cells (77, 151, 152), and has been demonstrated to 
inhibit the CD4-gp120 interaction by directly binding in the CD4-binding site on 
gp120 (80). As can be seen from Figure 4.3, both compounds directly bound to 
monomeric HIV-1YU2 gp120 and SC12 binds approximately 5 times tighter than 
NBD-556. Both compounds inhibit viral entry and, therefore, both function in 
aqueous environment and do not have to cross cellular membranes to inhibit the 
infection. The KD value for NBD-556-gp120 interaction closely resembles the half 
inhibitory concentration of NBD-556 against HIV-1YU-2 islolate (IC50 = 6.19 µM). 
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Interestingly, the obtained KD value for the SC12-gp120 association is 
approximately 100 fold its IC50 value obtained by single-round infection assay 
(IC50 = 66nM). This discrepancy leads us to hypothesize that the fully mature 
interaction of SC12 may be influenced by the oligomeric status and presence of 
gp41 components in the Env complex.  
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Figure 4.3. Direct binding of compounds and CD4 to monomeric HIV-1YU-2 
gp120. (A) The direct binding of sCD4. (B) The direct binding of SC12. (C) The 
direct binding of NBD-556. Colored lines represent the actual data whereas black 
lines show fitting to a Langmuir 1:1 binding model.   
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SC12 interacts with trimeric HIV-1 Env with greater affinity than monomeric 
gp120 
 Having demonstrated a large KD versus IC50 discrepancy with SC12 when 
using soluble, monomeric gp120 in SPR binding assays, we next sought to 
investigate the interaction of SC12 with more physiologically relevant soluble Env 
constructs. To achieve this, we used surface plasmon resonance (SPR), so that 
we could determine a kinetic profile for the interaction, with monomeric and 
trimeric Env constructs. The Env we chose is the recently described B41 Env as 
it is derived from a founder virus (HIV-19032-08.A1.4685) and because there exists 
both monomeric gp120 and trimeric SOSIP.664 gp140 versions (153). Both the 
monomeric and trimeric B41 proteins were attached to a sensor chip and the 
responses to SC12 recorded and analyzed. In a similar way as above, a 
reference surface was similarly created by immobilizing a non-specific protein 
(CH1). Figure 4.4 shows representative sensorgrams for each interaction. As 
can be clearly seen, the interaction of SC12 with the trimeric B41 is more robust 
and approximately 30-fold tighter than that with the monomeric B41. Moreover, 
the KD derived for the trimeric B41 – SC12 interaction more closely resembles 
the IC50 for this isolate in the single-round infection assay (HIV-1B41 IC50 = 6.0 ± 
3.0 nM). Therefore, we believe that a component of the SC12 binding site is 
dependent upon oligomeric status of Env. This is the first time that an entry 
inhibitor of this class has been characterized by SPR and provides us with a 
unique platform for performing structure-affinity relationships.   
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Figure 4.4. Direct binding of SC12 to soluble Env constructs. (A) Direct 
binding of SC12 to B41 monomers, KD = 2.8 µM. (B) Direct binding of SC12 to 
B41 SOSIP.664, KD = 90.1 nM. Colored lines represent the actual data whereas 
black lines show fitting to a Langmuir 1:1 binding model. 
116 
 
116 
 
The effect of SC12 on soluble CD4-Env binding 
As SC12 is an entry inhibitor, and the majority of entry inhibitors 
developed to date function by disruption of the Env-CD4 interaction, we next 
investigated whether SC12 functions in a similar way and blocks HIV-1 entry by 
inhibiting viral attachment to the cellular receptor CD4.  To achieve this, we 
defined the effect of the presence of increasing concentrations of SC12 on the 
B41 – CD4 interaction. Using SPR, we mixed a constant concentration of sCD4 
with increased concentrations of SC12 up to a high test concentration of 1000 
nM (Fig. 4.5 A). To compare with BMS chemotype compounds, we chose BMS-
488043 (BMS-043), as it is one of the compounds used to create a 
pharmacophore used to identify SC12 and is the most characterized of the 
piperazine-based chemotypes in terms of its mechanism of HIV-1 entry inhibition 
as an attachment inhibitor. For the BMS-043 we used the highest concentration 
of 500nM (Fig. 4.5 B). Again, as a positive control, small molecule with a defined 
binding site and mechanism of action, we chose NBD-556, which we used at 
concentrations up to 300 µM (Fig. 4.5 C). As can be seen in Figure 4.5, NBD-
556 at its highest concentration (300 µM, which is only 3-fold the derived NBD-
556-B41 KD; Fig. 4.5 C), inhibited the sCD4 binding over 40%, and BMS-043 
moderately inhibited the interaction of sCD4 with B41 trimer at the highest 
concentration of 500 nM, which is 22-fold the derived BMS-043-B41 KD, resulted 
in 20% inhibition; but SC12 failed to do so even at the highest concentration 
tested (1000nm, 10-fold its derived SC12-B41 KD). This result demonstrates a 
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fundamental difference in the mechanism of action of SC12 versus that reported 
by Bristol Myers Squibb for the piperazine-scaffolded entry inhibitors. 
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Figure 4.5. The effects of inhibitor on sCD4-Env binding. Soluble four-
domain CD4 (NIH AIDS reagents) at the concentration 100 nM was mixed with 
different concentrations of (A) SC12, (B) BMS-043 or (C) NBD-556, injected 
over this surface and the response recorded. 
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SC12 inhibits CD4-independent HIV-1 
The proposed mechanism for the entry inhibition exerted by the BMS 
piperazine compounds is that of disruption of the interaction of Env with CD4 (84, 
86). To investigate this potential mechanism for our compound, we thought to 
make use of the availability of the CD4-independent virus J1Hx(197) (54). Should 
our compounds act solely by affecting the Env-CD4 interaction, they should not 
inhibit the entry of CD4-independent viruses.  As SC12 does not inhibit the 
interaction of CD4 with B41 trimer, we reasoned that it should therefore be able 
to inhibit the entry of a CD4-independent virus into CD4 negative cells. The HIV-
1J1Hx(197) mutant virus is capable of entering cells that are devoid of CD4 but that 
express the coreceptor CCR5 (54). We therefore tested the potency of SC12 
against the recombinant CD4-independent HIV-1 J1Hx(197) virus, and its CD4-
dependent parental virus J1Hx (54). J1Hx(197) was used to infect CD4-negative, 
CCR5-positive canine thymocytes (54, 152), whereas J1Hx was used to infect 
CD4-positive, CCR5-positive canine thymocytes. As can be clearly seen in 
Figure 4.6 A, SC12 inhibits both the CD4-dependent and CD4-independent 
viruses. This is consistent with the primary mechanism of action of SC12 not 
being CD4-dependent. Interestingly, and contrary to its proposed mechanism of 
action, BMS-043 inhibited infection of both viruses (Fig. 4.6 B). Our positive 
control NBD-556 was unable to inhibit CD4-independent HIV-1 J1Hx(197) virus 
(Fig. 4.6 C), which is consistent with its mode of action as a CD4-attachmnet 
inhibitor(151). 
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Figure 4.6. Potency of SC12, BMS-043 and NBD-556 at inhibiting the 
infection of the CD4-dependent HIV-1 J1Hx and the CD4-independent 
J1Hx(197) viruses.  The effects of SC12 (A), BMS-043 (B) and NBD-556 (C) on 
the infection of Cf2 CD4+CCR5+ cells by recombinant luciferase-expressing HIV-
1J1Hx or Cf2 CD4-CCR5+ cells by HIV-1J1Hx(197). Data represents the mean ± 
s.e.m. from three independent experiments (each performed in triplicate). 
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SC12 does not induce conformational changes similar to CD4-mimetics 
The binding of the CD4 mimetic NBD-556 to gp120/Env causes 
rearrangements similar to CD4 ligation that expose the coreceptor site (152) 
(Fig. 4.7 D). We have developed another assay that allows the detection of 
“activation” (or inhibition) by a particular compound to be assessed. This assay 
relies on the finding that immobilized gp120 or SOSIP trimer can undergo 
conformational rearrangements. To determine whether SC12 has an effect 
similar to sCD4 and NBD-556 using SPR, we mixed the coreceptor surrogate 
antibody 17b with an increased concentration of the inhibitor and injected over 
the surface with B41.SOSIP.664 gp140. Comparison with the response of the 
surface to antibody alone is used as a means to determine inhibitory or 
enhancing effects of the compound on the exposure of coreceptor binding site. 
As can be seen from Figure 4.7, SC12 and BMS-043 did not induce recognition 
of the coreceptor binding site by 17b antibody (Fig. 4.7 A, B). Interestingly, an 
active compound BMS-626529 (BMS-529) slightly increased the “activation” of 
the coreceptor binding site (Fig. 4.7 C). Our positive control, CD4-mimetic NBD-
556, increased the recognition in concentration-dependent manner (Fig. 4.7 D). 
These finding show that SC12 does not have an effect on the coreceptor binding 
site “activation”. 
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Figure 4.7. The effect of SC12 on coreceptor binding site 
activation/inhibition.  Coreceptor surrogate, 17b antibody (NIH AIDS reagents) 
at the concentration 100nM was mixed with different concentrations of (A) 
SC12, (B) BMS-043, (C) BMS-529 or (D) NBD-556, injected over the surface 
with B41.SOSIP.664 gp140 and the response recorded. 
  
123 
 
123 
 
SC12 does not block coreceptor binding 
Since SC12 did not block soluble Env trimer attachment to CD4, inhibited 
CD4-independent viruses, and did not induce conformational changes similar to 
sCD4, we reasoned that SC12 could block viral attachment to coreceptor as a 
mechanism of the inhibittion. To test that, we conducted a modified flow 
cytometry analysis (83) of BG505.SOSIP.664 gp140 binding to human 
lymphocytes expressing only coreceptor (Bc7HuR5, CD4-CCR5+CXCR4+). 
Even in the presence of 44 µM SC12, which is twenty times higher its IC50 value 
for this specific isolate (IC50 BG505 = 2.2 µM), the binding of soluble Env trimer to 
CD4-negative cells was similar to those expressing CD4 (SupT1huR5, 
CD4+/CCR5+/CXCR4+; Fig. 4.8 A and B). To verify and confirm that SC12 does 
not block coreceptor binding, we modified a cell-ELISA assay (54) using CD4-
CCR5+ canine thymocytes. SC12 and BMS-043 did not block B41.SOSIP.664 
gp140 binding to CCR5-expressing cells at the highest concentration tested, 
which exceeds their IC50 value for HIV-1B41 isolate by 20-fold (SC12 IC50 B41 = 
6.1 nM, BMS-043 IC50 B41 = 0.6 nM, Fig. 4.8 C). Addition of soluble CD4 
induced conformation within the SOSIP, allowing the exposure of the coreceptor 
binding site and, therefore, increased binding of soluble trimer to the coreceptor 
(Fig. 4.7 C, DMSO-vehicle control). Neither SC12 nor BMS-043 reduced these 
conformationally-induced binding. In contrast, our positive control NBD-556 by 
itself significantly induced conformational changes similar to sCD4, which is a 
well-known property of CD4-mimetic (Fig. 4.8 C).  
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Figure 4.8. The effect of compounds on SOSIP B41.664 attachment to 
cellular coreceptor. Binding of soluble D7324-tagged BG505.SOSIP.664 gp140 to 
human lymphocytes (A) Bc7HuR5 expressing CCR5 and CXCR4 but not CD4 or (B) 
SupT1huR5, expressing CD4, CCR5 and CXCR4. The mean fluorescence was 
normalized to the binding of BG505.SOSIP.664 gp140 to the cells in absence of the 
inhibitor. Data represents mean ± standard deviation from two independent 
experiments. (C) The effect of compounds SC12, BMS-043 and NBD-556 on the 
attachment of B41.SOSIP.664 gp140 to canine thymocytes (Cf2 CD4-CCR5+ 
cells). The inhibitors were used at the concentration 20x greater their IC50 value 
against HIV-1B41 isolate. The binding was normalized to the binding of SOSIP in 
the absence of inhibitor. Data represents the mean ± s.e.m. from six 
independent experiments. Statistical analysis was conducted by Student’s t-
test. * p < 0.05.  
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SC12 does not prevent viral attachment 
Thus far, we have demonstrated that SC12 does not appear to disrupt the 
interaction of Env with host cellular receptors. However, the assays to determine 
this are reductionist in nature, relying heavily on biochemical methods. To 
formally test this assertion, we next looked at the ability of SC12 to inhibit 
attachment of the native HIV-1 virus to cells. If SC12 functions in any capacity to 
disrupt cellular receptor-Env interactions, we should see diminished viral 
attachment to cells. To achieve this, we used two virological assays. 
The first assay to investigate whether SC12 could block viral attachment 
to cells is a modification of a temperature shift assay previously reported in the 
literature (154). The entry process of HIV-1 virus can be divided into two 
temperature-dependent stages, with receptor and coreceptor binding occurring 
over the temperature range 0-37°C, while the fusion process only occuring at 
temperatures above 25°C (154). Based upon differential ranges in temperatures 
at which binding and fusion/entry occur, we have developed a novel assay that is 
designed to detect viral attachment in the presence or absence of inhibitors. 
Recombinant single-round infectious HIV-1 virions are incubated with permissive 
cells at 4°C to only allow the initial receptor/coreceptor engagement. Unattached 
virions, and the compound, are then removed by washing the cells extensively 
with cold media, followed by replenishment with fresh media and transfer to 
37°C. After 48 hour of incubation, the level of infection is measured by luciferase 
activity as in the standard single-round infection assay. Using this methodology, 
differences in the levels of virion attachment to cells in the presence of the 
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compounds can be determined, as it can be expected that only virions that 
remain bound, through Env-CD4 or Env-CD4-coreceptor interactions, will be able 
to enter and infect the cells. A major point in the use of this assay must be 
mentioned – this assay is only valid if the compounds have been demonstrated 
to be solely dependent upon the presence of the HIV-1 Env for inhibition i.e., do 
not inhibit AMLV Env pseudotyped HIV-1, and therefore only work at the level of 
binding/fusion. Both SC12 and BMS-043 do not appear to block viral attachment 
to cells expressing CD4 and either CXCR4 or CCR5 (Fig. 4.9 A and B). 
Conversely, the small molecule CD4-mimetic NBD-556, which is known to disrupt 
the gp120-CD4 interaction (77, 80, 151, 152), reduces the level of infection to 
40% of vehicle (DMSO) alone (Fig. 4.9).  
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Figure 4.9. The effect of entry inhibitors on viral attachment. The effect of 
compounds BMS-488043 (BMS-043), SC12, and NBD-556 on the attachment 
of HIV-1 Hxbc2 to U87 CD4+CXCR4+ cells (A) or HIV-1 J1Hx to Cf2 
CD4+CCR5+ cells (B). The inhibitors were used at their IC50 value against 
indicated HIV-1 isolate. Data represents the mean ± standard error of the mean 
from three independent experiments (performed in eight replicates). Statistical 
analysis was conducted by Student’s t-test. ** p < 0.001 
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The second assay to look at viral attachment to cells in the 
presence/absence of SC12 is one of direct visualization. To visualize the 
attachment of HIV-1 to permissive cells in the presence or absence of our 
compound, we made use of previously reported fluorescent virus (modified from 
Stauber et al. (155)).  We produced a single-round infectious fluorescent virus by 
co-transfecting three vectors. The envelope-deficient HIV-1 NL4-3 vector (pNL4-
3–LucR+E-) (156) carries the luciferase reporter gene and wild type gag gene; the 
HIV Gag-iGFP vector carries green fluorescent protein (GFP) (HIV Gag-iGFP 
delta Env) (157) and the HIV-1HxBc2 gp160 expression vector. Co-transfection of 
all three plasmids produced fluorescent virus with the infectivity similar to the 
regular pseudotyped virus. Figure 4.10 demonstrates that in the presence of 
SC12 virus is able to attach to the cell expressing both cellular receptors, while 
our positive control NBD-556 significantly blocked viral attachment. This outcome 
validates and confirms the results of the temperature shift attachment assay.  
Taken together, these results clearly show that SC12 is a novel, 
potent, and specific HIV-1 fusion inhibitor of CD4-dependent and CD4-
independent strains and does not block receptors binding to monomeric 
gp120 or SOSIP.664 gp140. 
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Figure 4.10. The effect of entry inhibitors on Hxbc2-GFP attachment.  The 
effect of SC12, BMS-043 and NBD-556 used at their IC50 values on the 
attachment of HIV-1 Hxbc2 to U87 CD4+CXCR4+ cells. Representative images 
from single experiment. The DNA-dye DAPI in blue, fluorescent Hxbc2-GFP in 
green.  
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The effect of SC12 on the recognition of epitopes by bNAbs 
The Env complex is extremely conformationally flexible and undergoes 
specific rearrangements upon binding to its receptors. Binding of CD4 to a 
soluble Env trimer conveys two different conformational signals – bridging sheet 
formation and activation of gp41 (48). Opening of the Env complex involves the 
repositioning of the V1/V2 and V3 loops and exposure of the coreceptor binding 
site. Activation of gp41 involves rearrangements within the inner domain layers 2 
and 3, causing allosteric changes in the fusion peptide. The binding of NBD-556 
or BMS-378806 to soluble Env trimers has also been demonstrated to elicit 
specific conformational changes (48). The results above indicate that SC12 does 
not induce conformational changes similar to CD4. However, there are numerous 
unidentified post-receptor engagement conformational changes within the Env 
that are necessary for the fusion of viral and cell membranes. SC12 binding 
could potentially block any of those favorable changes. We next sought to 
understand the mechanism of SC12 inhibition of HIV-1 entry by evaluating the 
effect of SC12 on the conformational state of viral Env. The antigenic mapping of 
cleaved soluble trimers (BG505 SOSIP.664 gp140) using broad neutralizing 
(bNAbs) and epitope specific antibodies was recently completed (49). We 
performed capture ELISA developed and optimized for SOSIP trimers (41, 49) 
using SOSIPs B41.664 and BG505.664 and panel of antibodies with known 
binding sites in presence or absence of inhibitors (Table 4.3).  
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Table 4.3. Panel of monoclonal antibodies tested in SOSIP ELISA. 
 
CD4 bs – CD4 binding site, CD4i – CD4 induced epitope.  
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 Our results indicated that presence of SC12 did not significantly alter 
epitope recognition and binding of this panel of antibodies (Fig. 4.11 A, B). 
Moreover, we observed similar pattern with BMS-043 (Fig. 4.11 C, D). As 
expected, in the presence of our positive control NBD-556, we detected reduced 
binding of antibodies specific to CD4-binding site, and increased recognition of 
CD4i-epitopes. Overall, these results indicate that SC12 does not induce gross 
conformational changes within the Env that can be recognized by 
conformationally- and epitope-specific antibodies.  
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Figure 4.11. The effect of the inhibitors on the binding of monoclonal 
antibodies to soluble trimers.  The binding of compounds to 
BG505.SOSIP.664 (A, C, E) and B41.SOSIP.664 (B, D, F) was normalized to the 
antibody binding in presence of vehicle control DMSO. Antibodies were grouped 
according to their binding site on Env. Data represents the mean ± s.e.m. from 
three independent experiments (each performed in triplicate). 
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The effects of SC12 on conformational stability of the Env complex 
Some inhibitors, such as 18A (83) and the NBD-556 analogue, BNM-IV-
147 (82), interact with variable loops or the Phe43 cavity of gp120 (respectively) 
and elicit conformational changes, which do not have a notable effect upon the 
overall structure. As such, binding of a small molecule inhibitor may elicit 
rearrangements in the Env that are unfavorable for the fusion or may cause the 
stabilization of the Env, preventing any conformational changes. Since our 
results above demonstrate that SC12 does not seem to affect exposure or 
burying regions of the complex or inhibit its interaction with its receptors, we 
believe that SC12 indeed may stabilize the Env complex. To determine whether 
SC12 has an effect of soluble trimer stability, we performed Differential Scanning 
Calorimetry (DSC) to determine the melting temperature (Tm) of the Env 
complex. As can be seen from Figure 4.12, in the presence of SC12 the Tm of 
B41 soluble trimer is increased in 3.9 °C. Recently de Taeye et al. demonstrated 
that introducing four mutations to stabilize closed, ground states of soluble Env 
complex increased its Tm only 3 °C (158). SC12 solely increased Tm of B41 
SOSIP in over 3 °C. This indicates that SC12 indeed has a significant stabilizing 
effect on the Env complex. 
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Figure 4.12. Heat capacity versus temperature profile of the B41.SOSIP 
trimer in the presence of SC12. Green diagram indicates the heat capacity of 
B41 trimer with DMSO; blue diagram represents the heat capacity of B41 trimer 
in presence of SC12. 
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Proposed mechanism for viral inhibition by SC12 
CD4 binding to the Env induces the rearrangement of the V1/V2 loop to 
create a bridging sheet that allows coreceptor engagement. Binding of gp120 to 
coreceptor further induces conformational changes within gp120 and gp41 and 
through the series of post-engagement conformations within the Env complex, 
viral and cell membranes fuse, creating a pore for the entry of viral content. SC12 
directly binds to the Env complex. This binding does not prevent Env association 
with cellular receptor and therefore attachment to the cell surface. This could 
indicate the binding site of SC12 is not dependent on the conformational state of 
variable loops. Furthermore, SC12 inhibits a wide spectrum of HIV-1 strains, 
suggesting that it interacts with a conserved site on HIV-1 Env. Therefore, we 
believe that SC12 binds to a conserved region with the Env complex and blocks 
Env function in allosteric fashion. This hypothesis is supported by the 
thermodynamic studies showing the stabilization of the soluble trimer in the 
presence of SC12. In addition, the fact that SC12 does not alter conformational 
recognition of CD4bs and CD4i epitopes on the Env further supports that SC12 
allosterically blocks Env function.  
Based on the above findings this is our proposed model for SC12 (Figure 
4.13): the viral Env complex is structurally flexible and constantly sampling 
different conformations. They can be roughly divided into receptor-engagement 
conformations that are structurally defined and post engagement conformations, 
which are structurally elusive and not much is known about. SC12 can bind to 
any of receptor-engagement conformations, but this binding prevents transition to 
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fully open, fusogenic state. Therefore, we believe that SC12 is an allosteric 
fusion inhibitor that binds to HIV-1 Env without interrupting CD4 or co-
receptor attachment and prevents post-attachment conformational 
changes necessary for  fusion of viral and cell membranes. 
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Figure 4.13. Model for the HIV-1 entry inhibition by SC12. Binding of CD4 
triggers conformational transition in Env that exposes coreceptor binding site. 
Upon coreceptor engagement Env undergoes post-engagement conformational 
changes that lead to fully fusogenic conformational state of the Env that allows 
the fusion of viral and cell membranes. SC12 can bind any of the receptor 
engagement conformations, however, this binding locks the Env and prevents 
conformational transitions necessary for the formation of fusogenic state of the 
Env. 
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DISCUSSION 
In this study we report the identification of a novel compound SC12 that 
exhibits a broad therapeutic spectrum against diverse HIV-1 strains by targeting 
Env. This is in contrast to the early BMS-chemotype compound, BMS-378806, 
which is potent against clade B isolates and exhibits low or no antiviral activity 
against isolates of other clades or primary isolates. However, new generations of 
BMS compounds demonstrate gradually improved potencies and the latest and 
most potent inhibitor BMS-626529 demonstrates inhibition of isolates of most 
clades with an exception of clades A, E and group O (88, 159). SC12 shows high 
potency inhibition of all clades with the exception of recombinant CRF01-AE with 
IC50 at 35 µM, although only one isolate from this clade was tested. In order to 
expand the knowledge about SC12 potency and specificity, the inhibitor will be 
tested against a larger panel of HIV-1 isolates as well as HIV-2 and SIV.  
This study shows that SC12 has a unique mechanism of action which in 
some aspects is different from BMS-chemotype compounds. Based on 
mutagenesis studies, resistance mutations and a docking model, BMS-
chemotype compounds were proposed to bind the CD4-binding site (86, 92, 160) 
and block viral entry by preventing the binding of gp120 to CD4. Our study shows 
a fundamental difference between SC12 and BMS compounds, demonstrating 
that in the presence of SC12, gp120 binds cellular receptors, which allows viral 
attachment. Most importantly, unlike BMS compounds, SC12 has much higher 
affinity to trimeric Env compared to monomeric gp120. Therefore, while three 
molecules of BMS compound are necessary for the inhibition of function of one 
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viral spike, only one molecule of SC12 would be able to accomplish this, and 
therefore, the administration of less inhibitor will be necessary. These 
assumptions are based on the affinities of direct binding between gp120 
complexes and SC12, and further investigation will be done to determine the 
exact stoichiometry of Env trimer and SC12.  
The ability of SC12 to inhibit CD4-independent viruses further supports 
that SC12 functions in CD4-independent matter. Early generation BMS 
compound, BMS-378806, was not able to block these types of viruses, further 
supporting their hypothesis of being a CD4-attachment inhibitor. Next generation 
BMS-043 had moderate activity and BMS-529 was able to inhibit CD4-
independent viruses with similar potencies as seen with CD4-dependent isolates. 
An important factor for SC12 to block CD4-independent viruses is the ability of 
the inhibitor to prevent HIV-1 infection of CD4-negative cells. Although not 
prevalent in nature, HIV-1 is highly mutable and CD4-independent viruses could 
arise naturally or evolve due to escape from the therapeutic pressure (161). 
Interestingly, the amount of virus that binds CD4- cells is the same as cells 
expressing high levels of CD4 (162). Although, CD4- cells do not support viral 
replication, some studies have shown that attached virus to the CD4- cells can 
remain infectious and can infect T cells more efficiently than cell-free virus (163, 
164). Therefore, it is very important and beneficial to develop an inhibitor that can 
block a wide variety of both typical and atypical HIV-1 viruses.  
All known classes of entry inhibitors (BMS, NBD, 18A, SC) are proposed 
or proven to preferentially bind the native or unliganded state of the Env. 
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However, SC12 binding stabilizes the HIV-1 Env, increasing its Tm 3.9 °C. We 
believe this stabilization of trimer prevents from or makes it less likely to 
complete sequential conformation transitions, necessary for the fusion. Most 
importantly, we believe that the stabilization of the trimer could benefit in the 
clinic. The viral spike is known to be very conformationally mobile, which makes it 
very hard for neutralizing antibodies to recognize specific epitopes. Stabilization 
of the spike could lead to formation of a rigid structure and, subsequently, better 
recognition of neutralizing epitopes and clearance of virus by the host immune 
system. 
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CHAPTER 5 
GENERATION AND EVALUATION OF SC12-RESISTANCE MUTATIONS 
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ABSTRACT 
The emergence of resistance mutations to SC12 will not only influence the 
use of the inhibitor in HAART therapy and elucidate the resistance pathways by 
which the virus escapes the presence of SC12, but also can identify the potential 
residues involved in the binding of SC12 to HIV. Knowing the binding site of 
SC12 will help to determine its mechanism of inhibition of viral infection. Besides 
the analysis of large patient resistance data set, the results eliciting similar 
pathways of resistance to those observed in vivo can also be achieved in vitro by 
the generation of resistant mutations. Furthermore, the genotyping and 
phenotyping of resistant viruses obtained in vitro can be achieved rapidly, and 
confirmation with site-directed mutants (SDMs) enables the identification of each 
individual mutation affecting drug susceptibility. We have generated an SC12-
resistant virus that is able to replicate in the presence of 2 µM of SC12 with a 
similar replication kinetic profile to the wild type NL4-3 virus in absence of the 
inhibitor. The sequencing on the env gene revealed a number of mutations. 
Evaluation of each mutation separately and in combination resulted in 
identification of residues that are responsible for SC12-resistance. Mapping each 
individual mutation on the soluble Env trimer shows that SC12-resistant 
mutations do not cluster and most likely do not represent the binding site of the 
compound. Moreover, resistance to SC12 is correlated with an increase in the 
neutralization by bNAbs targeting the membrane proximal external (MPER) 
region, exposure of which is a characteristic of post-receptor engagement Env 
conformation. The results in this chapter demonstrate that HIV-1 virus evades the 
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selective inhibitory pressure of SC12 by mutating the env gene and these 
mutations may alter conformational state of the Env to one that is closer to the 
“open” or prefusogenic conformation, which comes with the loss of the binding 
site for SC12. 
 
 
The study contained in this chapter was conducted in collaboration with 
others, specifically Drs. Freed, Ablan, and Ozorowski. 
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INTRODUCTION 
The generation of HIV-1 variants in tissue culture systems that escape 
from inhibitory effects of SC12 provides insights into the binding/mechanism-of-
action that complement the studies in Chapter 4. The easiest mechanism for a 
virus to escape the pressure by the inhibitor is to mutate the residues involved in 
SC12 binding. Passaging the virus in various concentrations of SC12 and 
sequencing the Env-coding region of the virus from each passage can reveal 
genotypic changes that confer this resistance. Upon identifying a virus variant in 
the population with mutations that likely emerged due to drug pressure, and 
when this variant has become the predominant virus in the population, SC12-
susceptibility testing can be performed to determine the resistance phenotype (or 
fold-resistance) associated with the passaged virus. Some mutations arise in the 
absence of inhibitor, simply resulting from viral adaptation to growth in cell lines.  
Mutations that arise repeatedly in the presence, but not absence, of SC12 are 
those most likely to contribute to inhibitor resistance. Through site-directed 
mutagenesis, these mutations, individually or in combination, were introduced 
into the NL4-3 env gene. In order to verify that particular mutations are indeed 
conferring resistance, we evaluated them for single-round infectivity and 
replication and then susceptibility to SC12. We then examined the location of 
altered amino acids in available gp120 structural models (35, 46, 48, 80, 165, 
166) to provide clues regarding the likely importance of the specific residues, 
given our understanding of the mechanism of SC12 inhibition derived from the 
studies described in Chapter 4. Moreover, generation of resistance to other entry 
146 
 
146 
 
inhibitors has been shown to correlate with increased sensitivity to neutralizing 
antibodies (167). Therefore, we assessed the sensitivity of the SC12-resistant 
mutants to a panel of neutralizing antibodies directed to various regions on the 
Env surface (168). The results in this chapter show the importance of specific 
Env residues that contribute to the SC12-resistance and suggest a specific 
mechanism by which the virus escapes the inhibition imposed by SC12. 
RESULTS 
Generation of an isolate resistant to the entry inhibitor compound SC12  
A standard dose escalation method was used to select for SC12-resistant 
HIV-1 (142, 169, 170). This method is based on the sequential passage of virus 
in the presence of increasing concentrations of the selecting compound in which 
the first passage consists of the acute infection of cells with HIV-1 in the 
presence of varying concentrations of SC12. Next, supernatant virus from the 
culture at various time points after infection was collected and the day of peak 
virus expression based on supernatant HIV-1 reverse transcriptase activity was 
determined. The virus was serially passaged in this manner, using the virus from 
the day of peak virus expression to generate a new acute infection of cells and 
increasing the concentration of test compound approximately two-fold with each 
passage until drug resistance is identified or compound cytotoxicity becomes a 
limiting factor. 
Following this method, fully infectious NL4-3 virus was propagated in 
Jurkat cells in the presence of increasing concentrations of SC12 (0 - 2µM) for 30 
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days (Fig. 5.1 A). Virus propagated in the presence of 2µM SC12 displayed a 
considerable delay in replication (as measured by RT activity). Viruses were 
taken from this peak and repassaged twice in the presence of 2µM SC12, 
resulting in the generation of isolates, designated NL4-3R-SC12, that are fully 
resistant to the presence of 2µM SC12, with replication kinetics identical to the 
wild-type virus in the absence of compound (Fig. 5.1 B).  These resistant viruses 
were then subjected to sequence analysis to identify resistance-conferring 
mutations.  
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Figure 5.1. Passage of the virus to generate the SC12-resistant virus NL4-
3R-SC12. (A) Titration series of SC12 upon transfection of the HIV-1 NL4-3 
infectious molecular clone. (B) Comparison of the replication kinetics of wild-type 
HIV-1 NL4-3 virus in the absence of compound to that of the SC12-resistant virus 
NL4-3R-SC12 in the presence of 2µM SC12. RT CPM = reverse transcriptase 
counts per minute. (Generated by Dr. Eric Freed) 
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Evaluation of individual mutations for SC12 resistance 
Sequencing on the env gene of the SC12-resistant NL4-3 viruses revealed 
several mutations within both the gp120 and gp41 subunits. Table 5.1 illustrates 
the location of each mutation. Using site-directed mutagenesis each mutation 
individually was introduced into the wild type NL4-3 env and single-round 
pseudotyped viruses were produced by transfection of 293T cells. In order to 
determine that a specific mutation does not affect viral fitness as compared to 
wild type, we tested single-mutant viruses for infectivity and viral production. 
Infectivity of single-point mutant viruses in the absence of SC12 varied within a 
range of 10,000 and 115,000 luciferase units (Fig.5.2 A), however, these 
differences did not correlate with degree of viral production as can be seen from 
the p24 assay (Fig.5.2 B). We next sought to investigate which of these 
mutations confer SC12-resistance. In order to achieve this, NL4-3 Env mutant 
pseudotyped viruses were normalized by p24 and subjected to a single-round 
infection assay in the presence of SC12. While some of the mutants retained 
sensitivity to SC12 similar to the wild type NL4-3, such as M147I, I546V, and 
V486I, others increased resistance to SC12 to various degrees (Fig.5.2 C). NL4-
3M432I induced resistance to SC12 approximately 30-fold compared to NL4-3wt 
(IC50 = 400nM and 12nM, respectively). The highest resistance of 575- and 125-
fold was observed with NL4-3V253A and NL4-3M473I (IC50 = 6.9µM and 1.5µM, 
respectively). 
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Table 5.1. SC12-induced mutations within HIV-1 NL4-3 Env. Six independent 
mutant viruses were identified with indicated mutations. 
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Figure 5.2 Characterization of single-point HIV-1NL4-3 mutants. (A) Single-
round infectivity assay of pseudotyped NL4-3 mutants in U87.CD4+CXCR4+ 
cells in absence of SC12. (B) p24 analysis of pseudotyped single-round viruses. 
(A) and (B) Data represents percent of wild type ± standard deviation of one 
experiment preformed in triplicates. (C) Summary of single point mutants 
characterized by the location of the single point mutation, IC50, and fold 
resistance compared to wild type.   
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Although double and triple mutations might not derive from the same 
virus, we next sought to characterize recombinant viruses harboring double and 
triple mutations. The mutations were introduced into the env by site-directed 
mutagenesis, followed by the co-transfection of 293T cells. To validate that the 
combination of mutations does not affect viral production or fitness, mutants 
were then characterized for infectivity and viral production (Fig. 5.3). Similarly 
to single-point mutant viruses, mutants varied in infectivity but the p24 content 
was fairly similar (Fig. 5.3 A and B) and, most importantly, double and triple 
mutants retained the ability to infect target cells. Therefore, we next subjected 
normalized to p24 content viruses to SC12-sensitivity analysis by single-round 
infection assay. Contrary to our expected synergistic results, the addition of 
mutations reduced SC12-resistance to various levels (Fig. 5.3 C). For instance, 
the addition of the mutation in the gp41 region (I546V) to the most SC12-
resistant mutant V253A reduced SC12-resistance 10-fold compared to the 
single point mutant (NL4-3V253A/I546V IC50 = 0.652 µM and NL4-3V253A IC50 = 6.9 
µM, respectively), reducing the resistance 520-fold compared to single V253A 
mutant. Also, two additional mutations to V253A in the positions M147I and 
V486I reduced SC12-resistance compared to a single point V253A mutant 460-
fold (NL4-3M147I/V253A/V486I IC50 = 1.4 µM). The addition of mutation R296K to either 
M432I or M473I did not significantly affect SC12 resistance, with only minor 
differences in the half inhibitory concentration (NL4-3M432I IC50 = 400 nM, NL4-
3R296K/M432I IC50 = 357 nM, NL4-3M473I IC50 = 1.5 µM, NL4- 296K/M473I IC50 = 1.1 µM, 
Fig. 5.3 C).   
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Figure 5.3 Characterization of double and triple HIV-1NL4-3 mutants. (A) 
Single-round infectivity assay of pseudotyped NL4-3 mutants in 
U87.CD4+CXCR4+ cells in absence of SC12. (B) p24 analysis of pseudotyped 
single-round viruses. (A) and (B) Data represents percent of wild type ± standard 
deviation of one experiment preformed in triplicates. (C) Summary of mutants 
characterized by the location of the mutations, IC50, and fold resistance 
compared to wild type, and fold resistance lost compared to the single point 
mutants.   
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The location of SC12-induced mutations on the cleaved soluble Env 
Having isolated and verified resistance-conferring mutations from the 
passaging experiments, we next sought to visualize the location of these 
mutations on the available structures of the monomeric and soluble trimeric Env 
complexes, in an attempt to identify whether these mutations represent the 
binding site of SC12.   
As can be seen from Fig. 5.4 A, the mapping of all mutations identified 
through the resistance mutation generation studies do not appear to identify a 
discrete cluster on soluble cleaved HIV-1 trimer and therefore most likely do not 
represent the binding site of SC12.We next looked only at the mutations that 
confer resistance to SC12 (V253A, M432I, M473I). Although these mutations did 
not arise in the same virus, they are located fairly close to each other and may 
potentially represent the binding site for SC12 (Fig. 5.4 B). All three mutations 
are located close to, but do not overlap with, the CD4-binding site nor form any 
bonds with CD4 (Fig. 5.4 B). Based on these findings we believe that the SC12-
resistant viruses escape the presence of the inhibitor by mutating the residues 
directly involved in the binding of SC12. However, the alternative mechanism of 
escape could be the altering of the conformational state of Env resulting in the 
blocking of access of SC12 to its binding site or, ultimately, the total loss of the 
binding site for SC12.   
155 
 
155 
 
 
 
Figure 5.4. The position of the SC12-resistant mutations on the native HIV-1 
BG505 Env complex identified through the resistance mutation generation 
studies. (A) The position of all substitutions identified through the RMG on the 
soluble cleaved HIV-1 unliganded BG505 trimer. (B) Side view of the HIV-1 
BG505 gp140 protomer. The position of V253A, M432I and M473I mutations that 
cause the most SC12-resistantce. Gp120 aspartate 367D (in yellow) forms the 
salt bridge with the Arginine R59 of CD4. Gp120 serine S375 (in red) occupies 
CD4-cavity on the native unliganded  Env complex.  (This figure was generated 
using Pymol, Ligand-free soluble cleaved trimer PDB: 4ZMJ).  
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The location of BMS-resistant mutations on unliganded cleaved soluble 
Env complex 
Small-molecule attachment inhibitors of BMS-chemotype bind gp120 (85, 
87) and the lead compound in this class, BMS-626529, has been suggested to 
allosterically block CD4-binding (88, 92, 115, 171). Additionally, a number of 
studies designed to investigate the preexisting and induced resistance to BMS 
entry inhibitors have yielded interesting results. Resistance generation 
experiments implicate numerous residues within Env, and mutational studies 
confirm several residues in close proximity but not limited to the Phe-43 cavity 
that confer viral resistance to BMS compounds. These mutations include some 
that induce partial resistance to BMS-626529 (S375, M426, M434, M475) (172), 
BMS-488043 (V68, L116, S375, M426) (173) and BMS-378806 (W112, T257, 
F382, W427) (174). We mapped these BMS-chemotype resistant mutations on 
the soluble cleaved trimer Env construct (Fig. 5.5). The results indicate that all 
of the mutations cluster around the CD4-binding site and could potentially 
directly block CD4-binding. Interestingly, although SC12 was originally 
designed using a pharmacophore derived from the BMS chemotype, the 
mechanism it uses to block viral infection seems to be a little different. While 
BMS-resistant mutations cluster to the CD4-binding site and are potentially 
involved in the direct binding with the compound, SC12-resistant mutations are 
located in close proximity to the Phe-43 cavity without affecting CD4 binding 
and we have not ruled out that these resistant mutations are compound-contact 
residues.   
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Figure 5.5. Mapping of the BMS-resistant mutation of the native cleaved 
soluble Env complex. Gp120 aspartate 367D (in yellow) forms the salt bridge 
with the Arginine R59 of CD4. Gp120 serine S375 (in red) occupies CD4-cavity 
on the native unliganded Env complex.  (A) The location of BMS-resistant 
mutation (in blue) on the gp140 protomer. The gp120 is shown in green and 
gp41 helices are shown in light blue. (B) The locations of BMS-resistant 
mutations are shown on the trimeric Env structure. 
  
158 
 
158 
 
Determine the effect of selected mutation on susceptibility to neutralization 
by bNAbs.  
The SC12-resistant viruses could potentially escape the pressure by the 
compound and keep replicating in presence of SC12 by mutating the residues 
directly involved in SC12 binding. However, the SC12-resistant viruses may 
alter the Env conformation to the point that the binding site for SC12 is lost. If 
SC12-resistance mutations alter the gross conformation of the Env complex, this 
could manifest in an increased or decreased sensitivity to neutralization by 
specific bNAbs. We next sought to investigate what effect SC12-resistant 
mutants have on neutralization by bNAbs compared to the wild type virus. We 
used a panel of eleven bNAbs that interact with different epitopes on the Env 
glycoprotein, some of which are also conformational. We performed single-round 
infection assays with the SC12-resistant viruses the presence of potent bNabs 
targeting different epitopes such as CD4-binding site (VRC01), CD4-induced 
epitope (17b, 48d), variable loops (39F, 2909), glycan dependent Ab (2G12), 
gp120-gp41 interface (35O22, PGT151), and gp41 (2F5, 10e8, 167-D IV).   
Several tested antibodies that target various sites on the Env (VRC01, 
48d, 39F, 2909, 167-DIV) did not show any difference in neutralization of mutants 
compared to wild type (data not shown). 2G12 antibody has 2-fold increase in 
neutralization of mutants compared to wild type virus (NL4-3wt IC50 = 202 ± 13 
ng/ml, NL4-3V253A IC50 = 100 ± 11 ng/ml, NL4-3M432I IC50 = 110 ± 22 ng/ml, NL4-
3M473I IC50 = 98 ± 9 ng/ml, Table 5.2). 17b has a 2-fold increase in neutralization 
of the M473I mutant (NL4-3wt IC50 = 1.15 ± 0.5 µg/ml and NL4-3M473I IC50 = 0.6 ± 
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0.27 µg/ml) indicating that the M473I mutant adopts a more activated 
conformation. PGT151 and 35O22 both recognize different epitopes on the 
interface of gp120 and gp41. 35O22 has around 2-fold increase in neutralizing 
V253A and M432I mutants (NL4-3wt IC50 = 77 ± 17 ng/ml, NL4-3V253A IC50 = 33 ± 
4.9 ng/ml, NL4-3M432I IC50 = 44 ± 10 ng/ml, Table 5.2).  
The most notable increase in sensitivity to neutralization was observed 
with the mutants and antibodies targeting the MPER region of gp41, 10E8 and 
7H6. 10E8 has over 2-fold increase in neutralization of mutants compared to the 
NL4-3wt (NL4-3wt IC50 = 285 ± 20 ng/ml, NL4-3V253A IC50 = 114 ± 12 ng/ml, NL4-
3M432I IC50 = 101 ± 13 ng/ml). Mutants were much more sensitivity to 
neutralization by the 7H6 bNAb, resulting in 4- to 5-fold increase in sensitivity as 
compared to NL4-3wt. Interestingly, the broadly neutralizing MPER epitopes are 
commonly hidden on the native, unliganded Env trimer (175). Moreover, the 
exposure of the MPER region is commonly associated with the prefusogenic or 
otherwise known “open” state of the Env trimer (176-178). Therefore, we 
conclude from these combined results that SC12-resistant mutations alter the 
conformational state of the HIV-1 Env and these alterations lead to exposure of 
the well-conserved regions of the Env complex, most notably the MPER epitopes 
and, therefore, increased sensitivity to neutralization by the bNAbs.   
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Table 5.2. Neutralization of SC12-resistant mutants by bNAbs. bNAbs were 
tested by single-round infection assay against SC12-resistant NL4-3 mutants. 
Established half inhibitory concentrations (IC50) for the antibody against each 
mutant are indicated and fold increase in sensitivity to neutralization compared to 
wild type virus.  
 
NL4-3 
mutant/ 
bNAbs                                                        
2G12,  
ng/ml  
2G12, 
Fold 
WT
17b, 
µg/ml  
17b, 
Fold 
WT 
35O22,  
ng/ml  
35O22, 
Fold 
WT 
10e8,  
ng/ml  
10e8, 
Fold 
WT 
7H6,  
ng/ml  
7H6, 
Fold 
WT 
NL43wt  202±13     1 1.15±0.5  1 77±17  1 285±20  1 465±111  1 
V253A  100±11  2 2.1±0.5  0.6 33±4.9  2.3 114±12  2.5 82±16  5.7 
M432I  110±22  1.8 1.7±0.6  0.7 44±10  1.7 101±13  2.8 103±10  4.5 
M473I  98±9  2 0.6±0.27  1.9 74±9  1 150±27  1.2 113±25  4.1 
  
Data represents half inhibitory concentration ± SEM (standard error of mean) and 
fold increase in sensitivity to neutralization compared to wild type virus. The 
results from three independent experiments preformed in triplicates are shown.  
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DISCUSSION 
SC12 represents a novel class of HIV-1 entry inhibitors discovered by our 
group, with broad therapeutic spectrum and good potency (Chapter 4). Some 
isolates could have a natural resistance to SC12 (AE and AC recombinant 
clades), and understanding the way virus escapes the constant pressure by the 
compound and keeps replicating in the presence of SC12 will lead to the 
development of a new generation of SC compounds that will potentially prevent 
this from occurring. In this study we performed resistance mutation generation to 
isolate SC12-resistant virus. Genotypic analysis of the resistant virus populations 
showed that amino acid substitutions that conferred resistance to the virus 
harboring them (M147I, V253A, R296K, M432I, M473I, and V486I) were located 
primarily within the conserved regions of the gp120 envelope protein and I546V 
was located in the gp41 protein. This finding is an independent validation of the 
viral target of SC12, demonstrating that it acts as an entry inhibitor by interacting 
with and altering the normal function of the Env complex. Introduction of these 
mutations into the HIV-1NL4-3 backbone resulted in variable fold changes in 
susceptibility to SC12. Some of the mutations did not have any effect on 
sensitivity to SC12 compared to the wild type NL4-3 virus (M147I, R296K, V486I, 
I546V), indicating that these mutations most likely randomly emerged during the 
passaging of the virus. Both M147I and R296K are located in the variable loops 
(V1 and V3, respectively). The mutations in these variable loops may affect the 
binding to the coreceptor or neutralization by early neutralizing antibodies and 
those targeting the CD4i epitope (83, 179-181). However, we previously 
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established that SC12 does not affect coreceptor binding (Chapter 4). Therefore, 
mutations M147I and R296K together with V486I in C5 of gp120 and I546V in 
gp120 (or position 37 in gp41) most likely randomly emerged during the 
passaging the virus and, therefore, do not confer resistance to SC12.  
The mutation that causes the most SC12 resistance is V253A, which is 
located in the constant region C2 of gp120. The mutations of the Valine at 
position of 253 (or 223 in the gp120) to A, I, M and S have been previously 
implicated in the drug resistance (182). The same mutations arose during virus 
escape studies with the NBD-chemotype compound NBD-556 and sCD4 (78). 
This single-point mutation resulted in a 575-fold resistance to SC12. Most 
importantly, Valine 253 located in layer 3 of gp120, away from the CD4 or 
coreceptor binding sites and buried deep in the hydrophobic core of gp120. 
Therefore, it could be important to retain hydrophobicity in that location and the 
mutation to Alanine could not only disrupt the hydrophobicity in this area, but may 
also alter the helical structures that are connected by the loop-B. Interestingly, 
the addition of the I546V mutation to V253A reduced SC12-resistance 10-fold 
compared to V253A mutant alone (NL4-3V253A/I546V IC50 = 652 nM, NL4-3V253A IC50 
= 6900 nM), which is still nearly 50- or 575-fold more resistant than NL4-3 wt, 
respectively (NL4-3wt IC50 = 12 nM).   
SC12-resistant mutations M432I and M473I, identified in this study, are 
both located in the constant regions of gp120 (C4 and C5, respectively). They 
are also known to induce resistance to BMS-chemotype compounds (92, 174). 
C4 forms an α-helix and some of the residues directly involved in CD4 binding 
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(183, 184) but the residue M432 is located away from the CD4-binding pocket.  
As we have previously shown, SC12 does not interfere with CD4 binding.  
The residue M473 is in close proximity to Serine at the position 375 that, 
in the unliganded state on the HIV-1 Env, occupies the Phe-43 cavity. But most 
importantly, the C5 region of gp120 is closely associated with HR1 of gp41 and 
the mutation in the C5 helix could affect the crosstalk between gp120 and gp41. 
Therefore, we believe that the M473I mutation causes substantial change in the 
α5 helix of the gp120, either by altering the conformation of the gp120 or by 
leading to “premature” activation of gp41. Any of these hypotheses could lead to 
the partial loss of the binding site for SC12 or reduced sensitivity to this inhibitor.  
Based on the close location of SC12-resistant mutations, V253A, M432I 
and M473I we reason that they may represent the binding site of SC12 and the 
mutation of these residues may negatively affect the direct binding of Env with 
SC12. However, in order to conclude whether these are compound-contact 
residues, we need to perform structural studies of soluble Env in complex with 
SC12.  
Our findings also suggest that the SC12-resistant mutations may have an 
effect on the conformational state of the HIV-1 Env. We noticed that the SC12-
resistant mutants are more susceptible to neutralization by bNAbs compared to 
NL4-3wt pseudotyped virus. We also noticed that the most SC12-resistant 
mutant is more susceptible to neutralization by the antibody directed to the 
MPER region, exposure of which is associated with the more advanced or 
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“fusogenic” conformation of the Env. This could indicate that the alteration of the 
Env complex and the exposure of the MPER region is due to pressure by SC12.  
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CHAPTER 6 
MATERIALS AND METHODS 
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CELLS 
Human embryonic kidney 293T (a gift from Dr. Irwin Chaiken, Drexel 
University, Philadelphia, PA) were cultured in Dulbecco's Modified Eagle’s 
Medium (DMEM), 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 
2mM L-glutamine. Human astroglioma U87 cells stably expressing CD4/CCR5 or 
CD4 /CXCR4 (obtained from Prof. Hongkui Deng, Peking University, and Prof. 
Dan Littman, New York University, USA, through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH (119, 185)) cells were 
cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2mM L-glutamine, 300µg/ml G418 (Thermo Scientific, Waltham, 
MA) and 1µg/ml Puromycin (Thermo Scientific). Canine thymocytes Cf2 stably 
expressing CD4/CCR5 or CCR5 alone (Cf2-CD4-CCR5, Cf2-CCR5; obtained 
from Dr. Joe Sodroski and Dr. Navid Madani, Harvard, MA) were cultured in 
DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin 
and 0.4 mg/ml geneticin. For Cf2-CD4-CCR5 0.2 mg/ml hydromycin was added 
for stable CD4 expression. Human T-cells SupT1huR5 and Bc7huR5 stably 
expressing CD4/CXCR4/CCR5 and CXCR4/CCR5, respectively (SupT1huR5-
CD4-CXCR4-CCR5 and Bc7huR5-CXCR4-CCR5, obtained from Dr. Jim Hoxie, 
UPENN, PA) were cultured in RPMI supplemented with 10% FBS. Cells were 
incubated continuously, unless otherwise stated, at 37°C in a humidified 5% CO2 
/ 95% air environment.  
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PRODUCTION OF PSEUDOTYPED VIRUSES 
Single-round infectious envelope-pseudotyped luciferase-reporter viruses 
were produced by dual transfection of two vectors (3µg of vector 1 and 4µg of 
vector 2) in 6-well plated 293T cells (1x106 cells/well) (119). Vector 1 is an 
envelope-deficient HIV-1 pNL4-3-Luc+R-E plasmid which carries the luciferase-
reporter gene (156). Vector 2 is a plasmid expressing either the HIV-1 gp160 
Env, vesicular stomatitis virus glycoprotein (VSV-G) or amphotropic murine 
leukemia virus Env (AMLV) (186, 187). Transfections of these vectors were 
carried out via calcium phosphate (ProFection Mammalian Transfection System, 
Promega, Madison, WI) for 5 h. Following the 5 h transfection incubation, DNA-
containing medium was removed, cells were washed with DMEM and 
replenished with fresh culture media. Supernantants containing pseudovirus 
were collected 72 h post transfection, clarified, filtered, aliquoted and stored at -
80°C.  
VIRAL ENVS USED IN THIS STUDY 
Clade  Env Tropism Tier Source Ref. 
A  BG505  R5 2 Dr. Ward, Scripps, 
CA 
(42) 
QG984.21M.ENV.A  R5 unk  
 
 
 
 
NIH AIDS 
Reagents 
 
 
 
(188) 
AC 246F3 env R5 2 (168) 
CRF01_AE CNE55 env R5 2 (168) 
B  Bal  R5 1B (189) 
AC10.0.29  R5 2 (190) 
RHPA4259  R5 2 (190) 
1054.TC4.1499 R5 2 (191) 
1059_09.A4.1460 R5 2 (191) 
9021_14.B2.4571  R5 2 (191) 
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JR-CSF R5 2 Dr. Dennis Burton, 
Scripps, CA 
(192) 
JR-FL  R5 1 (192) 
Hxbc2  X4 1B  
Dr. Joe Sodroski, 
Harvard, MA  
(193) 
YU-2  R5 2 (194) 
J1Hx(197) R5 2 (54) 
J1Hx R5 2 (54) 
IIIB R5 1B (195) 
ADA160   R5 2 (196) 
9014_01.TB1.476
9  
R5 2 NIH AIDS 
Reagents 
(191) 
B41 R5 2 Dr. Ward, Scripps, 
CA 
(153) 
THR04156   R5 2  
 
 
 
 
 
NIH AIDS 
Reagents 
 
 
(190) 
X2278 env R5 2 (168) 
TRO11 env R5 2 (168) 
398F1 env R5 2 (168) 
CRF07_BC BJOX2000 env R5 2 (168) 
CH119 env R5 2 (168) 
C  DU156 R5 2 (64) 
25710 env R5 1B (168) 
CE0217 env R5 2 (168) 
ZM53M.PB12 R5 2 (197) 
D  QA465.59M.env.A1  R5 unk (188) 
G X1632 R5 2 (168) 
 
ANTIBODIES 
Antibodies were obtained from the following sources: 19b, 2G12, 35O22, 
b6, b12, PGT128, PGT145, PGT151, PGV04, VRC34 from Dr. Ozorowski (The 
Scripps Research Institute); 2909, 2F5, 39F, 48d, 50-69, 98-6, 167-D IV, NC-1, 
F105, 17b, 7H6, 10e8, ID6, PG9, PGT121PGT126, VRC01, VRC03 from NIH 
AIDS Reagents (NIH); 412d from Peter Kwong; and D7324 from Aalto Bio 
Reagents, Ireland (catalog code D7324). Mouse anti-p24 and rabbit anti-p24 
from Abcam, Cambridge, United Kingdom (cat # ab9071 and ab63913, 
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respectively). HRP-conjugated rabbit anti-sheep FITC conjugated from Thermo 
Scientific, Rockford, IL (cat # 31627); goat anti-mouse, goat anti-rabbit, goat anti-
human antibodies from Life Technologies, Carlsbad, CA. Antibodies were used 
at a concentration of 1 μg/ml unless otherwise indicated. 
COMPOUNDS 
All of the compounds used in this study were purchased from commercial 
vendors and were >95% pure. Compounds 11, 12, 28, 32, 34, SC04 were from 
Enamine Ltd. (Kiev, Ukraine); SC07, SC08, SC12, SC45, NBD-556 (77), BMS-
488043 (87), SC45 from AsisChem, Inc. (Watertown, MA); SC11, from HD 
Biosciences Co., Ltd. (Shanghai, China); SC14, SC15, SC26, SC27, SC28 from 
WuXi Apptec (Shanghai, China); BMS-378806 (84), BMS-626529 (92) from 
MedChem Express (Monmouth Junction, NJ). All of the compounds were 
dissolved in sterile-filtered DMSO (Sigma, cat # D2438) at 50-100 μM 
concentration and stored in aliquots at −80 °C. 
PROTEINS 
All proteins were generous gifts from other laboratories. YU-2 gp120 from 
Dr. Chaiken (Drexel University, PA) was purified as previously described in (198); 
soluble cleaved trimers BG505.664 gp140 (42), D7324-BG505.664 gp140 (41), 
B41.664 gp140, B41 gp120 (153) from Dr. Andrew Ward (Scripps Institute, CA); 
2d CD4 from Dr. Peter Kwong (NIH, NIAID/VRC); p24 was produced in house as 
described in (121).  
170 
 
170 
 
ELISA-BASED QUANTIFICATION OF P24 CONTENT 
ELISA plate was coated with 50ng of mouse anti-p24 (Abcam, ab9071) for 
overnight at 4°C, blocked with 3% BSA for 2 h at room temperature and washed 
with 0.5% Tween in PBS. Pseudoviral stocks were lysed with 0.1% Triton X-100 
(Sigma-Aldrich, St. Louis, MO) at 37°C for 1 h and added to the plate overnight at 
4°C. Simultaneously, p24 protein (produced, purified and validated as described 
section 2.2.9) was added for the generation of a standard curve. Following the 
overnight incubation, the plate was washed with PBST and 1:5000 dilution of 
rabbit anti-p24 (Abcam, ab63913) was added for 2 h at room temperature. After 
washing the unbound rabbit anti-p24 off the plate with PBST, goat anti-rabbit-
HRP at a 1:5000 dilution was added for 1 h at room temperature. Plate was then 
extensively washed with PBST. Subsequently, a solution of 0.4mg/ml o-
phenylenediamine in a phosphate-citrate buffer with sodium perborate (Sigma-
Aldrich) was added and incubated in the dark for 30 min. Optical densities were 
then obtained at 450 nm in a Multiskan™ GO Microplate Spectrophotometer 
(Thermo Scientific).  
RECOMBINANT P24 OVERPRODUCTION AND PURIFICATION 
The overproduction and purification of p24 (HIV-1 CA) was performed as 
previously described (121). Briefly, a vector containing C-terminally His-tagged 
HIV-1NL4-3CA (a gift from Dr. Eric Barklis, Oregon Health and Science Unverisity, 
Portland, OR) was transformed into BL21-Codon Plus (DE3)-RIL Competent 
Cells (Agilent Technologies, Wilmington, DE) and grown up in autoinduction 
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ZYP-5052 medium overnight with shaking (225 rpm) at 30°C (199). Bacterial 
cultures were spun down at 7000 rpm and the supernatant was discarded. Cell 
pellets were resuspended in PBS and lysed via sonication. Resultant 
supernantant was clarified and immediately applied to a Talon cobalt resin affinity 
column (Clonetech Laboratories, Mountain View, CA). Purified CA-H6 was 
dialyzed overnight into 20mM Tris-HCl pH 8.0 at 4°C, concentrated to 120µM, 
flash frozen in liquid nitrogen, aliquoted and stored at -80°C.  
SINGLE-ROUND INFECTION ASSAY 
The details of the single-round HIV-1 infection assay have been published 
previously (156, 200, 201). Briefly,  U87.CD4.CCR5/CXCR4 (1.2 × 104 cells/well) 
, Cf2 CD4+/CD4-CCR5+ (8 × 103 cells/well), SupT1huR5 CD4+CCR5+CXCR4+ 
or Bc7huR5 CD4-CCR5+CXCR4+(7 × 103 cells/well)  target cells were seeded in 
96-well luminometer-compatible tissue culture plates (Greiner bio-one). After 24 
hours compound, DMSO (vehicle control for compounds, Sigma) or antibodies 
were mixed with pseudotyped viruses (normalized to p24 content) and the 
mixture was added to the target cells and incubated for 48 hours at 37°C. 
Following this, the media was removed from each well, and the cells were lysed 
by the addition of 50 μl of luciferase lysis buffer (Promega) and one freeze-thaw 
cycle. A GloMax 96 microplate luminometer (Promega) was used to measure the 
luciferase activity of each well after the addition of 50 μl of luciferase assay 
substrate (Promega).  
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CELLULAR TOXICITY 
The viability of U87.CD4.CCR5/CXCR4 cells was determined by the Cell 
Counting Kit-8 cell proliferation and cytotoxicity assay (Dojindo Molecular 
Technologies, Rockville, MD) per the manufacturer’s instructions. 
U87.CD4.CCR5/CXCR4 cell were seeded at a density of 1.2 × 104 cells/well in 
96 well tissue culture plates (Olympus plastics) 24 hours before treatment. Cells 
were treated with compound (1mM-0.1µM) or DMSO (Sigma) for 48 hours at 
37°C. Subsequently, 10µl of the CCK-8 solution was added to each well and 
allowed to incubate at 37°C for 4 h before absorbance at 450nm was measured 
in a Multiskan™ GO Microplate Spectrophotometer (Thermo Scientific). 
Untreated cells were used as medium control and 0.1% SDS treated cells served 
as a positive control. The 50% cytotoxicity (CC50) value was defined as the 
concentration of SC12 that reduced the absorbance of treated cells by 50% as 
compared with control cells. 
GFP VIRUS PRODUCTION, INFECTION AND IMMUNOFLUORESCENCE  
GFP containing pseudovirus was produced in a similar manner as 
explained above. Briefly, an optimized amount of 2µg HIV Gag-iGFP vector 
which carries green fluorescent protein (GFP) (HIV Gag-iGFP delta Env; 
obtained through AIDS  Research and Reference Reagent Program)(157) was 
transfected alongside the 1µg envelope-deficient HIV-1 NL4-3 vector (pNL4-3–
LucR+E-)(156) which carries the luciferase reporter gene, and 4 µg HIV-1HxBc2 
gp160 expression vector in 293T producer cells by calcium phosphate 
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precipitation method. Pseudoviral supernatants containing GFP were collected 
72 hrs post-transfection, clarified, filtered, aliquoted and stored at -80°C until 
used for subsequent assays. For immunofluorescence, U87 cells were plated on 
glass chamber slides (Corning) at 3x105 cells per well and cultured as described 
above. Synchronized infections were conducted by pre-incubating cells at 4°C for 
1 h, at which time cells were challenged with chilled GFP pseudovirus. Cells 
were then washed extensively with chilled PBS and fixed with a cold 1:1 solution 
of methanol and acetone for 20 min at -20°C. Subsequently, cells were washed 
with PBS and mounted onto glass coverslips with ProLong Gold Antifade 
Mountant with DAPI (Thermo Scientific). Confocal images were acquired on a 
fully automated Leica DM6000 B microscope (Leica Microsystems, Deerfield, IL). 
TEMPERATURE SHIFT ATTACHMENT ASSAY 
A novel temperature shift attachment assay was implemented in this study 
which was based upon known temperature-dependent entry events, in which Env 
binding to cellular receptors has been demonstrated to occur over the 
temperature range 0-37°C, while the fusion process only occurs at temperatures 
above 25°C (154). The target cells U87 CD4+CXCR4+ (3x104 cells well) or Cf2 
CD4+CCR5+ (1x104 cells/well) were seeded in the 96-well luminometer-
compatible tissue culture plates (Greiner bio-one). The recombinant single-round 
infectious viruses were mixed with the compound or DMSO to the final 
concentration equal to its IC50 value against the particular HIV-1 isolate. The 
mixture was then added to the cells and incubated at 4°C to only allow the initial 
receptor/coreceptor engagement. After 2 h unattached virions and the compound 
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were then removed by washing the cells extensively with cold media by 
centrifugation at 1500rpm at 4°C followed by replenishment with fresh media and 
transferal to 37°C. After 48 hour of incubation, the level of infection is measured 
by luciferase activity as described above in the single-round infection assay. 
Using this methodology, differences in the levels of virion attachment to cells in 
the presence of the compounds can be determined, as it can be expected that 
only the virions that remain bound, through Env-CD4 or Env-CD4-coreceptor 
interactions, will be able to enter and infect the cells. A major point in the use of 
this assay must be mentioned – this assay is only valid if the compounds have 
been demonstrated to be solely dependent upon the presence of the HIV-1 Env 
for inhibition i.e., do not inhibit non-HIV Env pseudotyped viruses, and therefore 
only work at the level of binding/fusion.  
FLOW CYTOMETRY 
The binding of gp120 to the CCR5 on the cell surface was described 
previously (83). The method was modified with utilization of D7324-tagged 
BG505.SOSIP.664. The SOSIP (2 μg/ml) was mixed with SC12 to the final 
concentration of 2.2 μM (IC50 value for HIV-1 BG505 against SC12) or 44 μM 
(20x IC50).  The mixture was then added to 1 million of Bc7HuR5 (CD4-
CCR5+CXCR4+) cells for 1hr. After two washes by centrifugation at 1500 rpm for 
5 min, the cells were incubated with the D7324 (10 μg/ml) antibody followed by 
the rabbit anti-sheep HRP-conjugated antibody (Life Technologies) to detect 
bound SOSIPs. The binding of D7324-tagged BG505 SOSIP in the presence of 
SC12 was normalized to the binding of the SOSIP to the cells in the presence of 
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the vehicle control, DMSO. Cells were analyzed by flow cytometer using a Guava 
Easy-Cyte Mini flow cytometer. All steps were performed at the room 
temperature. 
CELL-BASED ELISA 
Cell-based ELISA was modified from previously described methods (34, 
54). A sensitive cell-based ELISA was developed to measure the binding of HIV-
1 envelope glycoprotein trimers to the CCR5 receptor expressed on cells. Canine 
thymocytes (Cf2Th) stably expressing CCR5 on the cell surface were seeded in 
96-well plates (1x104 cells per well). The next day the cells were fixed with 4% 
paraformaldehyde (PFA) for 20 min at the room temperature followed by the 
three washed with PBS. Cells were then blocked with 3% bovine serum albumin 
(BSA) for 2 hours at the room temperature followed by the washed with PBS. 
Purified B41.SOSIP.664 (0.5 μg/ml) was mixed with the inhibitor at the final 
concentration equal to IC50 or 20x IC50 for each tested inhibitor against HIV-1 B41 
isolate. To induce coreceptor epitope exposure within the SOSIP soluble CD4 
(sCD4) was added to some samples at the final concentration of 0.5 μg/ml. The 
mixtures of supernatant and cells were incubated at 4°C. The next day cells were 
washed three times with 0.5% Tween in PBS. 2G12 (1 μg/ml, NIH AIDS 
Reagents) was added for 2 h at room temperature. After washing the unbound 
human 2G12 antibody off the plate with 0.5% PBST, goat anti-human-HRP at a 
1:3000 dilution was added for 1 h at room temperature. Plate was then 
extensively washed with PBST. Subsequently, a solution of 0.4mg/ml o-
phenylenediamine in a phosphate-citrate buffer with sodium perborate (Sigma-
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Aldrich) was added and incubated in the dark for 30 min. Optical densities were 
then obtained at 450 nm in a Multiskan™ GO Microplate Spectrophotometer 
(Thermo Scientific).  
SOSIP ELISA 
96 well microtiter plate was coated with soluble HIV-1 Env trimer 
(B41.SOSIP.664 and BG505.SOSIP.664, Andrew Ward, Scripps Institute, CA) 2 
μg/ml for 16 hrs (ON) at 4°C. The next day plates were blocked with 3% BSA for 
2 h at room temperature. bNAbs and non-neutralizing human Abs (1 μg/ml) were 
mixed with inhibitors at the final concentration equal to the 20x IC50 value of the 
inhibitor for the particular HIV-1 isolate in the blocking buffer (0.05% BSA in 
PBS).  The mixture was added to the wells and incubated at room temperature. 
After 3 h the plates were washed three times with 0.1% Tween in PBS. HRP-
labeled goat anti-human secondary antibody (1:5000, 50 μl/well) was added to 
each well in the blocking buffer (0.05% BSA in PBS) for 1 h at room temperature. 
Rest of the protocol followed was same as described above. The binding of each 
antibody to the SOSIP in presence of the inhibitor was normalized to that binding 
in presence of DMSO. Increase or decrease binding was presented as the 
percentage of binding in absence of the inhibitor.  
SURFACE PLASMON RESONANCE 
Immobilization of Env constructs  
Interaction analyses were performed on a ProteOn XPR36 SPR Protein 
Interaction Array System (Bio-Rad Laboratories, Hercules, CA). The instrument 
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temperature was set at 25 °C for all kinetic analyses. ProteOn GLH sensor chips 
were preconditioned with two short pulses each (10 s) of 50 mM NaOH, 100 mM 
HCl, and 0.5% sodium dodecyl sulfide. Then the system was equilibrated with 
PBS-T buffer (20 mM Na-phosphate, 150 mM NaCl, and 0.005% polysorbate 20, 
pH 7.4). The surface of a GLH sensorchip was activated with a 1:100 dilution of a 
1:1 mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.2 
M) and sulfo-N-hydroxysuccinimide (0.05 M). Immediately after chip activation, 
monomeric gp120 at a concentration of 25 µg ml-1 for YU-2 and 100 µg ml-1 for 
B41 or soluble cleaved gp140 B41.SOSIP.664 at a concentration of 50 µg ml-1 in 
10 mM sodium acetate, pH 4.0 was injected across ligand flow channels for 5 
min at a flow rate of 30 µl min-1. Excess active ester groups on the sensor 
surface were capped by a 5-min injection of 1 M ethanolamine HCl (pH 8.5). This 
resulted in the coupling of Env constructs at a density of 17,000 RUs (response 
unit, which is an arbitrary unit that corresponds to 1 pg/mm2) for monomeric and 
5000 RUs for SOSIPs. A reference surface was similarly created by immobilizing 
a non-specific protein (CH1) in 10 mM sodium acetate, pH 5.0 to match the 
density of immobilized HIV-1 proteins.  
Direct binding analysis 
To prepare the compound for analysis, 10 μL of the compound stock 
solution was added to 20 μL of 100% DMSO and this was made to a final volume 
of 1 mL by addition of sample preparation buffer (PBS, pH 7.4). Preparation of 
analyte in this manner ensured that the concentration of DMSO was matched 
with that of running buffer with 3% DMSO. Two-fold dilutions from a starting 
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concentrating as indicated in the result section (Chapter 4) were then prepared in 
running buffer (PBS, 3% DMSO, 0.005% polysorbate 20, pH 7.4) and injected 
across the Env surfaces at a flow rate of 100 μL min−1, for a 1-min association 
phase, followed by up to a 5-min dissociation phase using the “one shot kinetics” 
capability of the Proteon instrument (202). To prepare CD4 for direct binding 
analysis the CD4 stock solution was diludted to the concentration of 200 nM in 
the running buffer and two-fold dilutions were injected across the Env surfaces at 
a flow rate of 100 μL min−1, for a 1-min association phase, followed by up to a 5-
min dissociation phase. Surface regeneration was achieved by pulsing 10mM 
glycine pH 1.5 over each surface followed by multiple injection of running buffer. 
Data were analyzed using the ProteOn Manager Software version 3.0 (Bio-Rad). 
The responses of a buffer injection and responses from the reference flow cell 
were subtracted to account for nonspecific binding and injection artifacts. 
Experimental data were fitted to a simple 1:1 binding model (where applied). The 
average kinetic parameters (association [ka] and dissociation [kd] rates) 
generated from 3-6 data sets were used to define the equilibrium dissociation 
constant (KD). 
CD4 - competition 
Soluble CD4 at the concentration of 50 nM alone or in combination with 
small molecule inhibitor at a range of concentrations was flown across the 
surface containing Env constructs. The concentrations of the five 1:2 serial 
dilution of each compound were as following: 1000 nM-62.5 nM (SC12), 500 nM-
31.25 nM (BMS-043), 300 µM-18.8 µM (NBD-556). 
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17b enhancement binding 
17b the concentration of 100 nM alone or in combination with small 
molecule inhibitor at a range of concentrations was flown across the surface 
containing Env constructs. The concentrations of the five 1:2 serial dilution of 
each compound were as follows: 1000 nM-62.5 nM (SC12, BMS-043, BMS-529), 
100 µM -6.25 µM (NBD-556). 
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CHAPTER 7 
DISCUSSION  
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SIGNIFICANCE 
The current therapy for treatment of HIV-1 infection includes a 
combination of medications that inhibit the various viral enzymes used by HIV-1 
to infect and replicate in host cells. HAART is a combination of medications that 
is used to treat HIV-1 infected individuals. This therapy consists of a combination 
of RT inhibitors, IN inhibitors, and PR inhibitors. In cases when HAART therapy is 
not sufficient, CCR5 receptor antagonists and viral fusion inhibitors are used as a 
salvage therapy. While these combinations often result in a decrease in viral load 
and prolonged life expectancy, HAART does not cure the disease and usually 
can be complicated by variable factors such as high cost, the need for 
customized regiments, severe side effects, and, most importantly, the emergence 
of drug-resistant viruses. Therefore, new therapies and drugs with different 
mechanisms of action are still needed.  
CONCLUSIONS AND DISCUSSION 
The entry of HIV-1 into host cells is an attractive and underexploited drug 
target. Unlike most pH-dependent viruses that enter through endocytosis, HIV-1 
uses cellular surface receptors during viral entry. This process is facilitated by the 
viral glycoprotein complex composed of gp120 and gp41 subunits. Being the only 
proteins on the viral surface, the Env complex was used to study and develop 
novel therapeutics. Among those, Bristol Myers Squibb has developed a series of 
compounds that have been the most successful and have progressed to Phase 
III clinical trials. The BMS-chemotype compounds inhibit viruses in the low 
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nanomolar range and show a favorable safety profile in the infected individuals. A 
persistent problem in the BMS entry inhibitor series has been their solubility, oral 
bioavailability and, to a lesser degree, their metabolic stability. However, the 
recent development of a pro-drug version of a lead compound in this series has 
been found to circumvent the initial problem of solubility. Nonetheless, once 
processed, the active component still has the same aforementioned problems. 
Taking into consideration the great potential of the previously undescribed BMS 
entry inhibitor binding site, we wished to see if we could exploit it further.  We 
sought to identify and develop new compounds with improved properties that 
maintain the potency and broad therapeutic spectrum of the BMS entry inhibitors. 
Work completed in Chapter 2 addressed this fundamental question. Using a 
combination of high-content pharmacophore in silico screening, chemical 
syntheses, bioisosteric replacement, and antiviral testing, we successfully 
developed a novel core chemotype that functions as an entry inhibitor.  We 
showed that this chemotype inhibits the entry of HIV-1 into susceptible cells in 
the nanomolar range with improved predicted ADME profile. Our compound 
contains a dipyrrolodine core as opposed to the piperazine core of BMS entry 
inhibitors. 
Having successfully demonstrated that scaffold-hopping of the piperazine 
moiety of BMS-chemotype compounds can be achieved, we next asked whether 
or not we could further extend the range of core chemotypes for the entry 
inhibitors to  develop a compound with improved drug-like properties. This 
question was addressed in the studies in Chapter 3. Again, using a combination 
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of field-based bioisosteric replacement we have developed 4 new core 
chemotypes, amongst which a novel pyrrolo-pyrazole core scaffold displayed 
good potency and the best predicted drug-like physicochemical properties. This 
compound, designated SC12, was then chosen for mechanistic analyses.   
The most promising compound in the field of HIV-1 entry inhibitors, BMS-
626529, had low solubility and bioavailability. To compensate for this, BMS 
synthesized a prodrug of BMS-626529 (designated BMS-663068) containing a 
phosphonooxymethyl group, which is designed to be cleaved in the intestine by 
host alkaline phosphatase to release the active component. Although reasonably 
effective, this prodrug cannot be included in a once-daily pill combination with 
other drugs as a first line of therapy due to the high pill burden (203). In addition, 
BMS-663068 has to be administered twice-daily which is why BMS-663068 is 
being developed for those patients who are resistant to all but two HIV drug 
classes and, hence, falls into the salvage therapy category, just like other 
approved HIV-1 entry/fusion inhibitors. Therefore, it is extremely desirable to 
develop an entry inhibitor that does not rely upon the prodrug approach, which 
will allow for its inclusion in the first line therapies. SC12 and its analogs are a 
step in this direction, demonstrating that other chemical moieties can function like 
the piperazine-based entry inhibitors.  
Most HIV-1 entry inhibitors bind to gp120 and prevent CD4 attachment 
(BMS analogs and NBD analogs), although the precise mechanism of BMS 
analogs is still a topic of debate. 18A, a compound discovered by Sodroski and 
co-workers, appears to have a different mechanism of action, functioning by 
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preventing CD4-induced rearrangement of V1/V2 loops without blocking gp120 
binding to CD4 or coreceptor. Similarly to 18A, SC12 does not block gp120 
binding to cellular receptors, indicating it functions in CD4-independent manner. 
In addition, SC12 inhibits CD4-independent viruses, further supporting that its 
mechanism is independent of CD4 binding inhibition. Moreover, SC12 does not 
inhibit the interaction of gp120/Env with the co-receptor. Biophysical studies 
using differential scanning calorimetry demonstrate that SC12 has a stabilizing 
effect on the Env trimer.  HIV-1 is known to evade detection by the immune 
system due to three main reasons: heavy glycosylation of the Env spike (47), 
highly diverse variable loops that leave only 10% of the Env accessible to 
immunoglobulins (47), and a wide range of structural flexibility that complicates 
the recognition of neutralizing epitopes on the accessible 10% of the trimer. 
Therefore, stabilization of the Env complex by SC12 could be beneficial not only 
for further structural studies of trimer dynamics, but also have a clinical 
implication through combinatorial treatments with bNAbs.  
To better understand the mechanism of action of the different classes of 
entry inhibitory compounds and to perhaps gain detailed information about its 
binding site on the HIV-1 Env, HIV-1 entry inhibitors were subjected to both 
structural and resistance development studies.  
Shortly after its discovery, NBD-556 and its analogs were shown by in 
vitro experiments to function as CD4-mimetics, being able to elicit the same 
conformational changes as interaction of the Env with CD4. Successful co-
crystallization with monomeric gp120 and an antibody targeting coreceptor-
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binding epitope revealed the binding site of the NBD compounds was the Phe-43 
cavity (77, 80, 137, 204). This binding site was further confirmed in results of 
resistance mutation selection experiments with NBD-556 wherein all resistant 
mutations mapped in gp120 at the CD4 binding site (78).  
Unlike the NBD-chemotype compounds, there is no crystal structure of 
BMS-chemotype compounds in complex with gp120. However, resistance 
mutation selection studies were performed in an attempt to identify the binding 
site. These mutational studies revealed a number of mutations but the two that 
imparted the most resistance to the inhibitory effects of the compound were 
mutations in gp120 (M434I and M475I) (160). These results led to the conclusion 
that the BMS compounds bind to Phe-43 cavity. This binding site and the 
attachment inhibition mechanism of action is disputed by Sodroski and co-
workers (205). 
Just like BMS compounds, 18A has not been co-crystallized with gp120 as 
of yet. Moreover, due to its low therapeutic index, it has also not been subjected 
to resistance mutations generation studies. However, the analysis of the potency 
of 18A against a panel of site-directed mutants in Env revealed that resistant 
mutations mapped around the CD4 binding site and also within the V1/V2 loop, 
suggesting that this compound does not bind within the Phe-43 cavity.   
In parallel with ongoing structural studies, we also performed resistance 
mutation generation to gain insight into the binding site and mechanism of action 
of SC12. We were able to obtain SC12-resistance mutants by continually 
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culturing the fully infectious virus in the presence of SC12 (Chapter 5). SC12-
resistant mutations included two that are the same as those of BMS compounds 
(M432I and M473I). Although both are located close to the CD4 binding site, we 
do not reason that SC12 binds to the Phe-43 cavity. Our hypothesis is supported 
by our mechanistic studies which demonstrate that SC12 binds to gp120 without 
inhibiting the gp120-sCD4 interaction (Chapter 4). Moreover, the most SC12-
resistant mutant contained a V253A substitution in conserved region C2 of 
gp120, located in layer 3 of gp120, away from the CD4 or coreceptor binding 
sites. This single-point mutation resulted in a 575-fold resistance to the inhibitor. 
Sequencing of the env of SC12-resistant mutants revealed other mutations in 
gp120 and gp41 regions but those substitutions had little to no effect on SC12-
resistance. This may indicate that those mutations simple arose due to the 
passaging the virus in cell culture. However, the close proximity of three 
mutations that induce the most resistance to SC12 (V253A, M432I and M473I) 
may represent the binding site of SC12 and may potentially directly affect SC12 
binding.  
We were eager to know whether these residues represent a binding site 
for SC12 but still considered an alternative mechanism of escape from the 
inhibition imposed by SC12. These SC12-resistant mutations could potentially 
alter the Env conformation to the point that the binding site for SC12 is lost. 
Several studies have demonstrated that mutations elicited under constant 
pressure of entry inhibitors, or even point mutations identified that confer 
resistance to entry inhibitors, predispose those viruses carrying them to 
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increased neutralization by antibodies (206-209). Some studies show that 
mutations in the HR1 of gp41 and even those located in CD4-binding site can 
increase neutralization of viruses to antibodies targeting the MPER region (167, 
175, 210). Therefore, we subjected our mutants to a panel of neutralizing 
antibodies targeting different epitopes on the viral spike. We observed that SC12-
resistant mutants were more sensitive to neutralization by antibodies directed to 
glycans (2G12), gp120-gp41 interface (PGT151 and 35O22) and the MPER 
region (10e8, 7H6). We noticed 5.7-fold increase in sensitivity to 7H6. This 
indicates that adaptation of the Env to SC12 alters the conformation/structure of 
the Env, allowing increased recognition and neutralization by certain bNAbs. 
These alterations of Env conformations could potentially provide novel 
immunogenic epitopes for neutralization. Furthermore, the SC12-resistant 
mutants could serve as a tool to better understand the HIV entry process and to 
develop relevant therapeutic applications. 
Overall, our study demonstrates that SC12 functions as an allosteric 
fusion inhibitor that binds to HIV-1 Env without interrupting CD4 or co-receptor 
attachment and prevents post-attachment conformational changes necessary for  
fusion of viral and cell membranes. Adaptation of the virus to SC12 results in the 
alteration of the Env conformations leading to the exposure of well conserved 
epitopes and increased neutralization by bNAbs. 
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FUTURE DIRECTIONS 
Although we have partially demonstrated the mechanism of action of 
SC12 and the effect of the inhibitor on Env conformations, we still would like to 
further explore the function of our novel entry inhibitor. Our mechanistic study 
shows that SC12 prevents viral entry without interfering with viral attachment to 
the cell. However, the binding of gp120 to CD4 and coreceptor ultimately alters 
the conformation in gp41. We next can look at the effect of SC12 on gp41 
activation and the ability to directly bind post-engagement Env conformations. 
Although we do not expect SC12 to directly block 6-HB formation, we 
hypothesize that SC12 blocks numerous post-engagement conformational 
transitions. To test this hypothesis we are facing challenges associated with the 
difficulty to identify and isolate all the conformational transitions of Env after 
binding to both cellular receptors. With the development of the high resolution 
electron microscopes we could be able to visualize HIV-1 entry process and with 
the improvement of the techniques we will be able to isolate short- and long-lived 
conformational transitions of Env, which then can be used in different structural 
and functional studies.  
Identification of SC12-resistant mutations benefits defining both the 
mechanism and the binding site of SC12. Therefore, we are also interested in 
whether discovered SC12-resistant mutations are isolate-specific. In order to test 
that, we will introduce these specific mutations in other SC12-sensitive isolates 
from different clades and determine the effect of those mutations on sensitivity to 
the compound. Another way to look at the specificity of these mutations is by 
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developing SC12-resistant viruses from other clades and comparing the SC12-
resistant mutations to those developed in NL4-3 isolate from clade B. 
The SC12-resistant mutations discovered here could potentially represent 
the binding site of SC12 and these mutations individually or in combination my 
affect the binding of the inhibitor. In order to confirm that three identified SC12-
resistant mutations are compound-contact residues, we can co-crystallize the 
native unliganded Env complex with SC12. We can also determine whether any 
of the SC12-resistant mutations have an effect on the binding kinetics of mutant 
Env complexes with SC12. Moreover, we can perform DSC with mutant SOSIPs 
and determine whether SC12 has the stabilizing effect as with wild type SOSIP. 
This direct approach will reveal whether the loss of sensitivity of virus can be 
directly linked to the loss of binding site of SC12.  
Investigation of the mechanism of action of the inhibitor provides 
knowledge not only about the compound itself, but also about the complexity of 
Env structure and the detailed functions of each part of viral spike. Small 
molecule inhibitors have played vital role to the field of HIV-1 entry. Putting all 
information about all existing inhibitors, one can alter different regions of the 
compound and target specific residues on the Env to create the best version of 
the inhibitor by improving its binding affinity, preventing conformational flexibility 
of the spike, increasing anti-viral potency and perfecting the drug-like properties. 
I believe that SC12 and its analogs have the potential to succeed in this field and 
to become a valuable addition for the treatment of HIV/AIDS patients.  
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